{"schema_version":1,"summary":{"researcher_names":15455,"connections":79939,"papers":4770,"matching_names":15455,"displayed_names":25,"omitted_large_author_lists":0},"nodes":[{"id":847,"entity_id":"https://psilocybin-research.com/authors.php?author=Carhart-Harris%20R#person","name":"Carhart-Harris R","papers":[128,237,325,408,413,415,436,497,560,571,623,625,631,710,712,793,808,840,845,848,878,932,970,997,1046,1058,1074,1111,1122,1135,1145,1148,1231,1390,1600,1642,1651,1669,1698,1727,1798,1802,1916,2142,2153,2165,2201,2281,2284,2324,2425,2552,2557,3104,3116,3126,3188,3201,3244,3268,3298,3303,3315,3400,3730,3770,3775],"connections":404},{"id":1101,"entity_id":"https://psilocybin-research.com/authors.php?author=Husain%20MI#person","name":"Husain MI","papers":[171,188,203,255,325,354,369,391,394,395,408,473,521,629,767,808,816,961,1042,1080,1342,1427,1495,1502,1561,1608,1642,1649,1762],"connections":264},{"id":1223,"entity_id":"https://psilocybin-research.com/authors.php?author=Carhart-Harris%20RL#person","name":"Carhart-Harris RL","papers":[187,457,635,664,824,850,889,1128,1233,1286,1293,1295,1407,1422,1449,1464,1487,1528,1594,1602,1668,1719,1867,1894,2149,2300,2321,2327,2338,2350,2374,2376,2385,2388,2405,2410,2416,2427,2429,2431,2432,2452,2456,2472,2503,2511,2536,2547,2560,2563,2565,2573,2575,2576,2578,2606,2608,2616,3023,3026,3108,3131,3209,3216,3269,3342,3347,3372,3406,3731],"connections":252},{"id":969,"entity_id":"https://psilocybin-research.com/authors.php?author=Erritzoe%20D#person","name":"Erritzoe D","papers":[150,315,436,497,560,571,625,631,664,710,816,845,848,850,878,885,947,997,1074,1111,1122,1135,1145,1148,1231,1233,1263,1286,1293,1295,1390,1407,1449,1602,1698,1719,1798,1802,1867,1894,2149,2165,2181,2201,2284,2331,2374,2511,2573,2603,2606,2608,3023,3024,3026,3104,3106,3153,3187,3230,3728,3730,3785,3799],"connections":236},{"id":844,"entity_id":"https://psilocybin-research.com/authors.php?author=Roseman%20L#person","name":"Roseman L","papers":[128,187,571,623,625,631,664,1231,1277,1464,1487,1505,1528,1600,1602,1613,1651,1668,1669,1698,1727,1732,1798,2300,2327,2374,2376,2388,2425,2431,2452,2560,3106,3108,3116,3126,3130,3131,3147,3153,3216,3227,3230,3268,3269,3298,3303,3315,3347,3372],"connections":223},{"id":135,"entity_id":"https://psilocybin-research.com/authors.php?author=Nutt%20DJ#person","name":"Nutt DJ","papers":[19,116,187,664,885,1148,1231,1233,1267,1286,1293,1295,1330,1390,1449,1528,1602,1605,1668,1698,1719,1815,1894,2165,2201,2300,2327,2334,2374,2376,2377,2410,2416,2427,2429,2431,2452,2503,2511,2536,2560,2565,2573,2575,2576,2578,2606,2608,2616,3023,3026,3104,3108,3131,3153,3227,3269,3347,3728,3730],"connections":206},{"id":885,"entity_id":"https://psilocybin-research.com/authors.php?author=Barrett%20FS#person","name":"Barrett FS","papers":[137,138,187,453,793,1105,1199,1278,1287,1372,1447,1658,1697,1794,1827,1833,1888,1911,2128,2160,2179,2182,2255,2298,2347,2386,2393,2421,2438,2442,2451,2464,2498,2500,2528,3209,3306,3321,3328,3370,3398,3400,3421,3731,3796,5886],"connections":196},{"id":1212,"entity_id":"https://psilocybin-research.com/authors.php?author=Preller%20KH#person","name":"Preller KH","papers":[187,460,587,684,793,932,1097,1102,1157,1263,1264,1356,1483,1566,1567,1732,1853,1883,2148,2199,2229,2263,2296,2312,2393,2406,2444,2448,2453,2460,2516,2518,2525,2530,3071,3178,3188,3209,3258,3306,3321,3327,3328,3421,3731],"connections":191},{"id":84,"entity_id":"https://psilocybin-research.com/authors.php?author=Rosenblat%20JD#person","name":"Rosenblat JD","papers":[9,171,237,326,390,395,408,473,502,521,540,629,794,1042,1064,1080,1108,1177,1204,1342,1427,1495,1561,1608,1649,1675,1744,1858,2145,2228,2343],"connections":191},{"id":1217,"entity_id":"https://psilocybin-research.com/authors.php?author=Vollenweider%20FX#person","name":"Vollenweider FX","papers":[187,684,793,1097,1102,1157,1163,1192,1356,1483,1566,1567,1883,2229,2263,2296,2323,2336,2406,2444,2445,2448,2453,2460,2516,2518,2525,2530,2553,2583,2597,2607,2609,2610,2615,2624,2629,2630,2647,2652,2657,2664,2668,2689,2692,2698,2703,2709,2713,2722,2726,2727,2750,2753,2759,2764,3033,3071,3178,3287,3327],"connections":188},{"id":644,"entity_id":"https://psilocybin-research.com/authors.php?author=Rucker%20J#person","name":"Rucker J","papers":[93,139,401,448,598,663,735,795,846,974,1072,1121,1198,1642,1677,1875,2276,2427,2511,3055,3165,5781],"connections":177},{"id":2446,"entity_id":"https://psilocybin-research.com/authors.php?author=Nutt%20D#person","name":"Nutt D","papers":[436,497,625,631,710,845,848,997,1066,1111,1122,1135,1257,1289,1392,1527,1600,1651,1669,1798,1802,2284,2324,2331,2363,2425,2496,2552,2557,2563,3024,3106,3126,3187,3216,3230,3268,3381],"connections":174},{"id":495,"entity_id":"https://psilocybin-research.com/authors.php?author=Timmermann%20C#person","name":"Timmermann C","papers":[76,187,232,457,645,888,997,1045,1046,1128,1145,1233,1464,1487,1527,1528,1602,1651,1669,1690,1798,1867,3106,3147,3298,3351,3372,3799],"connections":174},{"id":2171,"entity_id":"https://psilocybin-research.com/authors.php?author=Griffiths%20RR#person","name":"Griffiths RR","papers":[383,641,968,1045,1105,1199,1315,1372,1379,1390,1443,1447,1627,1650,1658,1710,1794,1827,1833,1851,1888,1911,1916,2128,2158,2160,2179,2182,2255,2261,2298,2303,2332,2347,2349,2369,2375,2386,2402,2428,2438,2442,2451,2464,2467,2468,2485,2494,2498,2500,2507,2528,2534,2555,2566,2596,2601,2604,2611,2612,2680,3359,3398,3756,3793],"connections":171},{"id":933,"entity_id":"https://psilocybin-research.com/authors.php?author=P%C3%A1len%C3%AD%C4%8Dek%20T#person","name":"Páleníček T","papers":[143,325,489,544,607,622,800,808,852,1396,1502,1642,1757,2285,2426,2562,3064,3983,5151],"connections":171},{"id":190,"entity_id":"https://psilocybin-research.com/authors.php?author=Ross%20S#person","name":"Ross S","papers":[30,383,560,635,793,900,968,980,1272,1368,1379,1407,1424,1466,1630,1681,1689,2168,2302,2394,2413,2423,2441,2495],"connections":162},{"id":1890,"entity_id":"https://psilocybin-research.com/authors.php?author=Aaronson%20ST#person","name":"Aaronson ST","papers":[325,793,808,902,1119,1123,1205,1386,1434,1502,1513,1642,1674,3244],"connections":157},{"id":1895,"entity_id":"https://psilocybin-research.com/authors.php?author=Dunlop%20BW#person","name":"Dunlop BW","papers":[325,550,790,808,814,826,1379,1502,1642,3244,5721],"connections":154},{"id":439,"entity_id":"https://psilocybin-research.com/authors.php?author=Kelly%20JR#person","name":"Kelly JR","papers":[70,235,325,392,808,962,1393,1502,1515,1633,1642,1777,1872,2151,4197],"connections":150},{"id":643,"entity_id":"https://psilocybin-research.com/authors.php?author=Young%20AH#person","name":"Young AH","papers":[93,139,325,808,846,1066,1380,1453,1502,1642,1728,1847,2164,2230,2276,2497,3244,3724],"connections":149},{"id":207,"entity_id":"https://psilocybin-research.com/authors.php?author=Liechti%20ME#person","name":"Liechti ME","papers":[33,145,187,374,592,596,681,793,881,1001,1154,1196,1257,1290,1367,1518,1574,1771,1791,1800,1860,2434,2457,2471,2506,5873],"connections":147},{"id":2247,"entity_id":"https://psilocybin-research.com/authors.php?author=Agin-Liebes%20G#person","name":"Agin-Liebes G","papers":[399,441,560,793,968,1067,1248,1451,1706,1708,1804,1857,2168,2238,2413,2495,3746,5903],"connections":146},{"id":2174,"entity_id":"https://psilocybin-research.com/authors.php?author=Johnson%20MW#person","name":"Johnson MW","papers":[383,534,543,793,884,1202,1282,1338,1372,1434,1783,1801,1827,1837,1841,1845,1867,1878,2128,2143,2160,2179,2261,2273,2303,2332,2347,2349,2375,2386,2402,2428,2438,2451,2467,2468,2477,2485,2494,2498,2500,2507,2523,2528,2534,2544,2550,2555,2566,2568,2596,2601,2604,2611,2612],"connections":144},{"id":2874,"entity_id":"https://psilocybin-research.com/authors.php?author=Davis%20AK#person","name":"Davis AK","papers":[521,705,793,1018,1045,1199,1390,1491,1612,1685,1700,1708,1804,1827,1857,1888,2158,2160,2182,2210,2271,2303,2332,2349,2369,3134,3402],"connections":140},{"id":886,"entity_id":"https://psilocybin-research.com/authors.php?author=Nayak%20SM#person","name":"Nayak SM","papers":[137,396,468,641,793,828,909,951,1124,1278,1372,1379,1443,1851,1911,3070,3158,3159,3187,3359,3730,3793,5709],"connections":136}],"edges":[{"source":643,"target":644,"papers":[93,139,846,1642,2276],"weight":5},{"source":844,"target":847,"papers":[128,571,623,625,631,1231,1600,1651,1669,1698,1727,1798,2425,3116,3126,3268,3298,3303,3315],"weight":19},{"source":885,"target":886,"papers":[137,793,1278,1372,1911],"weight":5},{"source":84,"target":1101,"papers":[171,395,408,473,521,629,1042,1080,1342,1427,1495,1561,1608,1649],"weight":14},{"source":844,"target":1212,"papers":[187,1732],"weight":2},{"source":844,"target":885,"papers":[187],"weight":1},{"source":495,"target":844,"papers":[187,1464,1487,1528,1602,1651,1669,1798,3106,3147,3298,3372],"weight":12},{"source":207,"target":844,"papers":[187],"weight":1},{"source":844,"target":1217,"papers":[187],"weight":1},{"source":135,"target":844,"papers":[187,664,1231,1528,1602,1668,1698,2300,2327,2374,2376,2431,2452,2560,3108,3131,3153,3227,3269,3347],"weight":20},{"source":844,"target":1223,"papers":[187,664,1464,1487,1528,1602,1668,2300,2327,2374,2376,2388,2431,2452,2560,3108,3131,3216,3269,3347,3372],"weight":21},{"source":885,"target":1212,"papers":[187,793,2393,3209,3306,3321,3328,3421,3731],"weight":9},{"source":495,"target":1212,"papers":[187],"weight":1},{"source":207,"target":1212,"papers":[187,793],"weight":2},{"source":1212,"target":1217,"papers":[187,684,793,1097,1102,1157,1356,1483,1566,1567,1883,2229,2263,2296,2406,2444,2448,2453,2460,2516,2518,2525,2530,3071,3178,3327],"weight":26},{"source":135,"target":1212,"papers":[187],"weight":1},{"source":1212,"target":1223,"papers":[187,3209,3731],"weight":3},{"source":495,"target":885,"papers":[187],"weight":1},{"source":207,"target":885,"papers":[187,793],"weight":2},{"source":885,"target":1217,"papers":[187,793],"weight":2},{"source":135,"target":885,"papers":[187],"weight":1},{"source":885,"target":1223,"papers":[187,3209,3731],"weight":3},{"source":207,"target":495,"papers":[187],"weight":1},{"source":495,"target":1217,"papers":[187],"weight":1},{"source":135,"target":495,"papers":[187,1233,1528,1602],"weight":4},{"source":495,"target":1223,"papers":[187,457,1128,1233,1464,1487,1528,1602,1867,3372],"weight":10},{"source":207,"target":1217,"papers":[187,793],"weight":2},{"source":135,"target":207,"papers":[187],"weight":1},{"source":207,"target":1223,"papers":[187],"weight":1},{"source":135,"target":1217,"papers":[187],"weight":1},{"source":1217,"target":1223,"papers":[187],"weight":1},{"source":135,"target":1223,"papers":[187,664,1233,1286,1293,1295,1449,1528,1602,1668,1719,1894,2300,2327,2374,2376,2410,2416,2427,2429,2431,2452,2503,2511,2536,2560,2565,2573,2575,2576,2578,2606,2608,2616,3023,3026,3108,3131,3269,3347],"weight":40},{"source":84,"target":847,"papers":[237,408],"weight":2},{"source":847,"target":1890,"papers":[325,793,808,1642,3244],"weight":5},{"source":1890,"target":1895,"papers":[325,808,1502,1642,3244],"weight":5},{"source":1101,"target":1890,"papers":[325,808,1502,1642],"weight":4},{"source":439,"target":1890,"papers":[325,808,1502,1642],"weight":4},{"source":933,"target":1890,"papers":[325,808,1502,1642],"weight":4},{"source":643,"target":1890,"papers":[325,808,1502,1642,3244],"weight":5},{"source":847,"target":1895,"papers":[325,808,1642,3244],"weight":4},{"source":847,"target":1101,"papers":[325,408,808,1642],"weight":4},{"source":439,"target":847,"papers":[325,808,1642],"weight":3},{"source":847,"target":933,"papers":[325,808,1642],"weight":3},{"source":643,"target":847,"papers":[325,808,1642,3244],"weight":4},{"source":1101,"target":1895,"papers":[325,808,1502,1642],"weight":4},{"source":439,"target":1895,"papers":[325,808,1502,1642],"weight":4},{"source":933,"target":1895,"papers":[325,808,1502,1642],"weight":4},{"source":643,"target":1895,"papers":[325,808,1502,1642,3244],"weight":5},{"source":439,"target":1101,"papers":[325,808,1502,1642],"weight":4},{"source":933,"target":1101,"papers":[325,808,1502,1642],"weight":4},{"source":643,"target":1101,"papers":[325,808,1502,1642],"weight":4},{"source":439,"target":933,"papers":[325,808,1502,1642],"weight":4},{"source":439,"target":643,"papers":[325,808,1502,1642],"weight":4},{"source":643,"target":933,"papers":[325,808,1502,1642],"weight":4},{"source":2171,"target":2174,"papers":[383,1372,1827,2128,2160,2179,2261,2303,2332,2347,2349,2375,2386,2402,2428,2438,2451,2467,2468,2485,2494,2498,2500,2507,2528,2534,2555,2566,2596,2601,2604,2611,2612],"weight":33},{"source":190,"target":2171,"papers":[383,968,1379],"weight":3},{"source":190,"target":2174,"papers":[383,793],"weight":2},{"source":969,"target":2446,"papers":[436,497,625,631,710,845,848,997,1111,1122,1135,1798,1802,2284,2331,3024,3106,3187,3230],"weight":19},{"source":847,"target":969,"papers":[436,497,560,571,625,631,710,845,848,878,997,1074,1111,1122,1135,1145,1148,1231,1390,1698,1798,1802,2165,2201,2284,3104,3730],"weight":27},{"source":847,"target":2446,"papers":[436,497,625,631,710,845,848,997,1111,1122,1135,1600,1651,1669,1798,1802,2284,2324,2425,2552,2557,3126,3268],"weight":23},{"source":84,"target":2874,"papers":[521],"weight":1},{"source":1101,"target":2874,"papers":[521],"weight":1},{"source":190,"target":2247,"papers":[560,793,968,2168,2413,2495],"weight":6},{"source":969,"target":2247,"papers":[560],"weight":1},{"source":847,"target":2247,"papers":[560,793],"weight":2},{"source":190,"target":969,"papers":[560,1407],"weight":2},{"source":190,"target":847,"papers":[560,793],"weight":2},{"source":844,"target":969,"papers":[571,625,631,664,1231,1602,1698,1798,2374,3106,3153,3230],"weight":12},{"source":844,"target":2446,"papers":[625,631,1600,1651,1669,1798,2425,3106,3126,3216,3230,3268],"weight":12},{"source":190,"target":1223,"papers":[635,1407],"weight":2},{"source":886,"target":2171,"papers":[641,1372,1379,1443,1851,1911,3359,3793],"weight":8},{"source":135,"target":969,"papers":[664,885,1148,1231,1233,1286,1293,1295,1390,1449,1602,1698,1719,1894,2165,2201,2374,2511,2573,2606,2608,3023,3026,3104,3153,3728,3730],"weight":27},{"source":969,"target":1223,"papers":[664,850,1233,1286,1293,1295,1407,1449,1602,1719,1867,1894,2149,2374,2511,2573,2606,2608,3023,3026],"weight":20},{"source":1890,"target":2247,"papers":[793],"weight":1},{"source":885,"target":2247,"papers":[793],"weight":1},{"source":2247,"target":2874,"papers":[793,1708,1804,1857],"weight":4},{"source":2174,"target":2247,"papers":[793],"weight":1},{"source":207,"target":2247,"papers":[793],"weight":1},{"source":886,"target":2247,"papers":[793],"weight":1},{"source":1212,"target":2247,"papers":[793],"weight":1},{"source":1217,"target":2247,"papers":[793],"weight":1},{"source":885,"target":1890,"papers":[793],"weight":1},{"source":1890,"target":2874,"papers":[793],"weight":1},{"source":1890,"target":2174,"papers":[793,1434],"weight":2},{"source":207,"target":1890,"papers":[793],"weight":1},{"source":886,"target":1890,"papers":[793],"weight":1},{"source":1212,"target":1890,"papers":[793],"weight":1},{"source":190,"target":1890,"papers":[793],"weight":1},{"source":1217,"target":1890,"papers":[793],"weight":1},{"source":847,"target":885,"papers":[793,3400],"weight":2},{"source":885,"target":2874,"papers":[793,1199,1827,1888,2160,2182],"weight":6},{"source":885,"target":2174,"papers":[793,1372,1827,2128,2160,2179,2347,2386,2438,2451,2498,2500,2528],"weight":13},{"source":190,"target":885,"papers":[793],"weight":1},{"source":847,"target":2874,"papers":[793,1390],"weight":2},{"source":847,"target":2174,"papers":[793],"weight":1},{"source":207,"target":847,"papers":[793],"weight":1},{"source":847,"target":886,"papers":[793,3730],"weight":2},{"source":847,"target":1212,"papers":[793,932,3188],"weight":3},{"source":847,"target":1217,"papers":[793],"weight":1},{"source":2174,"target":2874,"papers":[793,1827,2160,2303,2332,2349],"weight":6},{"source":207,"target":2874,"papers":[793],"weight":1},{"source":886,"target":2874,"papers":[793],"weight":1},{"source":1212,"target":2874,"papers":[793],"weight":1},{"source":190,"target":2874,"papers":[793],"weight":1},{"source":1217,"target":2874,"papers":[793],"weight":1},{"source":207,"target":2174,"papers":[793],"weight":1},{"source":886,"target":2174,"papers":[793,1372],"weight":2},{"source":1212,"target":2174,"papers":[793],"weight":1},{"source":1217,"target":2174,"papers":[793],"weight":1},{"source":207,"target":886,"papers":[793],"weight":1},{"source":190,"target":207,"papers":[793],"weight":1},{"source":886,"target":1212,"papers":[793],"weight":1},{"source":190,"target":886,"papers":[793,1379],"weight":2},{"source":886,"target":1217,"papers":[793],"weight":1},{"source":190,"target":1212,"papers":[793],"weight":1},{"source":190,"target":1217,"papers":[793],"weight":1},{"source":969,"target":1101,"papers":[816],"weight":1},{"source":2171,"target":2247,"papers":[968],"weight":1},{"source":495,"target":969,"papers":[997,1145,1233,1602,1798,1867,3106,3799],"weight":8},{"source":495,"target":2446,"papers":[997,1527,1651,1669,1798,3106],"weight":6},{"source":495,"target":847,"papers":[997,1046,1145,1651,1669,1798,3298],"weight":7},{"source":495,"target":2874,"papers":[1045],"weight":1},{"source":2171,"target":2874,"papers":[1045,1199,1390,1827,1888,2158,2160,2182,2303,2332,2349,2369],"weight":12},{"source":495,"target":2171,"papers":[1045],"weight":1},{"source":643,"target":2446,"papers":[1066],"weight":1},{"source":885,"target":2171,"papers":[1105,1199,1372,1447,1658,1794,1827,1833,1888,1911,2128,2160,2179,2182,2255,2298,2347,2386,2438,2442,2451,2464,2498,2500,2528,3398],"weight":26},{"source":135,"target":847,"papers":[1148,1231,1390,1698,2165,2201,3104,3730],"weight":8},{"source":207,"target":2446,"papers":[1257],"weight":1},{"source":969,"target":1212,"papers":[1263],"weight":1},{"source":886,"target":1895,"papers":[1379],"weight":1},{"source":190,"target":1895,"papers":[1379],"weight":1},{"source":1895,"target":2171,"papers":[1379],"weight":1},{"source":847,"target":2171,"papers":[1390,1916],"weight":2},{"source":135,"target":2874,"papers":[1390],"weight":1},{"source":969,"target":2874,"papers":[1390],"weight":1},{"source":135,"target":2171,"papers":[1390],"weight":1},{"source":969,"target":2171,"papers":[1390],"weight":1},{"source":644,"target":1890,"papers":[1642],"weight":1},{"source":644,"target":847,"papers":[1642],"weight":1},{"source":644,"target":1895,"papers":[1642],"weight":1},{"source":644,"target":1101,"papers":[1642],"weight":1},{"source":439,"target":644,"papers":[1642],"weight":1},{"source":644,"target":933,"papers":[1642],"weight":1},{"source":495,"target":2174,"papers":[1867],"weight":1},{"source":969,"target":2174,"papers":[1867],"weight":1},{"source":1223,"target":2174,"papers":[1867],"weight":1},{"source":644,"target":1223,"papers":[2427,2511],"weight":2},{"source":135,"target":644,"papers":[2427,2511],"weight":2},{"source":644,"target":969,"papers":[2511],"weight":1},{"source":1223,"target":2446,"papers":[2563,3216],"weight":2},{"source":886,"target":969,"papers":[3187,3730],"weight":2},{"source":886,"target":2446,"papers":[3187],"weight":1},{"source":135,"target":886,"papers":[3730],"weight":1}],"edge_encoding":"named fields","papers":[{"id":128,"title":"Effects of psychedelic use on authoritarian attitudes revisited.","authors":"Simonsson O, Lyons T, Marks J, Kettner H, Roseman L, Haijen E, Kaelen M, Carhart-Harris R","journal":"Journal of psychopharmacology (Oxford, England)","publication_date":"2026-05-01","publication_year":2026,"doi":"10.1177/02698811261443677","topic_tags":"Depression,Observational Study,Healthy Volunteers","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":237,"title":"The combination of exercise and psychedelics for the treatment of major depressive disorder.","authors":"Fabiano N, Stubbs B, Lawrence DW, Rosenblat JD, Teixeira PJ, Wong S, Zhou C, Carhart-Harris R","journal":"Discover mental health","publication_date":"2026-03-07","publication_year":2026,"doi":"10.1007/s44192-026-00408-5","topic_tags":"Depression,Neuroplasticity,Neurogenesis,Mechanism of Action,Receptor Pharmacology,Default Mode Network,Resilience,Emotional Processing,Psychological Flexibility,Safety,Inflammation","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":325,"title":"Corrigendum to \"The role of the psychedelic experience in psilocybin treatment for treatment-resistant depression\" [Journal of Affective Disorders, Volume 372 (2025), Pages 523-532].","authors":"Goodwin GM, Aaronson ST, Alvarez O, Carhart-Harris R, Chai-Rees J, Croal M, DeBattista C, Dunlop BW, Feifel D, Hellerstein DJ, Husain MI, Kelly JR, Kirlic N, Licht RW, Marwood L, Meyer TD, Mistry S, Nowakowska A, Páleníček T, Repantis D, Schoevers RA, Simmons H, Somers M, Teoh E, Tsai J, Wahba M, Williams S, Young AH, Young MB, Zisook S, Malievskaia E","journal":"Journal of affective disorders","publication_date":"2026-01-15","publication_year":2026,"doi":"10.1016/j.jad.2025.120352","topic_tags":"Depression,Treatment-Resistant Depression","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":408,"title":"Efficacy, all-cause discontinuation, and safety of serotonergic psychedelics and MDMA to treat mental disorders: A living systematic review with meta-analysis.","authors":"Højlund M, Kafali HY, Kırmızı B, Fusar-Poli P, Correll CU, Cortese S, Sabé M, Fiedorowicz J, Saraf G, Zein J, Berk M, Husain MI, Rosenblat JD, Rubaiyat R, Corace K, Wong S, Hatcher S, Kaluzienski M, Yatham LN, Cipriani A, Gosling CJ, Carhart-Harris R, Tanuseputro P, Myran DT, Fabiano N, Moher D, Mayo LM, Nicholls SG, White T, Prisco M, Radua J, Vieta E, Ladha KS, Katz J, Veroniki AA, Solmi M","journal":"European neuropsychopharmacology: the journal of the European College of Neuropsychopharmacology","publication_date":"2025-12-01","publication_year":2025,"doi":"10.1016/j.euroneuro.2025.09.011","topic_tags":"Depression,Anxiety,PTSD,Addiction,Clinical Trial,Randomized Controlled Trial,Meta-Analysis,Systematic Review,Review Article,Safety","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":413,"title":"Correction: Short- and long-term modulation of rat prefrontal cortical activity following single doses of psilocybin.","authors":"Purple RJ, Gupta R, Thomas CW, Golden CT, Palomero-Gallagher N, Carhart-Harris R, Froudist-Walsh S, Jones MW","journal":"Molecular psychiatry","publication_date":"2025-12-01","publication_year":2025,"doi":"10.1038/s41380-025-03231-6","topic_tags":"Animal Study","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":415,"title":"Short- and long-term modulation of rat prefrontal cortical activity following single doses of psilocybin.","authors":"Purple RJ, Gupta R, Thomas CW, Golden CT, Palomero-Gallagher N, Carhart-Harris R, Froudist-Walsh S, Jones MW","journal":"Molecular psychiatry","publication_date":"2025-12-01","publication_year":2025,"doi":"10.1038/s41380-025-03182-y","topic_tags":"Neuroplasticity,Brain Imaging,Biomarkers,Aging,Animal Study","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":436,"title":"Negative affective bias in depression following treatment with psilocybin or escitalopram - a secondary analysis from a randomized trial.","authors":"Martens MAG, Cunha BG, Erritzoe D, Nutt D, Carhart-Harris R, Harmer CJ","journal":"Translational psychiatry","publication_date":"2025-11-13","publication_year":2025,"doi":"10.1038/s41398-025-03693-w","topic_tags":"Depression,Mechanism of Action,Emotional Processing,Clinical Trial","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":497,"title":"Single-dose (10 mg) psilocybin reduces symptoms in adults with obsessive-compulsive disorder: A pharmacological challenge study.","authors":"Pellegrini L, Fineberg NA, O'Connor S, De Souza AMFLP, Godfrey K, Reed S, Peill J, Healy M, Rohani-Shukla C, Lee H, Carhart-Harris R, Robbins TW, Nutt D, Erritzoe D","journal":"Comprehensive psychiatry","publication_date":"2025-10-01","publication_year":2025,"doi":"10.1016/j.comppsych.2025.152619","topic_tags":"Depression,OCD,Mechanism of Action,Receptor Pharmacology,Clinical Trial,Healthcare Workers,Adverse Events","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":560,"title":"Psychedelic Therapy, Positive Emotional Experiences, and the Central Role of Self-Compassion.","authors":"Zeifman R, Danias G, Agin-Liebes G, Pagni B, Kettner H, Bhat V, Ross S, Erritzoe D, Carhart-Harris R","journal":"Research square","publication_date":"2025-08-22","publication_year":2025,"doi":"10.21203/rs.3.rs-7420529/v1","topic_tags":"Depression,Emotional Processing,Mystical Experience,Clinical Trial,Observational Study","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":571,"title":"Improved mental health outcomes and normalised spontaneous EEG activity in veterans reporting a history of traumatic brain injuries following participation in a psilocybin retreat.","authors":"Blest-Hopley G, Pasculli G, Ruffell SGD, Tsang W, Emmanuel O, Pate KM, Kettner H, Roseman L, Erritzoe D, Carhart-Harris R","journal":"Frontiers in psychiatry","publication_date":"2025-01-01","publication_year":2025,"doi":"10.3389/fpsyt.2025.1594307","topic_tags":"Depression,PTSD,Neuroplasticity,Brain Imaging,Wellbeing,Emotional Processing,Veterans","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":623,"title":"Exploring the Therapeutic Effects of Psychedelics Administered to Military Veterans in Naturalistic Retreat Settings.","authors":"Calnan M, Blest-Hopley G, Busch C, Adams M, Ruffell SGD, Piper T, Roseman L, Kettner H, Carhart-Harris R","journal":"Brain and behavior","publication_date":"2025-07-01","publication_year":2025,"doi":"10.1002/brb3.70660","topic_tags":"Depression,Anxiety,PTSD,Wellbeing,Veterans,Safety","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":625,"title":"Correction: Dissociable effects of psilocybin and escitalopram for depression on processing of musical surprises.","authors":"Harding R, Singer N, Wall MB, Hendler T, Erritzoe D, Nutt D, Carhart-Harris R, Roseman L","journal":"Molecular psychiatry","publication_date":"2025-07-01","publication_year":2025,"doi":"10.1038/s41380-025-03066-1","topic_tags":"Depression","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":631,"title":"Dissociable effects of psilocybin and escitalopram for depression on processing of musical surprises.","authors":"Harding R, Singer N, Wall MB, Hendler T, Erritzoe D, Nutt D, Carhart-Harris R, Roseman L","journal":"Molecular psychiatry","publication_date":"2025-07-01","publication_year":2025,"doi":"10.1038/s41380-025-03035-8","topic_tags":"Depression,Brain Imaging,Mechanism of Action,Receptor Pharmacology,Aging,Emotional Processing","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":710,"title":"Neuroplasticity and psychedelics: A comprehensive examination of classic and non-classic compounds in pre and clinical models.","authors":"Agnorelli C, Spriggs M, Godfrey K, Sawicka G, Bohl B, Douglass H, Fagiolini A, Parastoo H, Carhart-Harris R, Nutt D, Erritzoe D","journal":"Neuroscience and biobehavioral reviews","publication_date":"2025-05-01","publication_year":2025,"doi":"10.1016/j.neubiorev.2025.106132","topic_tags":"Neuroplasticity,Brain Imaging,Mechanism of Action,Biomarkers,Aging,Longevity,Review Article,Animal Study","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":712,"title":"Psilocybin for disorders of consciousness: A case-report study.","authors":"Cardone P, Núñez P, Alnagger NLN, Martial C, van der Lande GJM, Sandell R, Carhart-Harris R, Gosseries O","journal":"Clinical neurophysiology: official journal of the International Federation of Clinical Neurophysiology","publication_date":"2025-05-01","publication_year":2025,"doi":"10.1016/j.clinph.2025.02.264","topic_tags":"Brain Imaging,Mechanism of Action,Receptor Pharmacology,Consciousness,Clinical Trial,Case Report,Healthy Volunteers","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":793,"title":"A Field-Wide Review and Analysis of Study Materials Used in Psilocybin Trials: Assessment of Two Decades of Research.","authors":"Yaden DB, Graziosi M, Owen AM, Agin-Liebes G, Aaronson ST, Allen KE, Barrett FS, Bogenschutz MP, Carhart-Harris R, Ching THW, Cosimano MP, Danforth A, Davis AK, Garcia-Romeu A, Griffiths R, Grob CS, Gründer G, Gukasyan N, Heinzerling KG, Hendricks PS, Holze F, Horton DM, Johnson MW, Kelmendi B, Knatz Peck S, Koslowski M, Liechti ME, Mertens LJ, Moreno FA, Nayak SM, Nicholas CR, Preller KH, Rieser NM, Ross S, Sergi K, Sloshower J, Smigielski L, Stenbæk DS, Vollenweider FX, Weiss B, Wolff M, Yaden ME","journal":"Psychedelic medicine (New Rochelle, N.Y.)","publication_date":"2025-03-01","publication_year":2025,"doi":"10.1089/psymed.2024.0019","topic_tags":"Receptor Pharmacology,Consciousness,Wellbeing,Review Article,Safety,Adverse Events,Contraindications","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":808,"title":"The role of the psychedelic experience in psilocybin treatment for treatment-resistant depression.","authors":"Goodwin GM, Aaronson ST, Alvarez O, Carhart-Harris R, Chai-Rees J, Croal M, DeBattista C, Dunlop BW, Feifel D, Hellerstein DJ, Husain MI, Kelly JR, Kirlic N, Licht RW, Marwood L, Meyer TD, Mistry S, Nowakowska A, Páleníček T, Repantis D, Schoevers RA, Simmons H, Somers M, Teoh E, Tsai J, Wahba M, Williams S, Young AH, Young MB, Zisook S, Malievskaia E","journal":"Journal of affective disorders","publication_date":"2025-03-01","publication_year":2025,"doi":"10.1016/j.jad.2024.12.061","topic_tags":"Depression,Pharmacology,Mechanism of Action,Consciousness,Emotional Processing,Treatment-Resistant Depression,Safety","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":840,"title":"Examining differences in the effects and contexts of naturalistic psilocybin use for White participants vs. Participants of Color: A longitudinal online survey study.","authors":"Jones G, Lowe MX, Nayak S, Sepeda N, Kettner H, Carhart-Harris R, Jackson H, Garcia-Romeu A","journal":"Journal of affective disorders","publication_date":"2025-02-01","publication_year":2025,"doi":"10.1016/j.jad.2024.10.058","topic_tags":"Depression,Anxiety,Biomarkers,Wellbeing,Emotional Processing,Spirituality,Observational Study","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":845,"title":"Correction: Study Protocol for 'PsilOCD: A Pharmacological Challenge Study Evaluating the Effects of the 5-HT2A Agonist Psilocybin on the Neurocognitive and Clinical Correlates of Compulsivity'.","authors":"O'Connor S, Godfrey K, Reed S, Peill J, Rohani-Shukla C, Healy M, Robbins T, Frota Lisboa Pereira de Souza A, Tyacke R, Papasyrou M, Stenbæk D, Castro-Rodrigues P, Chiera M, Lee H, Martell J, Carhart-Harris R, Pellegrini L, Fineberg NA, Nutt D, Erritzoe D","journal":"Cureus","publication_date":"2025-01-01","publication_year":2025,"doi":"10.7759/cureus.c209","topic_tags":"OCD,Receptor Pharmacology","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":848,"title":"Study Protocol for 'PsilOCD: A Pharmacological Challenge Study Evaluating the Effects of the 5-HT2A Agonist Psilocybin on the Neurocognitive and Clinical Correlates of Compulsivity'.","authors":"O'Connor S, Godfrey K, Reed S, Peill J, Rohani-Shukla C, Healy M, Robbins T, Frota Lisboa Pereira de Souza A, Tyacke R, Papasyrou M, Stenbæk D, Castro-Rodrigues P, Chiera M, Lee H, Martell J, Carhart-Harris R, Pellegrini L, Fineberg NA, Nutt D, Erritzoe D","journal":"Cureus","publication_date":"2025-01-01","publication_year":2025,"doi":"10.7759/cureus.78171","topic_tags":"OCD,Neuroplasticity,Brain Imaging,Mechanism of Action,Receptor Pharmacology,Wellbeing,Emotional Processing,Randomized Controlled Trial","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":878,"title":"An investigation of acute physiological and psychological moderators of psychedelic-induced personality change among healthy volunteers.","authors":"Godfrey K, Weiss B, Zhang X, Spriggs M, Peill J, Lyons T, Carhart-Harris R, Erritzoe D","journal":"Neuroscience applied","publication_date":"2025-01-01","publication_year":2025,"doi":"10.1016/j.nsa.2024.104092","topic_tags":"Consciousness,Personality Change,Healthy Volunteers","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":932,"title":"Synergistic, multi-level understanding of psychedelics: three systematic reviews and meta-analyses of their pharmacology, neuroimaging and phenomenology.","authors":"Shinozuka K, Jerotic K, Mediano P, Zhao AT, Preller KH, Carhart-Harris R, Kringelbach ML","journal":"Translational psychiatry","publication_date":"2024-12-04","publication_year":2024,"doi":"10.1038/s41398-024-03187-1","topic_tags":"Depression,Addiction,Brain Imaging,Pharmacology,Receptor Pharmacology,Consciousness,Aging,Systematic Review,Review Article,Safety","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":970,"title":"Preliminary Evidence of Sleep Improvements Following Psilocybin Administration, and their Involvement in Antidepressant Therapeutic Action.","authors":"Reid MJ, Kettner H, Blanken TF, Weiss B, Carhart-Harris R","journal":"Current psychiatry reports","publication_date":"2024-11-01","publication_year":2024,"doi":"10.1007/s11920-024-01539-8","topic_tags":"Depression,Mechanism of Action,Clinical Trial,Drug Interactions","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":997,"title":"Effect of psilocybin versus escitalopram on depression symptom severity in patients with moderate-to-severe major depressive disorder: observational 6-month follow-up of a phase 2, double-blind, randomised, controlled trial.","authors":"Erritzoe D, Barba T, Greenway KT, Murphy R, Martell J, Giribaldi B, Timmermann C, Murphy-Beiner A, Jones MB, Nutt D, Weiss B, Carhart-Harris R","journal":"EClinicalMedicine","publication_date":"2024-10-01","publication_year":2024,"doi":"10.1016/j.eclinm.2024.102799","topic_tags":"Depression,Receptor Pharmacology,Clinical Trial,Observational Study,Safety,Contraindications","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1046,"title":"Within-subject comparison of near-death and psychedelic experiences: acute and enduring effects.","authors":"Martial C, Carhart-Harris R, Timmermann C","journal":"Neuroscience of consciousness","publication_date":"2024-01-01","publication_year":2024,"doi":"10.1093/nc/niae033","topic_tags":"Consciousness,Mystical Experience,Observational Study","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1058,"title":"Psilocybin desynchronizes the human brain.","authors":"Siegel JS, Subramanian S, Perry D, Kay BP, Gordon EM, Laumann TO, Reneau TR, Metcalf NV, Chacko RV, Gratton C, Horan C, Krimmel SR, Shimony JS, Schweiger JA, Wong DF, Bender DA, Scheidter KM, Whiting FI, Padawer-Curry JA, Shinohara RT, Chen Y, Moser J, Yacoub E, Nelson SM, Vizioli L, Fair DA, Lenze EJ, Carhart-Harris R, Raison CL, Raichle ME, Snyder AZ, Nicol GE, Dosenbach NUF","journal":"Nature","publication_date":"2024-08-01","publication_year":2024,"doi":"10.1038/s41586-024-07624-5","topic_tags":"Neuroplasticity,Brain Imaging,Default Mode Network,Aging,Clinical Trial,Animal Study","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1074,"title":"Longitudinal experiences of Canadians receiving compassionate access to psilocybin-assisted psychotherapy.","authors":"de la Salle S, Kettner H, Thibault Lévesque J, Garel N, Dames S, Patchett-Marble R, Rej S, Gloeckler S, Erritzoe D, Carhart-Harris R, Greenway KT","journal":"Scientific reports","publication_date":"2024-07-17","publication_year":2024,"doi":"10.1038/s41598-024-66817-0","topic_tags":"Depression,Anxiety,End-of-Life Distress,Chronic Pain,Mechanism of Action,Wellbeing,Spirituality,Clinical Trial,Observational Study","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1111,"title":"Study protocol for \"Psilocybin in patients with fibromyalgia: brain biomarkers of action\".","authors":"Bornemann J, Close JB, Ahmad K, Barba T, Godfrey K, Macdonald L, Erritzoe D, Nutt D, Carhart-Harris R","journal":"Frontiers in psychiatry","publication_date":"2024-01-01","publication_year":2024,"doi":"10.3389/fpsyt.2024.1320780","topic_tags":"Chronic Pain,Neuroplasticity,Brain Imaging,Mechanism of Action,Biomarkers,Aging,Randomized Controlled Trial,Observational Study","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1122,"title":"Assessing expectancy and suggestibility in a trial of escitalopram v. psilocybin for depression.","authors":"Szigeti B, Weiss B, Rosas FE, Erritzoe D, Nutt D, Carhart-Harris R","journal":"Psychological medicine","publication_date":"2024-06-01","publication_year":2024,"doi":"10.1017/s0033291723003653","topic_tags":"Depression,Clinical Trial","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1135,"title":"Predicting the outcome of psilocybin treatment for depression from baseline fMRI functional connectivity.","authors":"Copa D, Erritzoe D, Giribaldi B, Nutt D, Carhart-Harris R, Tagliazucchi E","journal":"Journal of affective disorders","publication_date":"2024-05-15","publication_year":2024,"doi":"10.1016/j.jad.2024.02.089","topic_tags":"Depression,Brain Imaging,Aging,Treatment-Resistant Depression","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1145,"title":"Psychedelics and the 'inner healer': Myth or mechanism?","authors":"Peill J, Marguilho M, Erritzoe D, Barba T, Greenway KT, Rosas F, Timmermann C, Carhart-Harris R","journal":"Journal of psychopharmacology (Oxford, England)","publication_date":"2024-05-01","publication_year":2024,"doi":"10.1177/02698811241239206","topic_tags":"Depression,Mechanism of Action,Randomized Controlled Trial","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1148,"title":"Effects of discontinuation of serotonergic antidepressants prior to psilocybin therapy versus escitalopram for major depression.","authors":"Erritzoe D, Barba T, Spriggs MJ, Rosas FE, Nutt DJ, Carhart-Harris R","journal":"Journal of psychopharmacology (Oxford, England)","publication_date":"2024-05-01","publication_year":2024,"doi":"10.1177/02698811241237870","topic_tags":"Depression,Receptor Pharmacology,Wellbeing,Clinical Trial,Safety,Drug Interactions","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1231,"title":"Psychedelics and sexual functioning: a mixed-methods study.","authors":"Barba T, Kettner H, Radu C, Peill JM, Roseman L, Nutt DJ, Erritzoe D, Carhart-Harris R, Giribaldi B","journal":"Scientific reports","publication_date":"2024-02-07","publication_year":2024,"doi":"10.1038/s41598-023-49817-4","topic_tags":"Depression,Receptor Pharmacology,Wellbeing,Clinical Trial,Adverse Events","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1390,"title":"Assessing the risk of symptom worsening in psilocybin-assisted therapy for depression: A systematic review and individual participant data meta-analysis.","authors":"Simonsson O, Carlbring P, Carhart-Harris R, Davis AK, Nutt DJ, Griffiths RR, Erritzoe D, Goldberg SB","journal":"Psychiatry research","publication_date":"2023-09-01","publication_year":2023,"doi":"10.1016/j.psychres.2023.115349","topic_tags":"Depression,Meta-Analysis,Systematic Review,Review Article,Safety","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1600,"title":"Changes in music-evoked emotion and ventral striatal functional connectivity after psilocybin therapy for depression.","authors":"Shukuroglou M, Roseman L, Wall M, Nutt D, Kaelen M, Carhart-Harris R","journal":"Journal of psychopharmacology (Oxford, England)","publication_date":"2023-01-01","publication_year":2023,"doi":"10.1177/02698811221125354","topic_tags":"Depression,Brain Imaging,Mechanism of Action,Default Mode Network,Aging,Emotional Processing,Treatment-Resistant Depression","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1642,"title":"Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression.","authors":"Goodwin GM, Aaronson ST, Alvarez O, Arden PC, Baker A, Bennett JC, Bird C, Blom RE, Brennan C, Brusch D, Burke L, Campbell-Coker K, Carhart-Harris R, Cattell J, Daniel A, DeBattista C, Dunlop BW, Eisen K, Feifel D, Forbes M, Haumann HM, Hellerstein DJ, Hoppe AI, Husain MI, Jelen LA, Kamphuis J, Kawasaki J, Kelly JR, Key RE, Kishon R, Knatz Peck S, Knight G, Koolen MHB, Lean M, Licht RW, Maples-Keller JL, Mars J, Marwood L, McElhiney MC, Miller TL, Mirow A, Mistry S, Mletzko-Crowe T, Modlin LN, Nielsen RE, Nielson EM, Offerhaus SR, O'Keane V, Páleníček T, Printz D, Rademaker MC, van Reemst A, Reinholdt F, Repantis D, Rucker J, Rudow S, Ruffell S, Rush AJ, Schoevers RA, Seynaeve M, Shao S, Soares JC, Somers M, Stansfield SC, Sterling D, Strockis A, Tsai J, Visser L, Wahba M, Williams S, Young AH, Ywema P, Zisook S, Malievskaia E","journal":"The New England journal of medicine","publication_date":"2022-11-03","publication_year":2022,"doi":"10.1056/nejmoa2206443","topic_tags":"Depression,Clinical Trial,Treatment-Resistant Depression,Safety","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1651,"title":"The Watts Connectedness Scale: a new scale for measuring a sense of connectedness to self, others, and world.","authors":"Watts R, Kettner H, Geerts D, Gandy S, Kartner L, Mertens L, Timmermann C, Nour MM, Kaelen M, Nutt D, Carhart-Harris R, Roseman L","journal":"Psychopharmacology","publication_date":"2022-11-01","publication_year":2022,"doi":"10.1007/s00213-022-06187-5","topic_tags":"Depression,Emotional Processing,Clinical Trial,Randomized Controlled Trial,Observational Study","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1669,"title":"Effects of classic psychedelic drugs on turbulent signatures in brain dynamics.","authors":"Cruzat J, Perl YS, Escrichs A, Vohryzek J, Timmermann C, Roseman L, Luppi AI, Ibañez A, Nutt D, Carhart-Harris R, Tagliazucchi E, Deco G, Kringelbach ML","journal":"Network neuroscience (Cambridge, Mass.)","publication_date":"2022-01-01","publication_year":2022,"doi":"10.1162/netn_a_00250","topic_tags":"Mechanism of Action,Default Mode Network","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1698,"title":"Effects of psilocybin versus escitalopram on rumination and thought suppression in depression.","authors":"Barba T, Buehler S, Kettner H, Radu C, Cunha BG, Nutt DJ, Erritzoe D, Roseman L, Carhart-Harris R","journal":"BJPsych open","publication_date":"2022-09-06","publication_year":2022,"doi":"10.1192/bjo.2022.565","topic_tags":"Depression,Mechanism of Action,Receptor Pharmacology,Clinical Trial,Randomized Controlled Trial,Drug Interactions","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1727,"title":"Serotonergic psychedelic drugs LSD and psilocybin reduce the hierarchical differentiation of unimodal and transmodal cortex.","authors":"Girn M, Roseman L, Bernhardt B, Smallwood J, Carhart-Harris R, Nathan Spreng R","journal":"NeuroImage","publication_date":"2022-08-01","publication_year":2022,"doi":"10.1016/j.neuroimage.2022.119220","topic_tags":"Brain Imaging,Aging","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1798,"title":"Increased global integration in the brain after psilocybin therapy for depression.","authors":"Daws RE, Timmermann C, Giribaldi B, Sexton JD, Wall MB, Erritzoe D, Roseman L, Nutt D, Carhart-Harris R","journal":"Nature medicine","publication_date":"2022-04-01","publication_year":2022,"doi":"10.1038/s41591-022-01744-z","topic_tags":"Depression,Brain Imaging,Receptor Pharmacology,Aging,Clinical Trial,Randomized Controlled Trial,Treatment-Resistant Depression","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1802,"title":"Therapeutic Alliance and Rapport Modulate Responses to Psilocybin Assisted Therapy for Depression.","authors":"Murphy R, Kettner H, Zeifman R, Giribaldi B, Kartner L, Martell J, Read T, Murphy-Beiner A, Baker-Jones M, Nutt D, Erritzoe D, Watts R, Carhart-Harris R","journal":"Frontiers in pharmacology","publication_date":"2021-01-01","publication_year":2021,"doi":"10.3389/fphar.2021.788155","topic_tags":"Depression,Emotional Processing,Mystical Experience,Randomized Controlled Trial","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1916,"title":"Trends in the Top-Cited Articles on Classic Psychedelics.","authors":"Lawrence DW, Sharma B, Griffiths RR, Carhart-Harris R","journal":"Journal of psychoactive drugs","publication_date":"2021-01-01","publication_year":2021,"doi":"10.1080/02791072.2021.1874573","topic_tags":"Addiction,Observational Study,Animal Study","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2142,"title":"Does Psychedelic Therapy Have a Transdiagnostic Action and Prophylactic Potential?","authors":"Kočárová R, Horáček J, Carhart-Harris R","journal":"Frontiers in psychiatry","publication_date":"2021-01-01","publication_year":2021,"doi":"10.3389/fpsyt.2021.661233","topic_tags":"Neuroplasticity,Biomarkers,Wellbeing,Resilience,Psychological Flexibility","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2153,"title":"Association Between Lifetime Classic Psychedelic Use and Hypertension in the Past Year.","authors":"Simonsson O, Hendricks PS, Carhart-Harris R, Kettner H, Osika W","journal":"Hypertension (Dallas, Tex.: 1979)","publication_date":"2021-05-05","publication_year":2021,"doi":"10.1161/hypertensionaha.120.16715","topic_tags":"General","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2165,"title":"Trial of Psilocybin versus Escitalopram for Depression.","authors":"Carhart-Harris R, Giribaldi B, Watts R, Baker-Jones M, Murphy-Beiner A, Murphy R, Martell J, Blemings A, Erritzoe D, Nutt DJ","journal":"The New England journal of medicine","publication_date":"2021-04-15","publication_year":2021,"doi":"10.1056/nejmoa2032994","topic_tags":"Depression,Receptor Pharmacology,Clinical Trial,Adverse Events","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2201,"title":"Therapeutic effects of classic serotonergic psychedelics: A systematic review of modern-era clinical studies.","authors":"Andersen KAA, Carhart-Harris R, Nutt DJ, Erritzoe D","journal":"Acta psychiatrica Scandinavica","publication_date":"2021-02-01","publication_year":2021,"doi":"10.1111/acps.13249","topic_tags":"Depression,Anxiety,Addiction,OCD,Systematic Review,Review Article,Safety,Adverse Events","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2281,"title":"Dynamic coupling of whole-brain neuronal and neurotransmitter systems.","authors":"Kringelbach ML, Cruzat J, Cabral J, Knudsen GM, Carhart-Harris R, Whybrow PC, Logothetis NK, Deco G","journal":"Proceedings of the National Academy of Sciences of the United States of America","publication_date":"2020-04-28","publication_year":2020,"doi":"10.1073/pnas.1921475117","topic_tags":"Depression,Anxiety,Addiction,Brain Imaging,Receptor Pharmacology,Aging","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2284,"title":"Psychedelic Psychiatry's Brave New World.","authors":"Nutt D, Erritzoe D, Carhart-Harris R","journal":"Cell","publication_date":"2020-04-02","publication_year":2020,"doi":"10.1016/j.cell.2020.03.020","topic_tags":"Depression,Addiction,Receptor Pharmacology","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2324,"title":"Spectral signatures of serotonergic psychedelics and glutamatergic dissociatives.","authors":"Pallavicini C, Vilas MG, Villarreal M, Zamberlan F, Muthukumaraswamy S, Nutt D, Carhart-Harris R, Tagliazucchi E","journal":"NeuroImage","publication_date":"2019-10-15","publication_year":2019,"doi":"10.1016/j.neuroimage.2019.06.053","topic_tags":"Mechanism of Action,Receptor Pharmacology,Consciousness","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2425,"title":"The hidden therapist: evidence for a central role of music in psychedelic therapy.","authors":"Kaelen M, Giribaldi B, Raine J, Evans L, Timmerman C, Rodriguez N, Roseman L, Feilding A, Nutt D, Carhart-Harris R","journal":"Psychopharmacology","publication_date":"2018-02-01","publication_year":2018,"doi":"10.1007/s00213-017-4820-5","topic_tags":"Depression,Addiction,Emotional Processing,Mystical Experience,Treatment-Resistant Depression,Safety","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2552,"title":"Homological scaffolds of brain functional networks.","authors":"Petri G, Expert P, Turkheimer F, Carhart-Harris R, Nutt D, Hellyer PJ, Vaccarino F","journal":"Journal of the Royal Society, Interface","publication_date":"2014-12-06","publication_year":2014,"doi":"10.1098/rsif.2014.0873","topic_tags":"Brain Imaging,Aging,Healthy Volunteers","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2557,"title":"Enhanced repertoire of brain dynamical states during the psychedelic experience.","authors":"Tagliazucchi E, Carhart-Harris R, Leech R, Nutt D, Chialvo DR","journal":"Human brain mapping","publication_date":"2014-11-01","publication_year":2014,"doi":"10.1002/hbm.22562","topic_tags":"Brain Imaging,Consciousness,Aging","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":3104,"title":"The effects of psilocybin therapy versus escitalopram on cognitive bias: A secondary analysis of a randomized controlled trial","authors":"Henry J, Giribaldi B, Nutt DJ, Erritzoe D, Carhart-Harris R, Lyons T.","journal":"medRxiv","publication_date":"2025-03-21","publication_year":2025,"doi":"10.1101/2025.03.17.25324123","topic_tags":"Depression,Randomized Controlled Trial","source_name":"medRxiv","publication_status":"preprint","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":3116,"title":"Revealing Changes in Linear and Nonlinear Functional Connectivity After Psilocybin and Escitalopram Treatment in Patients with Depression","authors":"Quah S, Glick C, Roseman L, Pasquini L, Carhart-Harris R, Saggar M.","journal":"bioRxiv","publication_date":"2025-03-10","publication_year":2025,"doi":"10.1101/2025.03.05.641592","topic_tags":"Depression,Brain Imaging,Mechanism of Action,Default Mode Network,Drug Interactions","source_name":"bioRxiv","publication_status":"preprint","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":3126,"title":"Brain dynamics predictive of response to psilocybin for treatment-resistant depression","authors":"Vohryzek J, Cabral J, Lord L, Fernandes H, Roseman L, Nutt D, Carhart-Harris R, Deco G, Kringelbach M.","journal":"Research Square","publication_date":"2022-09-20","publication_year":2022,"doi":"10.21203/rs.3.rs-2060381/v1","topic_tags":"Depression,Mechanism of Action,Receptor Pharmacology,Treatment-Resistant Depression","source_name":"Europe PMC","publication_status":"preprint","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":3188,"title":"Synergistic, Multi-level Understanding of Psychedelics: Three Systematic Reviews and Meta-analyses of Their Pharmacology, Neuroimaging and Phenomenology","authors":"Shinozuka K, Jerotic K, Mediano P, Zhao AT, Preller KH, Carhart-Harris R, Kringelbach ML.","journal":"bioRxiv","publication_date":"2023-10-07","publication_year":2023,"doi":"10.1101/2023.10.06.561183","topic_tags":"Depression,Addiction,Brain Imaging,Pharmacology,Receptor Pharmacology,Consciousness,Aging,Systematic Review,Review Article,Safety","source_name":"bioRxiv","publication_status":"preprint","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":3201,"title":"Perturbing whole-brain models of brain hierarchy: an application for depression following pharmacological treatment","authors":"Socoró Garrigosa M, Sanz Perl Y, Kringelbach ML, Carhart-Harris R, Vohryzek J, Deco G.","journal":"bioRxiv","publication_date":"2025-01-02","publication_year":2025,"doi":"10.1101/2025.01.01.631011","topic_tags":"Depression,Neuroplasticity,Clinical Trial","source_name":"bioRxiv","publication_status":"preprint","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":3244,"title":"Psilocybin Therapy for Treatment Resistant Depression: Prediction of Clinical Outcome by Natural Language Processing","authors":"Dougherty RF, Clarke P, Alti M, Kuc J, Schlosser D, Dunlop BW, Hellerstein DJ, Aaronson ST, Zisook S, Young AH, Carhart-Harris R, Goodwin G, Ryslik GA.","journal":"PsyArXiv","publication_date":"2022-09-30","publication_year":2022,"doi":"10.31234/osf.io/kh3cx","topic_tags":"Depression,Mechanism of Action,Emotional Processing,Clinical Trial,Safety","source_name":"PsyArXiv","publication_status":"preprint","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":3268,"title":"A virtual clinical trial of psychedelics to treat patients with disorders of consciousness","authors":"Alnagger NL, Cardone P, Martial C, Sanz Perl Y, Mindlin I, Sitt JD, Roseman L, Carhart-Harris R, Nutt D, Mallaroni P, Mason NL, Ramaekers JG, Bonhomme V, Laureys S, Deco G, Gosseries O, Nunez P, Annen J.","journal":"bioRxiv","publication_date":"2024-08-19","publication_year":2024,"doi":"10.1101/2024.08.16.608251","topic_tags":"Brain Imaging,Consciousness,Aging,Clinical Trial","source_name":"bioRxiv","publication_status":"preprint","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":3298,"title":"Brain dynamics of classical psychedelics show paradoxical hierarchical flattening with increased complexity","authors":"Vohryzek J, Garcia Guzman E, Kringelbach ML, Lopez-Sola E, Timmermann C, Roseman L, Tagliazucchi E, Ruffini G, Carhart-Harris R, Deco G, Sanz Perl Y.","journal":"bioRxiv","publication_date":"2024-12-22","publication_year":2024,"doi":"10.1101/2024.12.21.629922","topic_tags":"Consciousness,Drug Interactions","source_name":"bioRxiv","publication_status":"preprint","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":3303,"title":"Serotonergic psychedelic drugs LSD and psilocybin reduce the hierarchical differentiation of unimodal and transmodal cortex","authors":"Girn M, Roseman L, Bernhardt B, Smallwood J, Carhart-Harris R, Spreng RN.","journal":"bioRxiv","publication_date":"2020-05-03","publication_year":2020,"doi":"10.1101/2020.05.01.072314","topic_tags":"Brain Imaging,Aging","source_name":"bioRxiv","publication_status":"preprint","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":3315,"title":"Serotonergic Psychedelics LSD & Psilocybin Increase the Fractal Dimension of Cortical Brain Activity in Spatial and Temporal Domains","authors":"Varley T, Carhart-Harris R, Roseman L, Menon DK, Stamatakis E.","journal":"bioRxiv","publication_date":"2019-01-11","publication_year":2019,"doi":"10.1101/517847","topic_tags":"Brain Imaging,Consciousness","source_name":"bioRxiv","publication_status":"preprint","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":3400,"title":"Psychedelic resting-state neuroimaging: a review and perspective on balancing replication and novel analyses","authors":"McCulloch DE, Knudsen GM, Barrett FS, Doss M, Deco G, Carhart-Harris R, Rosas F, Preller K, Ramaekers J, Mason N, Müller F, Fisher PM.","journal":"PsyArXiv","publication_date":"2021-06-10","publication_year":2021,"doi":"10.31234/osf.io/64kyg","topic_tags":"Brain Imaging,Mechanism of Action,Biomarkers,Aging,Clinical Trial,Review Article","source_name":"PsyArXiv","publication_status":"preprint","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":3730,"title":"A Bayesian Reanalysis of a Trial of Psilocybin versus Escitalopram for Depression.","authors":"Nayak SM, Bari BA, Yaden DB, Spriggs MJ, Rosas FE, Peill JM, Giribaldi B, Erritzoe D, Nutt DJ, Carhart-Harris R","journal":"Psychedelic medicine (New Rochelle, N.Y.)","publication_date":"2023-03-01","publication_year":2023,"doi":"10.1089/psymed.2022.0002","topic_tags":"Depression","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":3770,"title":"A critique of: Skepticism About Recent Evidence that Psilocybin Opens Depressed Minds","authors":"Carhart-Harris R, Daws RE, Nutt D.","journal":"PsyArXiv","publication_date":"2022-05-10","publication_year":2022,"doi":"10.31234/osf.io/pdbf5","topic_tags":"General","source_name":"PsyArXiv","publication_status":"preprint","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":3775,"title":"Blunted psychedelic drug effects in older adults","authors":"Aday JS, Carhart-Harris R, Boehnke KF.","journal":"PsyArXiv","publication_date":"2025-09-04","publication_year":2025,"doi":"10.31234/osf.io/yz4cd_v2","topic_tags":"Aging,Longevity,Older Adults,Safety","source_name":"PsyArXiv","publication_status":"preprint","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":171,"title":"Blinding Integrity in Psychedelic Randomized Clinical Trials: A Systematic Review.","authors":"Orsini DK, Wong S, Di Luch S, Chan B, Vasudeva S, Lovell GFM, Le GH, Jones BDM, Chisamore N, Mollica A, Johnson DE, Kaczmarek ES, Goel A, Burke MJ, Mansur R, McIntyre RS, Husain MI, Rosenblat JD","journal":"JAMA psychiatry","publication_date":"2026-07-01","publication_year":2026,"doi":"10.1001/jamapsychiatry.2026.0255","topic_tags":"Clinical Trial,Randomized Controlled Trial,Systematic Review,Review Article","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":188,"title":"Psychedelic Therapies for Comorbid Major Depressive Disorder and Chronic Pain: A Review of Putative Mechanisms of Action.","authors":"Kazdan J, Ladha KS, Husain MI","journal":"Pharmacology research & perspectives","publication_date":"2026-04-01","publication_year":2026,"doi":"10.1002/prp2.70238","topic_tags":"Depression,Chronic Pain,Mechanism of Action,Receptor Pharmacology,Clinical Trial,Review Article,Inflammation","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":203,"title":"Preferences, Perceptions, and Environmental Considerations of Natural and Synthetic Psychedelic Substances: Findings from the Global Psychedelic Survey.","authors":"Syed OA, Petranker R, Fewster EC, Sobolenko V, Beidas Z, Husain MI, Lake S, Lucas P","journal":"Journal of psychoactive drugs","publication_date":"2026-01-01","publication_year":2026,"doi":"10.1080/02791072.2024.2446445","topic_tags":"Observational Study","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":255,"title":"Adverse events associated with classic psychedelics and MDMA: a real-world population-based study using the WHO pharmacovigilance database (VigiBase).","authors":"Syed OA, Nestor SM, Husain MI, Sinyor M, Alam F, Giacobbe P","journal":"Psychiatry research","publication_date":"2026-03-01","publication_year":2026,"doi":"10.1016/j.psychres.2025.116929","topic_tags":"Addiction,Safety,Adverse Events","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":354,"title":"Psilocybin in late-life mental health: Addressing depression, loneliness, and existential anxiety.","authors":"Konstantinou GN, Rosenblat J, Hales S, Husain MI, Blumberger DM","journal":"General hospital psychiatry","publication_date":"2026-01-01","publication_year":2026,"doi":"10.1016/j.genhosppsych.2025.12.005","topic_tags":"Depression,Anxiety,Neuroplasticity,Pharmacology,Mechanism of Action,Default Mode Network,Aging,Clinical Trial,Review Article,Safety,Drug Interactions","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":369,"title":"Global Trends in Psychedelic Microdosing: Demographics, Substance Testing Behavior, and Patterns of Use.","authors":"Syed OA, Petranker R, Fewster EC, Sobolenko V, Beidas Z, Husain MI, Lake S, Lucas P","journal":"Journal of psychoactive drugs","publication_date":"2026-01-01","publication_year":2026,"doi":"10.1080/02791072.2024.2424284","topic_tags":"Microdosing,Wellbeing,Observational Study","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":391,"title":"Adverse event reporting and management in psilocybin therapy clinical trials: A systematic review to guide clinical and research protocol development.","authors":"Bukovsky D, Amaev A, Song J, Kyte S, Carmona-Torres E, Ueno F, Deluca V, Strafella AP, Husain MI, Graff-Guerrero A, Gerretsen P","journal":"Progress in neuro-psychopharmacology & biological psychiatry","publication_date":"2025-12-20","publication_year":2025,"doi":"10.1016/j.pnpbp.2025.111541","topic_tags":"Depression,Anxiety,Addiction,Headache / Migraine,Clinical Trial,Systematic Review,Review Article,Safety,Adverse Events","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":394,"title":"Psilocybin-assisted psychotherapy for treatment-resistant obsessive-compulsive disorder: protocol for an open-label pilot study.","authors":"Ledwos N, Baer J, Husain MI, Blumberger DM, Patterson R, Hollingdrake E, Cheung E, Hawco C, Zrenner C, Zrenner B, Feusner JD, Rossell SL, Castle DJ, Zai G","journal":"BJPsych open","publication_date":"2025-12-15","publication_year":2025,"doi":"10.1192/bjo.2025.10895","topic_tags":"OCD,Brain Imaging,Mechanism of Action,Receptor Pharmacology,Biomarkers,Aging,Clinical Trial,Randomized Controlled Trial,Safety","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":395,"title":"Mapping psilocybin therapy: A systematic review of therapeutic frameworks, adaptations, and standardization across contemporary clinical trials.","authors":"Kittur ME, Burgos M LA, Jones BDM, Blumberger DM, Mulsant BH, Rosenblat JD, Husain MI","journal":"Journal of affective disorders","publication_date":"2025-12-15","publication_year":2025,"doi":"10.1016/j.jad.2025.119952","topic_tags":"Depression,Addiction,OCD,Eating Disorders,Mechanism of Action,Clinical Trial,Systematic Review,Review Article,Treatment-Resistant Depression","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":473,"title":"Biological markers of treatment response to serotonergic psychedelic therapies: a systematic review.","authors":"Wong S, Jones BDM, Thiyagarajah MT, Sabbah SG, Thompson C, Solmi M, Umer M, Zrenner C, Voineskos D, Rosenblat JD, Mulsant BH, Blumberger DM, Husain MI","journal":"Therapeutic advances in psychopharmacology","publication_date":"2025-01-01","publication_year":2025,"doi":"10.1177/20451253251384513","topic_tags":"Depression,Brain Imaging,Mechanism of Action,Biomarkers,Aging,Clinical Trial,Systematic Review,Review Article,Treatment-Resistant Depression","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":521,"title":"Effect of psilocybin therapy on suicidal ideation, attempts, and deaths in people with psychiatric diagnoses: a systematic review and meta-analysis.","authors":"Wong S, Meckling G, Fabiano N, Lee S, Jones BDM, Shorr R, Dargel A, Davis AK, Fiedorowicz JG, Solmi M, Rosenblat JD, Mulsant BH, Blumberger DM, Husain MI","journal":"Therapeutic advances in psychopharmacology","publication_date":"2025-01-01","publication_year":2025,"doi":"10.1177/20451253251372449","topic_tags":"Depression,Randomized Controlled Trial,Meta-Analysis,Systematic Review,Review Article,Treatment-Resistant Depression,Safety","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":629,"title":"Non-hallucinogenic psychedelics for mood and anxiety disorders: A systematic review.","authors":"Chen MJQ, Chen-Li D, Chisamore N, Husain MI, Di Vincenzo JD, Mansur RB, Phan L, Johnson D, McIntyre RS, Rosenblat JD","journal":"Psychiatry research","publication_date":"2025-07-01","publication_year":2025,"doi":"10.1016/j.psychres.2025.116532","topic_tags":"Depression,Anxiety,Consciousness,Clinical Trial,Systematic Review,Review Article,Case Report","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":767,"title":"Pharmacokinetics of Psilocybin: A Systematic Review.","authors":"Meshkat S, Al-Shamali H, Perivolaris A, Tullu T, Zeifman RJ, Zhang Y, Burback L, Winkler O, Greenshaw A, Husain MI, C Reichelt A, Vermetten E, Jha MK, Jetly R, Loebenberg R, Bhat V","journal":"Pharmaceutics","publication_date":"2025-03-25","publication_year":2025,"doi":"10.3390/pharmaceutics17040411","topic_tags":"Pharmacology,Systematic Review,Review Article,Animal Study,In Vitro Study,Drug Interactions","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":816,"title":"Psychedelics and Suicide-Related Outcomes: A Systematic Review.","authors":"Meshkat S, Malik T, Zeifman R, Swainson J, Zhang Y, Burback L, Winkler O, Greenshaw AJ, Claire Reichelt A, Vermetten E, Erritzoe D, Jha MK, Dunn W, Jetly R, Husain MI, Bhat V","journal":"Journal of clinical medicine","publication_date":"2025-02-20","publication_year":2025,"doi":"10.3390/jcm14051416","topic_tags":"PTSD,Mechanism of Action,Randomized Controlled Trial,Systematic Review,Review Article,Safety","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":961,"title":"Prospective Preference Assessment for the Psilocybin for Enhanced Analgesia in Chronic nEuropathic PAIN (PEACE-PAIN) Trial.","authors":"Lee J, Philip K, Wijeysundera DN, Clarke H, Pritlove C, Katz J, Ritvo P, Goel A, Husain MI, Ladha KS","journal":"Canadian journal of pain = Revue canadienne de la douleur","publication_date":"2024-01-01","publication_year":2024,"doi":"10.1080/24740527.2024.2406285","topic_tags":"Chronic Pain,Aging,Randomized Controlled Trial,Observational Study,Safety,Adverse Events","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1042,"title":"Beyond Psilocybin: Reviewing the Therapeutic Potential of Other Serotonergic Psychedelics in Mental and Substance Use Disorders.","authors":"Wong S, Yu AY, Fabiano N, Finkelstein O, Pasricha A, Jones BDM, Rosenblat JD, Blumberger DM, Mulsant BH, Husain MI","journal":"Journal of psychoactive drugs","publication_date":"2024-01-01","publication_year":2024,"doi":"10.1080/02791072.2023.2251133","topic_tags":"Anxiety,Addiction,Review Article,Safety,Adverse Events","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1080,"title":"Engaging Mood Brain Circuits with Psilocybin (EMBRACE): a study protocol for a randomized, placebo-controlled and delayed-start, neuroimaging trial in depression.","authors":"Poulin JM, Bigford GE, Lanctôt KL, Giacobbe P, Schaffer A, Sinyor M, Rabin JS, Masellis M, Singnurkar A, Pople CB, Lipsman N, Husain MI, Rosenblat JD, Cao X, MacIntosh BJ, Nestor SM","journal":"Trials","publication_date":"2024-07-03","publication_year":2024,"doi":"10.1186/s13063-024-08268-6","topic_tags":"Depression,Neuroplasticity,Brain Imaging,Mechanism of Action,Biomarkers,Aging,Randomized Controlled Trial,Inflammation","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1342,"title":"Psilocybin-assisted therapy for depression: A systematic review and meta-analysis.","authors":"Haikazian S, Chen-Li DCJ, Johnson DE, Fancy F, Levinta A, Husain MI, Mansur RB, McIntyre RS, Rosenblat JD","journal":"Psychiatry research","publication_date":"2023-11-01","publication_year":2023,"doi":"10.1016/j.psychres.2023.115531","topic_tags":"Depression,End-of-Life Distress,Clinical Trial,Meta-Analysis,Systematic Review,Review Article","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1427,"title":"Psilocybin for treatment-resistant depression without psychedelic effects: study protocol for a 4-week, double-blind, proof-of-concept randomised controlled trial.","authors":"Husain MI, Blumberger DM, Castle DJ, Ledwos N, Fellows E, Jones BDM, Ortiz A, Kloiber S, Wang W, Rosenblat JD, Mulsant BH","journal":"BJPsych open","publication_date":"2023-07-25","publication_year":2023,"doi":"10.1192/bjo.2023.535","topic_tags":"Depression,Receptor Pharmacology,Consciousness,Randomized Controlled Trial,Animal Study,Treatment-Resistant Depression,Safety,Adverse Events","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1495,"title":"Antidepressant Effects of Psilocybin in the Absence of Psychedelic Effects.","authors":"Rosenblat JD, Leon-Carlyle M, Ali S, Husain MI, McIntyre RS","journal":"The American journal of psychiatry","publication_date":"2023-05-01","publication_year":2023,"doi":"10.1176/appi.ajp.20220835","topic_tags":"Depression,Pharmacology,Receptor Pharmacology","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1502,"title":"Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life.","authors":"Goodwin GM, Aaronson ST, Alvarez O, Atli M, Bennett JC, Croal M, DeBattista C, Dunlop BW, Feifel D, Hellerstein DJ, Husain MI, Kelly JR, Lennard-Jones MR, Licht RW, Marwood L, Mistry S, Páleníček T, Redjep O, Repantis D, Schoevers RA, Septimus B, Simmons HJ, Soares JC, Somers M, Stansfield SC, Stuart JR, Tadley HH, Thiara NK, Tsai J, Wahba M, Williams S, Winzer RI, Young AH, Young MB, Zisook S, Malievskaia E","journal":"Journal of affective disorders","publication_date":"2023-04-14","publication_year":2023,"doi":"10.1016/j.jad.2023.01.108","topic_tags":"Depression,Anxiety,End-of-Life Distress,Clinical Trial,Randomized Controlled Trial,Treatment-Resistant Depression","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1561,"title":"Serotonergic psychedelics for depression: What do we know about neurobiological mechanisms of action?","authors":"Husain MI, Ledwos N, Fellows E, Baer J, Rosenblat JD, Blumberger DM, Mulsant BH, Castle DJ","journal":"Frontiers in psychiatry","publication_date":"2022-01-01","publication_year":2022,"doi":"10.3389/fpsyt.2022.1076459","topic_tags":"Depression,Brain Imaging,Mechanism of Action,Receptor Pharmacology,Default Mode Network,Aging,Review Article","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1608,"title":"The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Report: Serotonergic Psychedelic Treatments for Major Depressive Disorder.","authors":"Rosenblat JD, Husain MI, Lee Y, McIntyre RS, Mansur RB, Castle D, Offman H, Parikh SV, Frey BN, Schaffer A, Greenway KT, Garel N, Beaulieu S, Kennedy SH, Lam RW, Milev R, Ravindran AV, Tourjman V, Ameringen MV, Yatham LN, Taylor V","journal":"Canadian journal of psychiatry. Revue canadienne de psychiatrie","publication_date":"2023-01-01","publication_year":2023,"doi":"10.1177/07067437221111371","topic_tags":"Depression,Anxiety,Headache / Migraine,Clinical Trial,Randomized Controlled Trial,Systematic Review,Review Article,Cancer Patients,Treatment-Resistant Depression,Safety,Adverse Events","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1649,"title":"A Critical Appraisal of Evidence on the Efficacy and Safety of Serotonergic Psychedelic Drugs as Emerging Antidepressants: Mind the Evidence Gap.","authors":"Ledwos N, Rosenblat JD, Blumberger DM, Castle DJ, McIntyre RS, Mulsant BH, Husain MI","journal":"Journal of clinical psychopharmacology","publication_date":"2022-01-01","publication_year":2022,"doi":"10.1097/jcp.0000000000001608","topic_tags":"Depression,End-of-Life Distress,Clinical Trial,Randomized Controlled Trial,Review Article,Treatment-Resistant Depression,Safety,Adverse Events","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1762,"title":"Can the revival of serotonergic psychedelic drugs as treatments for mental disorders help to characterize their risks and benefits?","authors":"Husain MI, Umer M, Mulsant BH","journal":"Expert opinion on drug safety","publication_date":"2022-06-01","publication_year":2022,"doi":"10.1080/14740338.2022.2063274","topic_tags":"Depression,PTSD,Addiction,Safety","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":187,"title":"An international mega-analysis of psychedelic drug effects on brain circuit function.","authors":"Girn M, Doss MK, Roseman L, Preller KH, Palhano-Fontes F, Pasquini L, Barrett FS, Mallaroni P, Mason NL, Timmermann C, McCulloch DE, Fisher PM, Winston BS, Moujaes F, Muller F, Liechti ME, Vollenweider FX, Ramaekers JG, Kuypers K, Araujo DB, Sporns O, Siegel J, Dosenbach N, Nutt DJ, Carhart-Harris RL, Stamatakis EA, Bzdok D","journal":"Nature medicine","publication_date":"2026-04-01","publication_year":2026,"doi":"10.1038/s41591-026-04287-9","topic_tags":"Brain Imaging,Mechanism of Action,Aging","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":457,"title":"N,N-dimethyltryptamine effects on connectome harmonics, subjective experience and comparative psychedelic experiences.","authors":"Vohryzek J, Luppi AI, Atasoy S, Deco G, Carhart-Harris RL, Timmermann C, Kringelbach ML","journal":"Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology","publication_date":"2025-11-01","publication_year":2025,"doi":"10.1038/s41386-025-02190-4","topic_tags":"Mechanism of Action,Consciousness","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":635,"title":"Exploring serotonergic psychedelics as a treatment for personality disorders.","authors":"Carrithers BM, Roberts DE, Weiss BM, King JD, Carhart-Harris RL, Gordon AR, Pagni BA, Moreau M, Ross S, Zeifman RJ","journal":"Neuropharmacology","publication_date":"2025-07-01","publication_year":2025,"doi":"10.1016/j.neuropharm.2025.110413","topic_tags":"Pharmacology,Mechanism of Action,Personality Change,Review Article,Observational Study,Safety","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":664,"title":"Enhanced meaning in life following psychedelic use: converging evidence from controlled and naturalistic studies.","authors":"Roseby W, Kettner H, Roseman L, Spriggs MJ, Lyons T, Peill J, Giribaldi B, Erritzoe D, Nutt DJ, Carhart-Harris RL","journal":"Frontiers in psychology","publication_date":"2025-01-01","publication_year":2025,"doi":"10.3389/fpsyg.2025.1580663","topic_tags":"Depression,Mechanism of Action,Wellbeing,Emotional Processing,Mystical Experience,Clinical Trial,Observational Study,Healthy Volunteers","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":824,"title":"A qualitative analysis of the psychedelic mushroom come-up and come-down.","authors":"Brouwer A, Brown JK, Erowid E, Erowid F, Thyssen S, Raison CL, Carhart-Harris RL","journal":"Npj mental health research","publication_date":"2025-02-07","publication_year":2025,"doi":"10.1038/s44184-024-00095-6","topic_tags":"Consciousness,Clinical Trial","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":850,"title":"From relaxed beliefs under psychedelics (REBUS) to revised beliefs after psychedelics (REBAS).","authors":"Zeifman RJ, Spriggs MJ, Kettner H, Lyons T, Rosas FE, Mediano PAM, Erritzoe D, Carhart-Harris RL","journal":"Scientific reports","publication_date":"2025-01-29","publication_year":2025,"doi":"10.1038/s41598-023-28111-3","topic_tags":"Brain Imaging,Wellbeing","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":889,"title":"Human neuroimaging: fMRI.","authors":"Wall MB, Carhart-Harris RL","journal":"International review of neurobiology","publication_date":"2025-01-01","publication_year":2025,"doi":"10.1016/bs.irn.2025.04.013","topic_tags":"Brain Imaging,Pharmacology,Aging,Emotional Processing,Observational Study","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1128,"title":"Time-resolved coupling between connectome harmonics and subjective experience under the psychedelic DMT.","authors":"Vohryzek J, Luppi AI, Atasoy S, Deco G, Carhart-Harris RL, Timmermann C, Kringelbach ML","journal":"bioRxiv: the preprint server for biology","publication_date":"2024-05-30","publication_year":2024,"doi":"10.1101/2024.05.30.596410","topic_tags":"Brain Imaging,Mechanism of Action,Consciousness","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1233,"title":"Effects of DMT on mental health outcomes in healthy volunteers.","authors":"Timmermann C, Zeifman RJ, Erritzoe D, Nutt DJ, Carhart-Harris RL","journal":"Scientific reports","publication_date":"2024-02-07","publication_year":2024,"doi":"10.1038/s41598-024-53363-y","topic_tags":"Depression,Anxiety,Receptor Pharmacology,Wellbeing,Personality Change,Observational Study,Healthy Volunteers","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1286,"title":"Psilocybin and Other Classic Psychedelics in Depression.","authors":"Nutt DJ, Peill JM, Weiss B, Godfrey K, Carhart-Harris RL, Erritzoe D","journal":"Current topics in behavioral neurosciences","publication_date":"2024-01-01","publication_year":2024,"doi":"10.1007/7854_2023_451","topic_tags":"Depression,Brain Imaging,Mechanism of Action,Receptor Pharmacology,Aging,Emotional Processing,Mystical Experience","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1293,"title":"Personality Change in a Trial of Psilocybin Therapy vs Escitalopram Treatment for Depression - CORRIGENDUM.","authors":"Weiss B, Ginige I, Shannon L, Giribaldi B, Murphy-Beiner A, Murphy R, Baker-Jones M, Martell J, Nutt DJ, Carhart-Harris RL, Erritzoe D","journal":"Psychological medicine","publication_date":"2024-01-01","publication_year":2024,"doi":"10.1017/s0033291723002039","topic_tags":"Depression,Personality Change","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1295,"title":"Personality change in a trial of psilocybin therapy v. escitalopram treatment for depression.","authors":"Weiss B, Ginige I, Shannon L, Giribaldi B, Murphy-Beiner A, Murphy R, Baker-Jones M, Martell J, Nutt DJ, Carhart-Harris RL, Erritzoe D","journal":"Psychological medicine","publication_date":"2024-01-01","publication_year":2024,"doi":"10.1017/s0033291723001514","topic_tags":"Depression,Personality Change,Clinical Trial","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1407,"title":"Co-use of MDMA with psilocybin/LSD may buffer against challenging experiences and enhance positive experiences.","authors":"Zeifman RJ, Kettner H, Pagni BA, Mallard A, Roberts DE, Erritzoe D, Ross S, Carhart-Harris RL","journal":"Scientific reports","publication_date":"2023-08-22","publication_year":2023,"doi":"10.1038/s41598-023-40856-5","topic_tags":"Mystical Experience,Safety","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1422,"title":"How does psilocybin therapy work? An exploration of experiential avoidance as a putative mechanism of change.","authors":"Zeifman RJ, Wagner AC, Monson CM, Carhart-Harris RL","journal":"Journal of affective disorders","publication_date":"2023-08-01","publication_year":2023,"doi":"10.1016/j.jad.2023.04.105","topic_tags":"Depression,Anxiety,Wellbeing,Randomized Controlled Trial","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1449,"title":"A critical evaluation of QIDS-SR-16 using data from a trial of psilocybin therapy versus escitalopram treatment for depression.","authors":"Weiss B, Erritzoe D, Giribaldi B, Nutt DJ, Carhart-Harris RL","journal":"Journal of psychopharmacology (Oxford, England)","publication_date":"2023-07-01","publication_year":2023,"doi":"10.1177/02698811231167848","topic_tags":"Depression,Clinical Trial,Healthcare Workers","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1464,"title":"In vivo mapping of pharmacologically induced functional reorganization onto the human brain's neurotransmitter landscape.","authors":"Luppi AI, Hansen JY, Adapa R, Carhart-Harris RL, Roseman L, Timmermann C, Golkowski D, Ranft A, Ilg R, Jordan D, Bonhomme V, Vanhaudenhuyse A, Demertzi A, Jaquet O, Bahri MA, Alnagger NLN, Cardone P, Peattie ARD, Manktelow AE, de Araujo DB, Sensi SL, Owen AM, Naci L, Menon DK, Misic B, Stamatakis EA","journal":"Science advances","publication_date":"2023-06-16","publication_year":2023,"doi":"10.1126/sciadv.adf8332","topic_tags":"Brain Imaging,Pharmacology,Receptor Pharmacology,Aging","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1487,"title":"Time-resolved network control analysis links reduced control energy under DMT with the serotonin 2a receptor, signal diversity, and subjective experience.","authors":"Singleton SP, Timmermann C, Luppi AI, Eckernäs E, Roseman L, Carhart-Harris RL, Kuceyeski A","journal":"bioRxiv: the preprint server for biology","publication_date":"2023-05-12","publication_year":2023,"doi":"10.1101/2023.05.11.540409","topic_tags":"Brain Imaging,Pharmacology,Receptor Pharmacology,Consciousness","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1528,"title":"Canalization and plasticity in psychopathology.","authors":"Carhart-Harris RL, Chandaria S, Erritzoe DE, Gazzaley A, Girn M, Kettner H, Mediano PAM, Nutt DJ, Rosas FE, Roseman L, Timmermann C, Weiss B, Zeifman RJ, Friston KJ","journal":"Neuropharmacology","publication_date":"2023-03-15","publication_year":2023,"doi":"10.1016/j.neuropharm.2022.109398","topic_tags":"Neuroplasticity,Mechanism of Action","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1594,"title":"Among psychedelic-experienced users, only past use of psilocybin reliably predicts nature relatedness.","authors":"Forstmann M, Kettner HS, Sagioglou C, Irvine A, Gandy S, Carhart-Harris RL, Luke D","journal":"Journal of psychopharmacology (Oxford, England)","publication_date":"2023-01-01","publication_year":2023,"doi":"10.1177/02698811221146356","topic_tags":"Addiction,Pharmacology","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1602,"title":"Body mass index (BMI) does not predict responses to psilocybin.","authors":"Spriggs MJ, Giribaldi B, Lyons T, Rosas FE, Kärtner LS, Buchborn T, Douglass HM, Roseman L, Timmermann C, Erritzoe D, Nutt DJ, Carhart-Harris RL","journal":"Journal of psychopharmacology (Oxford, England)","publication_date":"2023-01-01","publication_year":2023,"doi":"10.1177/02698811221131994","topic_tags":"Receptor Pharmacology,Wellbeing,Emotional Processing,Mystical Experience","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1668,"title":"Receptor-informed network control theory links LSD and psilocybin to a flattening of the brain's control energy landscape.","authors":"Singleton SP, Luppi AI, Carhart-Harris RL, Cruzat J, Roseman L, Nutt DJ, Deco G, Kringelbach ML, Stamatakis EA, Kuceyeski A","journal":"Nature communications","publication_date":"2022-10-03","publication_year":2022,"doi":"10.1038/s41467-022-33578-1","topic_tags":"Brain Imaging,Receptor Pharmacology,Aging","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1719,"title":"Antidepressant effects of a psychedelic experience in a large prospective naturalistic sample.","authors":"Nygart VA, Pommerencke LM, Haijen E, Kettner H, Kaelen M, Mortensen EL, Nutt DJ, Carhart-Harris RL, Erritzoe D","journal":"Journal of psychopharmacology (Oxford, England)","publication_date":"2022-08-01","publication_year":2022,"doi":"10.1177/02698811221101061","topic_tags":"Depression,Anxiety,Emotional Processing,Mystical Experience,Observational Study","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1867,"title":"Psychedelics and health behaviour change.","authors":"Teixeira PJ, Johnson MW, Timmermann C, Watts R, Erritzoe D, Douglass H, Kettner H, Carhart-Harris RL","journal":"Journal of psychopharmacology (Oxford, England)","publication_date":"2022-01-01","publication_year":2022,"doi":"10.1177/02698811211008554","topic_tags":"Depression,Anxiety,Addiction,Eating Disorders,Mechanism of Action,Receptor Pharmacology,Wellbeing,Safety,Toxicity","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1894,"title":"Study Protocol for \"Psilocybin as a Treatment for Anorexia Nervosa: A Pilot Study\".","authors":"Spriggs MJ, Douglass HM, Park RJ, Read T, Danby JL, de Magalhães FJC, Alderton KL, Williams TM, Blemings A, Lafrance A, Nicholls DE, Erritzoe D, Nutt DJ, Carhart-Harris RL","journal":"Frontiers in psychiatry","publication_date":"2021-01-01","publication_year":2021,"doi":"10.3389/fpsyt.2021.735523","topic_tags":"Eating Disorders,End-of-Life Distress,Neuroplasticity,Brain Imaging,Mechanism of Action,Biomarkers,Aging,Clinical Trial,Randomized Controlled Trial","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2149,"title":"Sustained, Multifaceted Improvements in Mental Well-Being Following Psychedelic Experiences in a Prospective Opportunity Sample.","authors":"Mans K, Kettner H, Erritzoe D, Haijen ECHM, Kaelen M, Carhart-Harris RL","journal":"Frontiers in psychiatry","publication_date":"2021-01-01","publication_year":2021,"doi":"10.3389/fpsyt.2021.647909","topic_tags":"Wellbeing,Spirituality,Observational Study","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2300,"title":"Therapeutic mechanisms of psilocybin: Changes in amygdala and prefrontal functional connectivity during emotional processing after psilocybin for treatment-resistant depression.","authors":"Mertens LJ, Wall MB, Roseman L, Demetriou L, Nutt DJ, Carhart-Harris RL","journal":"Journal of psychopharmacology (Oxford, England)","publication_date":"2020-02-01","publication_year":2020,"doi":"10.1177/0269881119895520","topic_tags":"Depression,Brain Imaging,Mechanism of Action,Aging,Emotional Processing,Treatment-Resistant Depression,Drug Interactions","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2321,"title":"Replication and extension of a model predicting response to psilocybin.","authors":"Russ SL, Carhart-Harris RL, Maruyama G, Elliott MS","journal":"Psychopharmacology","publication_date":"2019-11-01","publication_year":2019,"doi":"10.1007/s00213-019-05279-z","topic_tags":"Depression,Anxiety,Wellbeing,Mystical Experience","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2327,"title":"Dynamical exploration of the repertoire of brain networks at rest is modulated by psilocybin.","authors":"Lord LD, Expert P, Atasoy S, Roseman L, Rapuano K, Lambiotte R, Nutt DJ, Deco G, Carhart-Harris RL, Kringelbach ML, Cabral J","journal":"NeuroImage","publication_date":"2019-10-01","publication_year":2019,"doi":"10.1016/j.neuroimage.2019.05.060","topic_tags":"Brain Imaging,Pharmacology,Aging","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2338,"title":"REBUS and the Anarchic Brain: Toward a Unified Model of the Brain Action of Psychedelics.","authors":"Carhart-Harris RL, Friston KJ","journal":"Pharmacological reviews","publication_date":"2019-07-01","publication_year":2019,"doi":"10.1124/pr.118.017160","topic_tags":"Mechanism of Action,Consciousness,Clinical Trial","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2350,"title":"Psychedelics as a treatment for disorders of consciousness.","authors":"Scott G, Carhart-Harris RL","journal":"Neuroscience of consciousness","publication_date":"2019-01-01","publication_year":2019,"doi":"10.1093/nc/niz003","topic_tags":"Consciousness","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2374,"title":"Effects of psilocybin therapy on personality structure.","authors":"Erritzoe D, Roseman L, Nour MM, MacLean K, Kaelen M, Nutt DJ, Carhart-Harris RL","journal":"Acta psychiatrica Scandinavica","publication_date":"2018-11-01","publication_year":2018,"doi":"10.1111/acps.12904","topic_tags":"Depression,Mechanism of Action,Consciousness,Personality Change,Treatment-Resistant Depression","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2376,"title":"Increased amygdala responses to emotional faces after psilocybin for treatment-resistant depression.","authors":"Roseman L, Demetriou L, Wall MB, Nutt DJ, Carhart-Harris RL","journal":"Neuropharmacology","publication_date":"2018-11-01","publication_year":2018,"doi":"10.1016/j.neuropharm.2017.12.041","topic_tags":"Depression,Brain Imaging,Emotional Processing,Randomized Controlled Trial,Treatment-Resistant Depression","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2385,"title":"More Realistic Forecasting of Future Life Events After Psilocybin for Treatment-Resistant Depression.","authors":"Lyons T, Carhart-Harris RL","journal":"Frontiers in psychology","publication_date":"2018-01-01","publication_year":2018,"doi":"10.3389/fpsyg.2018.01721","topic_tags":"Depression,Personality Change,Treatment-Resistant Depression","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2388,"title":"Psychedelics, Meditation, and Self-Consciousness.","authors":"Millière R, Carhart-Harris RL, Roseman L, Trautwein FM, Berkovich-Ohana A","journal":"Frontiers in psychology","publication_date":"2018-01-01","publication_year":2018,"doi":"10.3389/fpsyg.2018.01475","topic_tags":"Receptor Pharmacology,Consciousness","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2405,"title":"Increased nature relatedness and decreased authoritarian political views after psilocybin for treatment-resistant depression.","authors":"Lyons T, Carhart-Harris RL","journal":"Journal of psychopharmacology (Oxford, England)","publication_date":"2018-07-01","publication_year":2018,"doi":"10.1177/0269881117748902","topic_tags":"Depression,Personality Change,Treatment-Resistant Depression","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2410,"title":"Psilocybin and MDMA reduce costly punishment in the Ultimatum Game.","authors":"Gabay AS, Carhart-Harris RL, Mazibuko N, Kempton MJ, Morrison PD, Nutt DJ, Mehta MA","journal":"Scientific reports","publication_date":"2018-05-29","publication_year":2018,"doi":"10.1038/s41598-018-26656-2","topic_tags":"Pharmacology,Mechanism of Action,Healthy Volunteers,Drug Interactions","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2416,"title":"Natural speech algorithm applied to baseline interview data can predict which patients will respond to psilocybin for treatment-resistant depression.","authors":"Carrillo F, Sigman M, Fernández Slezak D, Ashton P, Fitzgerald L, Stroud J, Nutt DJ, Carhart-Harris RL","journal":"Journal of affective disorders","publication_date":"2018-04-01","publication_year":2018,"doi":"10.1016/j.jad.2018.01.006","topic_tags":"Depression,Treatment-Resistant Depression","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2427,"title":"Psilocybin with psychological support for treatment-resistant depression: six-month follow-up.","authors":"Carhart-Harris RL, Bolstridge M, Day CMJ, Rucker J, Watts R, Erritzoe DE, Kaelen M, Giribaldi B, Bloomfield M, Pilling S, Rickard JA, Forbes B, Feilding A, Taylor D, Curran HV, Nutt DJ","journal":"Psychopharmacology","publication_date":"2018-02-01","publication_year":2018,"doi":"10.1007/s00213-017-4771-x","topic_tags":"Depression,Receptor Pharmacology,Clinical Trial,Observational Study,Treatment-Resistant Depression,Safety","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2429,"title":"Psilocybin with psychological support improves emotional face recognition in treatment-resistant depression.","authors":"Stroud JB, Freeman TP, Leech R, Hindocha C, Lawn W, Nutt DJ, Curran HV, Carhart-Harris RL","journal":"Psychopharmacology","publication_date":"2018-02-01","publication_year":2018,"doi":"10.1007/s00213-017-4754-y","topic_tags":"Depression,Emotional Processing,Treatment-Resistant Depression,Drug Interactions","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2431,"title":"Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression.","authors":"Roseman L, Nutt DJ, Carhart-Harris RL","journal":"Frontiers in pharmacology","publication_date":"2017-01-01","publication_year":2017,"doi":"10.3389/fphar.2017.00974","topic_tags":"Depression,Anxiety,Receptor Pharmacology,Consciousness,Mystical Experience,Clinical Trial,Randomized Controlled Trial,Treatment-Resistant Depression,Drug Interactions","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2432,"title":"Common neural signatures of psychedelics: Frequency-specific energy changes and repertoire expansion revealed using connectome-harmonic decomposition.","authors":"Atasoy S, Vohryzek J, Deco G, Carhart-Harris RL, Kringelbach ML","journal":"Progress in brain research","publication_date":"2018-01-01","publication_year":2018,"doi":"10.1016/bs.pbr.2018.08.009","topic_tags":"General","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2452,"title":"Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms.","authors":"Carhart-Harris RL, Roseman L, Bolstridge M, Demetriou L, Pannekoek JN, Wall MB, Tanner M, Kaelen M, McGonigle J, Murphy K, Leech R, Curran HV, Nutt DJ","journal":"Scientific reports","publication_date":"2017-10-13","publication_year":2017,"doi":"10.1038/s41598-017-13282-7","topic_tags":"Depression,Brain Imaging,Mechanism of Action,Receptor Pharmacology,Default Mode Network,Aging,Treatment-Resistant Depression","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2456,"title":"The Therapeutic Potential of Psychedelic Drugs: Past, Present, and Future.","authors":"Carhart-Harris RL, Goodwin GM","journal":"Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology","publication_date":"2017-10-01","publication_year":2017,"doi":"10.1038/npp.2017.84","topic_tags":"Depression,Brain Imaging,Aging,Clinical Trial","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2472,"title":"Increased spontaneous MEG signal diversity for psychoactive doses of ketamine, LSD and psilocybin.","authors":"Schartner MM, Carhart-Harris RL, Barrett AB, Seth AK, Muthukumaraswamy SD","journal":"Scientific reports","publication_date":"2017-04-19","publication_year":2017,"doi":"10.1038/srep46421","topic_tags":"Consciousness","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2503,"title":"Question-based Drug Development for psilocybin - Authors' reply.","authors":"Carhart-Harris RL, Nutt DJ","journal":"The lancet. Psychiatry","publication_date":"2016-09-01","publication_year":2016,"doi":"10.1016/s2215-0366(16)30217-6","topic_tags":"General","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2511,"title":"Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study.","authors":"Carhart-Harris RL, Bolstridge M, Rucker J, Day CM, Erritzoe D, Kaelen M, Bloomfield M, Rickard JA, Forbes B, Feilding A, Taylor D, Pilling S, Curran VH, Nutt DJ","journal":"The lancet. Psychiatry","publication_date":"2016-07-01","publication_year":2016,"doi":"10.1016/s2215-0366(16)30065-7","topic_tags":"Depression,Anxiety,Addiction,OCD,End-of-Life Distress,Headache / Migraine,Receptor Pharmacology,Randomized Controlled Trial,Treatment-Resistant Depression,Safety,Adverse Events","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2536,"title":"Finding the self by losing the self: Neural correlates of ego-dissolution under psilocybin.","authors":"Lebedev AV, Lövdén M, Rosenthal G, Feilding A, Nutt DJ, Carhart-Harris RL","journal":"Human brain mapping","publication_date":"2015-08-01","publication_year":2015,"doi":"10.1002/hbm.22833","topic_tags":"Brain Imaging,Consciousness","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2547,"title":"Drug models of schizophrenia.","authors":"Steeds H, Carhart-Harris RL, Stone JM","journal":"Therapeutic advances in psychopharmacology","publication_date":"2015-02-01","publication_year":2015,"doi":"10.1177/2045125314557797","topic_tags":"Addiction,Review Article,Drug Interactions","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2560,"title":"The effects of psilocybin and MDMA on between-network resting state functional connectivity in healthy volunteers.","authors":"Roseman L, Leech R, Feilding A, Nutt DJ, Carhart-Harris RL","journal":"Frontiers in human neuroscience","publication_date":"2014-01-01","publication_year":2014,"doi":"10.3389/fnhum.2014.00204","topic_tags":"Mechanism of Action,Receptor Pharmacology,Consciousness,Healthy Volunteers","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2563,"title":"The entropic brain: a theory of conscious states informed by neuroimaging research with psychedelic drugs.","authors":"Carhart-Harris RL, Leech R, Hellyer PJ, Shanahan M, Feilding A, Tagliazucchi E, Chialvo DR, Nutt D","journal":"Frontiers in human neuroscience","publication_date":"2014-01-01","publication_year":2014,"doi":"10.3389/fnhum.2014.00020","topic_tags":"Brain Imaging,Receptor Pharmacology,Default Mode Network,Consciousness,Aging","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2565,"title":"A qualitative report on the subjective experience of intravenous psilocybin administered in an FMRI environment.","authors":"Turton S, Nutt DJ, Carhart-Harris RL","journal":"Current drug abuse reviews","publication_date":"2014-01-01","publication_year":2014,"doi":"10.2174/1874473708666150107120930","topic_tags":"Brain Imaging,Aging,Spirituality,Mystical Experience","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2573,"title":"Functional connectivity measures after psilocybin inform a novel hypothesis of early psychosis.","authors":"Carhart-Harris RL, Leech R, Erritzoe D, Williams TM, Stone JM, Evans J, Sharp DJ, Feilding A, Wise RG, Nutt DJ","journal":"Schizophrenia bulletin","publication_date":"2013-11-01","publication_year":2013,"doi":"10.1093/schbul/sbs117","topic_tags":"Brain Imaging,Receptor Pharmacology,Default Mode Network,Consciousness,Aging,Healthy Volunteers,Safety","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2575,"title":"Broadband cortical desynchronization underlies the human psychedelic state.","authors":"Muthukumaraswamy SD, Carhart-Harris RL, Moran RJ, Brookes MJ, Williams TM, Errtizoe D, Sessa B, Papadopoulos A, Bolstridge M, Singh KD, Feilding A, Friston KJ, Nutt DJ","journal":"The Journal of neuroscience: the official journal of the Society for Neuroscience","publication_date":"2013-09-18","publication_year":2013,"doi":"10.1523/jneurosci.2063-13.2013","topic_tags":"Mechanism of Action,Receptor Pharmacology,Consciousness","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2576,"title":"Experienced drug users assess the relative harms and benefits of drugs: a web-based survey.","authors":"Carhart-Harris RL, Nutt DJ","journal":"Journal of psychoactive drugs","publication_date":"2013-01-01","publication_year":2013,"doi":"10.1080/02791072.2013.825034","topic_tags":"Addiction,Observational Study","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2578,"title":"Psychiatry's next top model: cause for a re-think on drug models of psychosis and other psychiatric disorders.","authors":"Carhart-Harris RL, Brugger S, Nutt DJ, Stone JM","journal":"Journal of psychopharmacology (Oxford, England)","publication_date":"2013-09-01","publication_year":2013,"doi":"10.1177/0269881113494107","topic_tags":"Depression,Pharmacology","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2606,"title":"Implications for psychedelic-assisted psychotherapy: functional magnetic resonance imaging study with psilocybin.","authors":"Carhart-Harris RL, Leech R, Williams TM, Erritzoe D, Abbasi N, Bargiotas T, Hobden P, Sharp DJ, Evans J, Feilding A, Wise RG, Nutt DJ","journal":"The British journal of psychiatry: the journal of mental science","publication_date":"2012-03-01","publication_year":2012,"doi":"10.1192/bjp.bp.111.103309","topic_tags":"Brain Imaging,Aging,Emotional Processing,Clinical Trial,Healthy Volunteers","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2608,"title":"Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin.","authors":"Carhart-Harris RL, Erritzoe D, Williams T, Stone JM, Reed LJ, Colasanti A, Tyacke RJ, Leech R, Malizia AL, Murphy K, Hobden P, Evans J, Feilding A, Wise RG, Nutt DJ","journal":"Proceedings of the National Academy of Sciences of the United States of America","publication_date":"2012-02-07","publication_year":2012,"doi":"10.1073/pnas.1119598109","topic_tags":"Brain Imaging,Consciousness,Healthy Volunteers,Drug Interactions","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2616,"title":"The administration of psilocybin to healthy, hallucinogen-experienced volunteers in a mock-functional magnetic resonance imaging environment: a preliminary investigation of tolerability.","authors":"Carhart-Harris RL, Williams TM, Sessa B, Tyacke RJ, Rich AS, Feilding A, Nutt DJ","journal":"Journal of psychopharmacology (Oxford, England)","publication_date":"2011-11-01","publication_year":2011,"doi":"10.1177/0269881110367445","topic_tags":"Brain Imaging,Aging,Safety","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":3023,"title":"Distinct brain responses to psilocybin and escitalopram in depression captured by the Fluctuation-Dissipation Theorem","authors":"Dagnino PC, Acero-Pousa I, Zamora-López G, Escrichs A, Erritzoe D, Nutt DJ, Carhart-Harris RL, Sanz Perl Y, Kringelbach ML, Deco G.","journal":"bioRxiv","publication_date":"2026-06-16","publication_year":2026,"doi":"10.64898/2026.06.12.731811","topic_tags":"Depression,Brain Imaging,Mechanism of Action,Biomarkers,Aging,Randomized Controlled Trial","source_name":"bioRxiv","publication_status":"preprint","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":3026,"title":"Divergent changes in perturbation-induced brain reconfiguration following depression treatment with psilocybin and escitalopram","authors":"Dagnino PC, Acero-Pousa I, Carhart-Harris RL, Erritzoe D, Nutt DJ, Kringelbach ML, Perl YS, Deco G.","journal":"bioRxiv","publication_date":"2026-06-26","publication_year":2026,"doi":"10.64898/2026.06.22.733731","topic_tags":"Depression,Brain Imaging,Aging","source_name":"bioRxiv","publication_status":"preprint","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":3108,"title":"Long-term effects of psilocybin on dynamic and effectivity connectivity of fronto-striatal-thalamic circuits","authors":"Pasquini L, Vohryzek J, Escrichs A, Sanz Perl Y, Ponce-Alvarez A, Idesis S, Girn M, Roseman L, Mitchell JM, Gazzaley A, Kringelbach M, Nutt DJ, Lyons T, Carhart-Harris RL, Deco G.","journal":"bioRxiv","publication_date":"2024-11-07","publication_year":2024,"doi":"10.1101/2024.11.06.622302","topic_tags":"Depression,Eating Disorders,Brain Imaging,Mechanism of Action,Receptor Pharmacology,Wellbeing,Healthy Volunteers","source_name":"bioRxiv","publication_status":"preprint","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":3131,"title":"Brain dynamics predictive of response to psilocybin for treatment-resistant depression","authors":"Vohryzek J, Cabral J, Lord L, Fernandes HM, Roseman L, Nutt DJ, Carhart-Harris RL, Deco G, Kringelbach ML.","journal":"bioRxiv","publication_date":"2022-07-04","publication_year":2022,"doi":"10.1101/2022.06.30.497950","topic_tags":"Depression,Mechanism of Action,Receptor Pharmacology,Treatment-Resistant Depression","source_name":"bioRxiv","publication_status":"preprint","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":3209,"title":"Psychedelics align brain activity with context.","authors":"Stoliker D, Novelli L, Khajehnejad M, Biabani M, Greaves MD, Barta T, Williams M, Chopra S, Bazin O, Simonsson O, Chambers R, Barrett FS, Deco G, Preller KH, Carhart-Harris RL, Seth AK, Sundram S, Egan GF, Razi A.","journal":"Nature","publication_date":"2026-08-19","publication_year":2026,"doi":"10.1038/s41586-026-10910-z","topic_tags":"Brain Imaging,Consciousness,Aging","source_name":"Europe PMC","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":3216,"title":"Accurate and Interpretable Prediction of Antidepressant Treatment Response from Receptor-informed Neuroimaging","authors":"Tolle HM, Luppi AI, Lawn T, Roseman L, Nutt D, Carhart-Harris RL, Mediano PAM.","journal":"bioRxiv","publication_date":"2025-07-03","publication_year":2025,"doi":"10.1101/2025.07.02.662710","topic_tags":"Depression,Brain Imaging,Mechanism of Action,Receptor Pharmacology,Default Mode Network,Biomarkers,Aging,Clinical Trial","source_name":"bioRxiv","publication_status":"preprint","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":3269,"title":"LSD and psilocybin flatten the brain’s energy landscape: insights from receptor-informed network control theory","authors":"Singleton SP, Luppi AI, Carhart-Harris RL, Cruzat J, Roseman L, Nutt DJ, Deco G, Kringelbach ML, Stamatakis EA, Kuceyeski A.","journal":"bioRxiv","publication_date":"2021-05-17","publication_year":2021,"doi":"10.1101/2021.05.14.444193","topic_tags":"Brain Imaging,Receptor Pharmacology,Aging","source_name":"bioRxiv","publication_status":"preprint","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":3342,"title":"Statistical diversity distinguishes global states of consciousness","authors":"Starkey J, Carhart-Harris RL, Pigorini A, Nobili L, Barrett AB.","journal":"bioRxiv","publication_date":"2023-12-07","publication_year":2023,"doi":"10.1101/2023.12.05.570101","topic_tags":"Consciousness,Drug Interactions","source_name":"bioRxiv","publication_status":"preprint","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":3347,"title":"Altered trajectories in the dynamical repertoire of functional network states under psilocybin","authors":"Lord L, Expert P, Atasoy S, Roseman L, Rapuano K, Lambiotte R, Nutt DJ, Deco G, Carhart-Harris RL, Kringelbach ML, Cabral J.","journal":"bioRxiv","publication_date":"2018-07-25","publication_year":2018,"doi":"10.1101/376491","topic_tags":"Brain Imaging,Consciousness,Healthy Volunteers","source_name":"bioRxiv","publication_status":"preprint","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":3372,"title":"Mapping Pharmacologically-induced Functional Reorganisation onto the Brain’s Neurotransmitter Landscape","authors":"Luppi AI, Hansen JY, Adapa R, Carhart-Harris RL, Roseman L, Timmermann C, Golkowski D, Golkowski D, Ranft A, Ilg R, Jordan D, Bonhomme V, Vanhaudenhuyse A, Demertzi A, Jaquet O, Bahri MA, Alnagger NL, Cardone P, Peattie ARD, Manktelow AE, de Araujo DB, Sensi SL, Owen AM, Naci L, Menon DK, Misic B, Stamatakis EA.","journal":"bioRxiv","publication_date":"2022-07-13","publication_year":2022,"doi":"10.1101/2022.07.12.499688","topic_tags":"Receptor Pharmacology,Aging","source_name":"bioRxiv","publication_status":"preprint","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":3406,"title":"Decreased Directed Functional Connectivity in the Psychedelic State","authors":"Barnett L, Muthukumaraswamy SD, Carhart-Harris RL, Seth AK.","journal":"bioRxiv","publication_date":"2019-07-16","publication_year":2019,"doi":"10.1101/703660","topic_tags":"Brain Imaging,Mechanism of Action,Aging","source_name":"bioRxiv","publication_status":"preprint","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":3731,"title":"Psychedelic resting-state neuroimaging: A review and perspective on balancing replication and novel analyses.","authors":"McCulloch DE, Knudsen GM, Barrett FS, Doss MK, Carhart-Harris RL, Rosas FE, Deco G, Kringelbach ML, Preller KH, Ramaekers JG, Mason NL, Müller F, Fisher PM","journal":"Neuroscience and biobehavioral reviews","publication_date":"2022-07-01","publication_year":2022,"doi":"10.1016/j.neubiorev.2022.104689","topic_tags":"Brain Imaging,Mechanism of Action,Receptor Pharmacology,Aging,Review Article","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":150,"title":"The Music for Subanesthetic Infusions of Ketamine randomised clinical trial: ketamine as a psychedelic treatment for highly refractory depression.","authors":"Greenway KT, Garel N, Dinh-Williams LL, Thibault Lévesque J, Kaelen M, Dagenais-Beaulé V, de la Salle S, Erritzoe D, Looper K, Turecki G, Rej S, Richard-Devantoy S","journal":"The British journal of psychiatry: the journal of mental science","publication_date":"2026-05-01","publication_year":2026,"doi":"10.1192/bjp.2025.102","topic_tags":"Depression,Anxiety,Mechanism of Action,Personality Change,Emotional Processing,Mystical Experience,Clinical Trial,Randomized Controlled Trial,Treatment-Resistant Depression,Healthcare Workers","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":315,"title":"High hopes? Precision psychedelic addiction medicine.","authors":"Zafar RR, Kleine P, Kurtin D, Wall M, Erritzoe D","journal":"Frontiers in psychiatry","publication_date":"2025-01-01","publication_year":2025,"doi":"10.3389/fpsyt.2025.1681795","topic_tags":"Addiction,Neuroplasticity,Brain Imaging,Pharmacology,Biomarkers,Aging,Emotional Processing,Clinical Trial,Review Article,Cancer Patients","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":885,"title":"Serotonergic psychedelics for depression: A comprehensive overview.","authors":"Wingert AM, Agnorelli C, Peill J, Reed S, Nutt DJ, Erritzoe D","journal":"International review of neurobiology","publication_date":"2025-01-01","publication_year":2025,"doi":"10.1016/bs.irn.2025.04.009","topic_tags":"Depression,Mechanism of Action,Receptor Pharmacology,Clinical Trial,Review Article,Treatment-Resistant Depression,Safety","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":947,"title":"Impact of psilocybin on cognitive function: A systematic review.","authors":"Meshkat S, Tello-Gerez TJ, Gholaminezhad F, Dunkley BT, Reichelt AC, Erritzoe D, Vermetten E, Zhang Y, Greenshaw A, Burback L, Winkler O, Jetly R, Mayo LM, Bhat V","journal":"Psychiatry and clinical neurosciences","publication_date":"2024-12-01","publication_year":2024,"doi":"10.1111/pcn.13741","topic_tags":"Depression,Emotional Processing,Creativity,Systematic Review,Review Article,Healthy Volunteers,Treatment-Resistant Depression,Safety","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1263,"title":"Knowledge gaps in psychedelic medicalisation: Preclinical and neuroimaging mechanisms.","authors":"McCulloch DE, Lopez JP, Dalla C, Castrén E, Erritzoe D, Frokjaer VG, Lundberg J, Preller KH, Fisher PM, Knudsen GM","journal":"Neuroscience applied","publication_date":"2024-01-01","publication_year":2024,"doi":"10.1016/j.nsa.2023.103929","topic_tags":"Brain Imaging,Mechanism of Action,Receptor Pharmacology,Aging,Animal Study","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2181,"title":"Brain serotonin 2A receptor binding predicts subjective temporal and mystical effects of psilocybin in healthy humans.","authors":"Stenbæk DS, Madsen MK, Ozenne B, Kristiansen S, Burmester D, Erritzoe D, Knudsen GM, Fisher PM","journal":"Journal of psychopharmacology (Oxford, England)","publication_date":"2021-04-01","publication_year":2021,"doi":"10.1177/0269881120959609","topic_tags":"Receptor Pharmacology,Consciousness,Mystical Experience","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2331,"title":"Microdosing psychedelics: More questions than answers? An overview and suggestions for future research.","authors":"Kuypers KP, Ng L, Erritzoe D, Knudsen GM, Nichols CD, Nichols DE, Pani L, Soula A, Nutt D","journal":"Journal of psychopharmacology (Oxford, England)","publication_date":"2019-09-01","publication_year":2019,"doi":"10.1177/0269881119857204","topic_tags":"Pharmacology,Receptor Pharmacology,Microdosing,Safety","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2603,"title":"Simultaneous polysubstance use among Danish 3,4-methylenedioxymethamphetamine and hallucinogen users: combination patterns and proposed biological bases.","authors":"Licht CL, Christoffersen M, Okholm M, Damgaard L, Fink-Jensen A, Knudsen GM, Erritzoe D","journal":"Human psychopharmacology","publication_date":"2012-07-01","publication_year":2012,"doi":"10.1002/hup.2234","topic_tags":"Addiction,Observational Study","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":3024,"title":"Sex-Specific Effects of Psilocybin Versus Escitalopram on Anxiety and Anhedonia: A Bayesian Reanalysis of Antidepressant Treatment Outcomes","authors":"Frick A, Blest-Hopley G, Grin M, Erritzoe D, Nutt D, Carhart-Harris R.","journal":"Research Square","publication_date":"2026-06-19","publication_year":2026,"doi":"10.21203/rs.3.rs-9880403/v1","topic_tags":"Depression,Anxiety,Wellbeing,Clinical Trial,Randomized Controlled Trial,Drug Interactions","source_name":"Europe PMC","publication_status":"preprint","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":3106,"title":"Human brain changes after first psilocybin use","authors":"Lyons T, Spriggs M, Kerkelä L, Rosas F, Roseman L, Mediano P, Timmermann C, Oestreich L, Pagni B, Zeifman R, Hampshire A, Trender W, Douglass H, Girn M, Godfrey K, Kettner H, Sharif F, Espasiano L, Gazzaley A, Wall M, Erritzoe D, Nutt D, Carhart-Harris R.","journal":"bioRxiv","publication_date":"2024-10-14","publication_year":2024,"doi":"10.1101/2024.10.11.617955","topic_tags":"Brain Imaging,Aging,Wellbeing","source_name":"bioRxiv","publication_status":"preprint","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":3153,"title":"Reduced brain responsiveness to emotional stimuli with escitalopram but not psilocybin therapy for depression","authors":"Wall MB, Demetriou L, Giribaldi B, Roseman L, Ertl N, Erritzoe D, Nutt DJ, Carhart-Harris RL.","journal":"medRxiv","publication_date":"2023-06-03","publication_year":2023,"doi":"10.1101/2023.05.29.23290667","topic_tags":"Depression,Brain Imaging,Receptor Pharmacology,Biomarkers,Aging,Emotional Processing,Drug Interactions","source_name":"medRxiv","publication_status":"preprint","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":3187,"title":"A Bayesian Reanalysis of a Trial of Psilocybin versus Escitalopram for Depression","authors":"Nayak SM, Bari BA, Yaden DB, Spriggs MJ, Rosas F, Peill JM, Giribaldi B, Erritzoe D, Nutt D, Carhart-Harris R.","journal":"PsyArXiv","publication_date":"2022-07-01","publication_year":2022,"doi":"10.31234/osf.io/sb5ur","topic_tags":"Depression","source_name":"PsyArXiv","publication_status":"preprint","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":3230,"title":"Decreased brain modularity after psilocybin therapy for depression.","authors":"Daws R, Timmerman C, Giribaldi B, Sexton J, Wall M, Erritzoe D, Roseman L, Nutt D, Carhart-Harris R.","journal":"Research Square","publication_date":"2021-05-20","publication_year":2021,"doi":"10.21203/rs.3.rs-513323/v1","topic_tags":"Depression,Brain Imaging,Clinical Trial,Randomized Controlled Trial,Observational Study,Treatment-Resistant Depression","source_name":"Europe PMC","publication_status":"preprint","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":3728,"title":"Neuroimaging in psychedelic drug development: past, present, and future.","authors":"Wall MB, Harding R, Zafar R, Rabiner EA, Nutt DJ, Erritzoe D","journal":"Molecular psychiatry","publication_date":"2023-09-01","publication_year":2023,"doi":"10.1038/s41380-023-02271-0","topic_tags":"Depression,PTSD,Addiction,Neuroplasticity,Brain Imaging,Pharmacology,Receptor Pharmacology,Aging","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":3785,"title":"From Relaxed Beliefs Under Psychedelics (REBUS) to Revised Beliefs After Psychedelics (REBAS): Preliminary Development of the RElaxed Beliefs Questionnaire (REB-Q)","authors":"Zeifman R, Spriggs MJ, Kettner H, Lyons T, Rosas F, Mediano P, Erritzoe D, Carhart-Harris R.","journal":"PsyArXiv","publication_date":"2022-07-07","publication_year":2022,"doi":"10.31234/osf.io/w8j6t","topic_tags":"Brain Imaging,Mechanism of Action,Wellbeing","source_name":"PsyArXiv","publication_status":"preprint","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":3799,"title":"Psychedelics and Health Behavior Change - Journal of Psychopharmacology (in press)","authors":"Teixeira PJ, Johnson M, Timmermann C, Watts R, Erritzoe D, Douglass H, Kettner H, Carhart-Harris R.","journal":"PsyArXiv","publication_date":"2021-03-24","publication_year":2021,"doi":"10.31234/osf.io/8vks6","topic_tags":"Depression,Anxiety,Addiction,Eating Disorders,Pharmacology,Mechanism of Action,Wellbeing,Safety,Toxicity","source_name":"PsyArXiv","publication_status":"preprint","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1277,"title":"Is Poorly Assisted Psilocybin Treatment an Increasing Risk?","authors":"Schenberg EE, King F, da Fonseca JE, Roseman L","journal":"The American journal of psychiatry","publication_date":"2024-01-01","publication_year":2024,"doi":"10.1176/appi.ajp.20230664","topic_tags":"Depression,Safety","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1505,"title":"Psychedelic-induced mystical experiences: An interdisciplinary discussion and critique.","authors":"Mosurinjohn S, Roseman L, Girn M","journal":"Frontiers in psychiatry","publication_date":"2023-01-01","publication_year":2023,"doi":"10.3389/fpsyt.2023.1077311","topic_tags":"Mystical Experience","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1613,"title":"The Psychedelic Renaissance in Clinical Research: A Bibliometric Analysis of Three Decades of Human Studies with Psychedelics.","authors":"Hadar A, David J, Shalit N, Roseman L, Gross R, Sessa B, Lev-Ran S","journal":"Journal of psychoactive drugs","publication_date":"2023-01-01","publication_year":2023,"doi":"10.1080/02791072.2021.2022254","topic_tags":"Chronic Pain,Healthcare Workers","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1732,"title":"Editorial: Psychedelic sociality: Pharmacological and extrapharmacological perspectives.","authors":"Roseman L, Preller KH, Fotiou E, Winkelman MJ","journal":"Frontiers in pharmacology","publication_date":"2022-01-01","publication_year":2022,"doi":"10.3389/fphar.2022.979764","topic_tags":"Pharmacology,Receptor Pharmacology","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":3130,"title":"Co-administration of midazolam and psilocybin: Differential effects on subjective quality versus memory of the psychedelic experience","authors":"Nicholas CR, Banks MI, Lennertz RL, Wenthur CJ, Krause BM, Riedner BA, Smith RF, Hutson PR, Sauder CJ, Dunne JD, Roseman L, Raison CL.","journal":"bioRxiv","publication_date":"2024-06-13","publication_year":2024,"doi":"10.1101/2024.06.13.598878","topic_tags":"Neuroplasticity,Wellbeing,Healthy Volunteers","source_name":"bioRxiv","publication_status":"preprint","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":3147,"title":"Defining 'psychedelic'.","authors":"Ostrand AE, Nour MM, Timmermann C, Rosati A, Luan LX, Gomez-Emilsson A, Bornemann J, Greenway KT, Roseman L, R CH.","journal":"Journal of psychopharmacology (Oxford, England)","publication_date":"2026-08-17","publication_year":2026,"doi":"10.1177/02698811261464986","topic_tags":"General","source_name":"Europe PMC","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":3227,"title":"Increased low-frequency brain responses to music after psilocybin therapy for depression","authors":"Wall MB, Lam C, Ertl N, Kaelen M, Roseman L, Nutt DJ, Carhart-Harris RL.","journal":"bioRxiv","publication_date":"2022-02-15","publication_year":2022,"doi":"10.1101/2022.02.13.480302","topic_tags":"Depression,Brain Imaging,Aging,Emotional Processing,Treatment-Resistant Depression","source_name":"bioRxiv","publication_status":"preprint","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":19,"title":"The Australia story: Current status and future challenges for the clinical applications of psychedelics.","authors":"Nutt DJ, Hunt P, Schlag AK, Fitzgerald P","journal":"British journal of pharmacology","publication_date":"2026-07-01","publication_year":2026,"doi":"10.1111/bph.17398","topic_tags":"Depression,PTSD,Mechanism of Action,Review Article,Treatment-Resistant Depression","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":116,"title":"Exploring new avenues: Psychedelic-assisted therapy for young people.","authors":"Vamvakopoulou IA, Nicholls D, Nutt DJ, Di Simplicio M","journal":"British journal of clinical pharmacology","publication_date":"2026-05-08","publication_year":2026,"doi":"10.1002/bcp.70579","topic_tags":"Depression,Anxiety,PTSD,Wellbeing,Review Article,Observational Study,Adolescents,Safety","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1267,"title":"Psychedelics: From Cave Art to 21st-Century Medicine for Addiction.","authors":"Vamvakopoulou IA, Nutt DJ","journal":"European addiction research","publication_date":"2024-01-01","publication_year":2024,"doi":"10.1159/000540062","topic_tags":"Addiction,Pharmacology,Mechanism of Action,Review Article","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1330,"title":"Cost-effectiveness of psilocybin-assisted therapy for severe depression: exploratory findings from a decision analytic model.","authors":"McCrone P, Fisher H, Knight C, Harding R, Schlag AK, Nutt DJ, Neill JC","journal":"Psychological medicine","publication_date":"2023-12-01","publication_year":2023,"doi":"10.1017/s0033291723001411","topic_tags":"Depression,Treatment-Resistant Depression","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1605,"title":"Mescaline: The forgotten psychedelic.","authors":"Vamvakopoulou IA, Narine KAD, Campbell I, Dyck JRB, Nutt DJ","journal":"Neuropharmacology","publication_date":"2023-01-01","publication_year":2023,"doi":"10.1016/j.neuropharm.2022.109294","topic_tags":"Pharmacology,Mechanism of Action,Receptor Pharmacology,Wellbeing,Review Article,Animal Study","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1815,"title":"Adverse effects of psychedelics: From anecdotes and misinformation to systematic science.","authors":"Schlag AK, Aday J, Salam I, Neill JC, Nutt DJ","journal":"Journal of psychopharmacology (Oxford, England)","publication_date":"2022-03-01","publication_year":2022,"doi":"10.1177/02698811211069100","topic_tags":"Review Article,Healthcare Workers,Safety,Toxicity,Abuse Liability","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2334,"title":"Psilocybin lacks antidepressant-like effect in the Flinders Sensitive Line rat.","authors":"Jefsen O, Højgaard K, Christiansen SL, Elfving B, Nutt DJ, Wegener G, Müller HK","journal":"Acta neuropsychiatrica","publication_date":"2019-08-01","publication_year":2019,"doi":"10.1017/neu.2019.15","topic_tags":"Depression,Receptor Pharmacology,Animal Study,Treatment-Resistant Depression","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2377,"title":"Psychiatry & the psychedelic drugs. Past, present & future.","authors":"Rucker JJH, Iliff J, Nutt DJ","journal":"Neuropharmacology","publication_date":"2018-11-01","publication_year":2018,"doi":"10.1016/j.neuropharm.2017.12.040","topic_tags":"Aging,Clinical Trial,Randomized Controlled Trial,Meta-Analysis,Systematic Review,Review Article,Safety,Adverse Events","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":137,"title":"Trip sitting or just sitting? Session facilitators substantially influence psychedelic experiences in clinical trials but not in healthy ones.","authors":"Goldy SP, Sepeda ND, Hilbert SN, Bari BA, Garcia-Romeu A, Gukasyan N, Barrett FS, Yaden DB, Nayak SM","journal":"Psychiatry research","publication_date":"2026-05-01","publication_year":2026,"doi":"10.1016/j.psychres.2026.117010","topic_tags":"Depression,Anxiety,Clinical Trial,Healthy Volunteers","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":138,"title":"Challenges with clinical trial participants in studies with classical psychedelics: A position statement from the National Network of Depression Centers' task group on psychedelics and related compounds.","authors":"Lewis BR, Reid MJ, Novick AM, Byrne K, Niciu MJ, Fonzo GA, Meyer TD, Feifel D, El-Mallakh RS, Soares J, Suppes T, Barrett FS","journal":"Journal of psychopharmacology (Oxford, England)","publication_date":"2026-05-01","publication_year":2026,"doi":"10.1177/02698811251413490","topic_tags":"Depression,Clinical Trial,Healthcare Workers,Safety","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":453,"title":"Considerations and cautions for the integration of psilocybin into routine clinical care: a consensus statement from the US National Network of Depression Centers' Task Group on Psychedelics and Related Compounds.","authors":"Hosein MM, Reid MJ, Walser S, Charney S, Fonzo GA, Lewis BR, Yaden DB, Suppes T, Cordner ZA, Barrett FS","journal":"EClinicalMedicine","publication_date":"2025-11-01","publication_year":2025,"doi":"10.1016/j.eclinm.2025.103517","topic_tags":"Depression,Safety","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1105,"title":"Impact of Psilocybin on Peripheral Cytokine Production.","authors":"DiRenzo D, Barrett FS, Perin J, Darrah E, Christopher-Stine L, Griffiths RR","journal":"Psychedelic medicine (New Rochelle, N.Y.)","publication_date":"2024-06-01","publication_year":2024,"doi":"10.1089/psymed.2023.0039","topic_tags":"Depression,Anxiety,Addiction,Clinical Trial,Randomized Controlled Trial,Inflammation,Immune Function","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1199,"title":"The therapeutic alliance between study participants and intervention facilitators is associated with acute effects and clinical outcomes in a psilocybin-assisted therapy trial for major depressive disorder.","authors":"Levin AW, Lancelotta R, Sepeda ND, Gukasyan N, Nayak S, Wagener TL, Barrett FS, Griffiths RR, Davis AK","journal":"PloS one","publication_date":"2024-01-01","publication_year":2024,"doi":"10.1371/journal.pone.0300501","topic_tags":"Depression,Mystical Experience,Clinical Trial","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1278,"title":"Misinterpretations and Omissions: A Critical Response to Goodwin and Colleagues' Commentary on Psilocybin-Assisted Therapy.","authors":"O'Donnell KC, Anderson BT, Barrett FS, Bogenschutz MP, Grob CS, Hendricks PS, Kelmendi B, Nayak SM, Nicholas CR, Paleos CA, Stauffer CS, Gukasyan N","journal":"The American journal of psychiatry","publication_date":"2024-01-01","publication_year":2024,"doi":"10.1176/appi.ajp.20230661","topic_tags":"General","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1287,"title":"The psychedelic effects of cannabis: A review of the literature.","authors":"Wolinsky D, Barrett FS, Vandrey R","journal":"Journal of psychopharmacology (Oxford, England)","publication_date":"2024-01-01","publication_year":2024,"doi":"10.1177/02698811231209194","topic_tags":"Brain Imaging,Mechanism of Action,Consciousness,Aging,Mystical Experience,Clinical Trial,Review Article","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1372,"title":"Naturalistic psilocybin use is associated with persisting improvements in mental health and wellbeing: results from a prospective, longitudinal survey.","authors":"Nayak SM, Jackson H, Sepeda ND, Mathai DS, So S, Yaffe A, Zaki H, Brasher TJ, Lowe MX, Jolly DRP, Barrett FS, Griffiths RR, Strickland JC, Johnson MW, Jackson H, Garcia-Romeu A","journal":"Frontiers in psychiatry","publication_date":"2023-01-01","publication_year":2023,"doi":"10.3389/fpsyt.2023.1199642","topic_tags":"Depression,Anxiety,Wellbeing,Emotional Processing,Spirituality,Mystical Experience,Observational Study","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1447,"title":"Corrigendum to 'Psilocybin induces spatially constrained alterations in thalamic functional organizaton and connectivity': Neuroimage 2022 Oct 15;260:119434.","authors":"Gaddis A, Lidstone DE, Nebel MB, Griffiths RR, Mostofsky SH, Mejia AF, Barrett FS","journal":"NeuroImage","publication_date":"2023-07-01","publication_year":2023,"doi":"10.1016/j.neuroimage.2023.120130","topic_tags":"General","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1658,"title":"Psilocybin induces spatially constrained alterations in thalamic functional organizaton and connectivity.","authors":"Gaddis A, Lidstone DE, Nebel MB, Griffiths RR, Mostofsky SH, Mejia AF, Barrett FS","journal":"NeuroImage","publication_date":"2022-10-15","publication_year":2022,"doi":"10.1016/j.neuroimage.2022.119434","topic_tags":"Brain Imaging,Receptor Pharmacology,Default Mode Network","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1697,"title":"Skepticism about Recent Evidence That Psilocybin \"Liberates\" Depressed Minds.","authors":"Doss MK, Barrett FS, Corlett PR","journal":"ACS chemical neuroscience","publication_date":"2022-09-07","publication_year":2022,"doi":"10.1021/acschemneuro.2c00461","topic_tags":"Depression,Brain Imaging,Receptor Pharmacology,Aging,Drug Interactions","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1794,"title":"Models of psychedelic drug action: modulation of cortical-subcortical circuits.","authors":"Doss MK, Madden MB, Gaddis A, Nebel MB, Griffiths RR, Mathur BN, Barrett FS","journal":"Brain: a journal of neurology","publication_date":"2022-04-18","publication_year":2022,"doi":"10.1093/brain/awab406","topic_tags":"Receptor Pharmacology,Default Mode Network","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1827,"title":"Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up.","authors":"Gukasyan N, Davis AK, Barrett FS, Cosimano MP, Sepeda ND, Johnson MW, Griffiths RR","journal":"Journal of psychopharmacology (Oxford, England)","publication_date":"2022-02-01","publication_year":2022,"doi":"10.1177/02698811211073759","topic_tags":"Depression,Wellbeing,Spirituality,Mystical Experience,Safety,Adverse Events","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1833,"title":"Human Cortical Serotonin 2A Receptor Occupancy by Psilocybin Measured Using [C]MDL100,907 Dynamic PET and a Resting-State fMRI-Based Brain Parcellation.","authors":"Barrett FS, Zhou Y, Carbonaro TM, Roberts JM, Smith GS, Griffiths RR, Wong DF","journal":"Frontiers in neuroergonomics","publication_date":"2021-01-01","publication_year":2021,"doi":"10.3389/fnrgo.2021.784576","topic_tags":"Addiction,Brain Imaging,Pharmacology,Receptor Pharmacology,Default Mode Network,Healthy Volunteers","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1888,"title":"Psilocybin therapy increases cognitive and neural flexibility in patients with major depressive disorder.","authors":"Doss MK, Považan M, Rosenberg MD, Sepeda ND, Davis AK, Finan PH, Smith GS, Pekar JJ, Barker PB, Griffiths RR, Barrett FS","journal":"Translational psychiatry","publication_date":"2021-11-08","publication_year":2021,"doi":"10.1038/s41398-021-01706-y","topic_tags":"Depression,Brain Imaging,Mechanism of Action,Aging","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1911,"title":"Classic Psychedelic Coadministration with Lithium, but Not Lamotrigine, is Associated with Seizures: An Analysis of Online Psychedelic Experience Reports.","authors":"Nayak SM, Gukasyan N, Barrett FS, Erowid E, Erowid F, Griffiths RR","journal":"Pharmacopsychiatry","publication_date":"2021-09-01","publication_year":2021,"doi":"10.1055/a-1524-2794","topic_tags":"Depression,Safety","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2128,"title":"Psychedelics and Consciousness: Distinctions, Demarcations, and Opportunities.","authors":"Yaden DB, Johnson MW, Griffiths RR, Doss MK, Garcia-Romeu A, Nayak S, Gukasyan N, Mathur BN, Barrett FS","journal":"The international journal of neuropsychopharmacology","publication_date":"2021-08-20","publication_year":2021,"doi":"10.1093/ijnp/pyab026","topic_tags":"Consciousness,Review Article","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2160,"title":"Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial.","authors":"Davis AK, Barrett FS, May DG, Cosimano MP, Sepeda ND, Johnson MW, Finan PH, Griffiths RR","journal":"JAMA psychiatry","publication_date":"2021-05-01","publication_year":2021,"doi":"10.1001/jamapsychiatry.2020.3285","topic_tags":"Depression,Consciousness,Clinical Trial,Treatment-Resistant Depression","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2179,"title":"Optimal dosing for psilocybin pharmacotherapy: Considering weight-adjusted and fixed dosing approaches.","authors":"Garcia-Romeu A, Barrett FS, Carbonaro TM, Johnson MW, Griffiths RR","journal":"Journal of psychopharmacology (Oxford, England)","publication_date":"2021-04-01","publication_year":2021,"doi":"10.1177/0269881121991822","topic_tags":"Depression,Addiction,Receptor Pharmacology,Mystical Experience","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2182,"title":"Development of the Psychological Insight Questionnaire among a sample of people who have consumed psilocybin or LSD.","authors":"Davis AK, Barrett FS, So S, Gukasyan N, Swift TC, Griffiths RR","journal":"Journal of psychopharmacology (Oxford, England)","publication_date":"2021-04-01","publication_year":2021,"doi":"10.1177/0269881120967878","topic_tags":"Wellbeing,Mystical Experience,Psychological Flexibility,Observational Study","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2255,"title":"Psilocybin acutely alters the functional connectivity of the claustrum with brain networks that support perception, memory, and attention.","authors":"Barrett FS, Krimmel SR, Griffiths RR, Seminowicz DA, Mathur BN","journal":"NeuroImage","publication_date":"2020-09-01","publication_year":2020,"doi":"10.1016/j.neuroimage.2020.116980","topic_tags":"Brain Imaging,Mechanism of Action,Receptor Pharmacology,Default Mode Network,Healthy Volunteers","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2298,"title":"Emotions and brain function are altered up to one month after a single high dose of psilocybin.","authors":"Barrett FS, Doss MK, Sepeda ND, Pekar JJ, Griffiths RR","journal":"Scientific reports","publication_date":"2020-02-10","publication_year":2020,"doi":"10.1038/s41598-020-59282-y","topic_tags":"Anxiety,Addiction,Neuroplasticity,Emotional Processing,Healthy Volunteers","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2347,"title":"Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function.","authors":"Johnson MW, Hendricks PS, Barrett FS, Griffiths RR","journal":"Pharmacology & therapeutics","publication_date":"2019-05-01","publication_year":2019,"doi":"10.1016/j.pharmthera.2018.11.010","topic_tags":"Depression,Addiction,End-of-Life Distress,Brain Imaging,Mechanism of Action,Receptor Pharmacology,Consciousness,Aging,Mystical Experience,Review Article,Healthy Volunteers","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2386,"title":"Double-blind comparison of the two hallucinogens psilocybin and dextromethorphan: effects on cognition.","authors":"Barrett FS, Carbonaro TM, Hurwitz E, Johnson MW, Griffiths RR","journal":"Psychopharmacology","publication_date":"2018-10-01","publication_year":2018,"doi":"10.1007/s00213-018-4981-x","topic_tags":"Pharmacology,Receptor Pharmacology","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2393,"title":"Psychedelics and music: neuroscience and therapeutic implications.","authors":"Barrett FS, Preller KH, Kaelen M","journal":"International review of psychiatry (Abingdon, England)","publication_date":"2018-08-01","publication_year":2018,"doi":"10.1080/09540261.2018.1484342","topic_tags":"Emotional Processing,Review Article","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2421,"title":"\"Hallucinations\" Following Acute Cannabis Dosing: A Case Report and Comparison to Other Hallucinogenic Drugs.","authors":"Barrett FS, Schlienz NJ, Lembeck N, Waqas M, Vandrey R","journal":"Cannabis and cannabinoid research","publication_date":"2018-01-01","publication_year":2018,"doi":"10.1089/can.2017.0052","topic_tags":"Pharmacology,Mechanism of Action,Case Report,Adverse Events","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2438,"title":"Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors.","authors":"Griffiths RR, Johnson MW, Richards WA, Richards BD, Jesse R, MacLean KA, Barrett FS, Cosimano MP, Klinedinst MA","journal":"Journal of psychopharmacology (Oxford, England)","publication_date":"2018-01-01","publication_year":2018,"doi":"10.1177/0269881117731279","topic_tags":"Wellbeing,Spirituality,Mystical Experience,Healthy Volunteers","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2442,"title":"Classic Hallucinogens and Mystical Experiences: Phenomenology and Neural Correlates.","authors":"Barrett FS, Griffiths RR","journal":"Current topics in behavioral neurosciences","publication_date":"2018-01-01","publication_year":2018,"doi":"10.1007/7854_2017_474","topic_tags":"Depression,Anxiety,End-of-Life Distress,Default Mode Network,Mystical Experience,Review Article,Healthy Volunteers","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2451,"title":"Neuroticism is associated with challenging experiences with psilocybin mushrooms.","authors":"Barrett FS, Johnson MW, Griffiths RR","journal":"Personality and individual differences","publication_date":"2017-10-15","publication_year":2017,"doi":"10.1016/j.paid.2017.06.004","topic_tags":"Personality Change,Emotional Processing,Observational Study","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2464,"title":"Qualitative and Quantitative Features of Music Reported to Support Peak Mystical Experiences during Psychedelic Therapy Sessions.","authors":"Barrett FS, Robbins H, Smooke D, Brown JL, Griffiths RR","journal":"Frontiers in psychology","publication_date":"2017-01-01","publication_year":2017,"doi":"10.3389/fpsyg.2017.01238","topic_tags":"Mystical Experience,Clinical Trial,Observational Study","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2498,"title":"The Challenging Experience Questionnaire: Characterization of challenging experiences with psilocybin mushrooms.","authors":"Barrett FS, Bradstreet MP, Leoutsakos JS, Johnson MW, Griffiths RR","journal":"Journal of psychopharmacology (Oxford, England)","publication_date":"2016-12-01","publication_year":2016,"doi":"10.1177/0269881116678781","topic_tags":"Depression,Anxiety,Consciousness,Wellbeing,Spirituality,Case Report,Observational Study,Safety","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2500,"title":"Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences.","authors":"Carbonaro TM, Bradstreet MP, Barrett FS, MacLean KA, Jesse R, Johnson MW, Griffiths RR","journal":"Journal of psychopharmacology (Oxford, England)","publication_date":"2016-12-01","publication_year":2016,"doi":"10.1177/0269881116662634","topic_tags":"Wellbeing,Observational Study,Safety","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2528,"title":"Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin.","authors":"Barrett FS, Johnson MW, Griffiths RR","journal":"Journal of psychopharmacology (Oxford, England)","publication_date":"2015-11-01","publication_year":2015,"doi":"10.1177/0269881115609019","topic_tags":"Wellbeing,Spirituality,Mystical Experience,Observational Study","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":3306,"title":"Visual Hallucinations in Serotonergic Psychedelics and Lewy Body Diseases","authors":"Heller NH, Barrett FS, Buchborn T, Collerton D, Dupuis D, Halberstadt AL, Jardri R, Noorani TN, Preller KH, Taylor J, Waters F, Winston B, Leptourgos P.","journal":"PsyArXiv","publication_date":"2025-07-15","publication_year":2025,"doi":"10.31234/osf.io/7x8q4_v3","topic_tags":"Brain Imaging,Mechanism of Action,Receptor Pharmacology,Aging,Review Article,Animal Study","source_name":"PsyArXiv","publication_status":"preprint","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":3321,"title":"Visual Hallucinations in Serotonergic Psychedelics and Lewy Body Diseases","authors":"Heller NH, Barrett FS, Buchborn T, Collerton D, Dupuis D, Halberstadt AL, Jardri R, Noorani TN, Preller KH, Taylor J, Waters F, Winston B, Leptourgos P.","journal":"PsyArXiv","publication_date":"2025-03-29","publication_year":2025,"doi":"10.31234/osf.io/7x8q4_v2","topic_tags":"Brain Imaging,Mechanism of Action,Receptor Pharmacology,Aging,Review Article,Animal Study","source_name":"PsyArXiv","publication_status":"preprint","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":3328,"title":"Visual Hallucinations in Serotonergic Psychedelics and Lewy Body Diseases","authors":"Heller NH, Barrett FS, Buchborn T, Collerton D, Dupuis D, Halberstadt AL, Jardri R, Noorani TN, Preller KH, Taylor J, Waters F, Winston B, Leptourgos P.","journal":"PsyArXiv","publication_date":"2025-02-13","publication_year":2025,"doi":"10.31234/osf.io/7x8q4_v1","topic_tags":"Brain Imaging,Mechanism of Action,Receptor Pharmacology,Aging,Review Article,Animal Study","source_name":"PsyArXiv","publication_status":"preprint","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":3370,"title":"Classic psychedelic coadministration with lithium, but not lamotrigine, is associated with seizures: an analysis of online psychedelic experience reports","authors":"Nayak S, Gukasyan N, Barrett FS, Erowid E, Erowid F, Griffiths RR.","journal":"PsyArXiv","publication_date":"2021-02-24","publication_year":2021,"doi":"10.31234/osf.io/r726d","topic_tags":"Depression,Safety","source_name":"PsyArXiv","publication_status":"preprint","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":3398,"title":"Unique Effects of Sedatives, Dissociatives, Psychedelics, Stimulants, and Cannabinoids on Episodic Memory: A Review and Reanalysis of Acute Drug Effects on Recollection, Familiarity, and Metamemory","authors":"Doss MK, Samaha J, Barrett FS, Griffiths RR, de Wit H, Gallo DA, Koen JD.","journal":"bioRxiv","publication_date":"2022-05-24","publication_year":2022,"doi":"10.1101/2022.05.20.492842","topic_tags":"Pharmacology,Mechanism of Action,Consciousness,Systematic Review,Review Article","source_name":"bioRxiv","publication_status":"preprint","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":3421,"title":"Visual Hallucinations in Serotonergic Psychedelics and Lewy Body Diseases.","authors":"Heller NH, Barrett FS, Buchborn T, Collerton D, Dupuis D, Halberstadt AL, Jardri R, Noorani T, Preller KH, Taylor JP, Waters F, Winston BS, Leptourgos P","journal":"Schizophrenia bulletin","publication_date":"2025-10-06","publication_year":2025,"doi":"10.1093/schbul/sbaf068","topic_tags":"Brain Imaging,Mechanism of Action,Receptor Pharmacology,Aging,Review Article,Animal Study","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":3796,"title":"Skepticism About Recent Evidence that Psilocybin Opens Depressed Minds","authors":"Doss M, Barrett FS, Corlett PR.","journal":"PsyArXiv","publication_date":"2022-04-28","publication_year":2022,"doi":"10.31234/osf.io/a25wb","topic_tags":"General","source_name":"PsyArXiv","publication_status":"preprint","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":5886,"title":"Pilot study comparing the effects of high dose THC to high dose psilocybin and placebo in the set and setting of a classic psychedelic therapy session.","authors":"Barrett FS, Wolinsky D, Daily Z, Ciancio J, Arthur K, Vandrey R.","journal":"Psychopharmacology","publication_date":"2026-08-27","publication_year":2026,"doi":"10.1007/s00213-026-07138-0","topic_tags":"Pharmacology,Clinical Trial,Safety","source_name":"Europe PMC","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":460,"title":"The emotional architecture of the psychedelic brain.","authors":"Moujaes F, Rieser NM, Belinger L, Herdener M, Zahid Z, Preller KH","journal":"Trends in cognitive sciences","publication_date":"2025-11-01","publication_year":2025,"doi":"10.1016/j.tics.2025.07.006","topic_tags":"Depression,Chronic Pain,Neuroplasticity,Mechanism of Action,Emotional Processing,Review Article","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":587,"title":"Neurocognitive effects of psilocybin: A systematic and comprehensive review of neuroimaging studies in humans.","authors":"Berkovitch L, Fauvel B, Preller KH, Gaillard R","journal":"Neuroscience and biobehavioral reviews","publication_date":"2025-08-01","publication_year":2025,"doi":"10.1016/j.neubiorev.2025.106239","topic_tags":"Depression,Brain Imaging,Mechanism of Action,Default Mode Network,Aging,Personality Change,Emotional Processing,Clinical Trial,Systematic Review,Review Article,Healthy Volunteers","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":684,"title":"Psilocybin increases emotional empathy in patients with major depression.","authors":"Jungwirth J, von Rotz R, Dziobek I, Vollenweider FX, Preller KH","journal":"Molecular psychiatry","publication_date":"2025-06-01","publication_year":2025,"doi":"10.1038/s41380-024-02875-0","topic_tags":"Depression,Mechanism of Action,Emotional Processing,Healthy Volunteers,Drug Interactions","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1097,"title":"Neural Mechanisms of Resting-State Networks and the Amygdala Underlying the Cognitive and Emotional Effects of Psilocybin.","authors":"Stoliker D, Novelli L, Vollenweider FX, Egan GF, Preller KH, Razi A","journal":"Biological psychiatry","publication_date":"2024-07-01","publication_year":2024,"doi":"10.1016/j.biopsych.2024.01.002","topic_tags":"Mechanism of Action,Default Mode Network,Emotional Processing,Clinical Trial","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1102,"title":"The influence of psilocybin on subconscious and conscious emotional learning.","authors":"Casanova AF, Ort A, Smallridge JW, Preller KH, Seifritz E, Vollenweider FX","journal":"iScience","publication_date":"2024-06-21","publication_year":2024,"doi":"10.1016/j.isci.2024.110034","topic_tags":"Pharmacology,Mechanism of Action,Receptor Pharmacology,Emotional Processing","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1157,"title":"Comparing Neural Correlates of Consciousness: From Psychedelics to Hypnosis and Meditation.","authors":"Moujaes F, Rieser NM, Phillips C, de Matos NMP, Brügger M, Dürler P, Smigielski L, Stämpfli P, Seifritz E, Vollenweider FX, Anticevic A, Preller KH","journal":"Biological psychiatry. Cognitive neuroscience and neuroimaging","publication_date":"2024-05-01","publication_year":2024,"doi":"10.1016/j.bpsc.2023.07.003","topic_tags":"Brain Imaging,Mechanism of Action,Consciousness,Aging","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1264,"title":"Amygdala response to emotional faces following acute administration of psilocybin in healthy individuals.","authors":"Armand S, Larsen K, Madsen MK, Ozenne B, Preller KH, Knudsen GM, Stenbæk DS, Fisher PM","journal":"Neuroscience applied","publication_date":"2024-01-01","publication_year":2024,"doi":"10.1016/j.nsa.2023.103934","topic_tags":"Depression,Brain Imaging,Aging,Emotional Processing","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1356,"title":"Psilocybin-induced changes in cerebral blood flow are associated with acute and baseline inter-individual differences.","authors":"Rieser NM, Gubser LP, Moujaes F, Duerler P, Lewis CR, Michels L, Vollenweider FX, Preller KH","journal":"Scientific reports","publication_date":"2023-10-14","publication_year":2023,"doi":"10.1038/s41598-023-44153-z","topic_tags":"Mechanism of Action,Biomarkers,Healthy Volunteers","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1483,"title":"TMS-EEG and resting-state EEG applied to altered states of consciousness: oscillations, complexity, and phenomenology.","authors":"Ort A, Smallridge JW, Sarasso S, Casarotto S, von Rotz R, Casanova A, Seifritz E, Preller KH, Tononi G, Vollenweider FX","journal":"iScience","publication_date":"2023-05-19","publication_year":2023,"doi":"10.1016/j.isci.2023.106589","topic_tags":"Brain Imaging,Receptor Pharmacology,Consciousness,Aging,Emotional Processing,Drug Interactions","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1566,"title":"Corrigendum to 'Single-dose psilocybin-assisted therapy in major depressive disorder: a placebo-controlled, double-blind, randomised clinical trial'.","authors":"von Rotz R, Schindowski EM, Jungwirth J, Schuldt A, Rieser NM, Zahoranszky K, Seifritz E, Nowak A, Nowak P, Jäncke L, Preller KH, Vollenweider FX","journal":"EClinicalMedicine","publication_date":"2023-02-01","publication_year":2023,"doi":"10.1016/j.eclinm.2023.101841","topic_tags":"Depression,Clinical Trial","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1567,"title":"Single-dose psilocybin-assisted therapy in major depressive disorder: A placebo-controlled, double-blind, randomised clinical trial.","authors":"von Rotz R, Schindowski EM, Jungwirth J, Schuldt A, Rieser NM, Zahoranszky K, Seifritz E, Nowak A, Nowak P, Jäncke L, Preller KH, Vollenweider FX","journal":"EClinicalMedicine","publication_date":"2023-02-01","publication_year":2023,"doi":"10.1016/j.eclinm.2022.101809","topic_tags":"Depression,Clinical Trial,Randomized Controlled Trial,Adverse Events","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1853,"title":"Psychedelic-Assisted Therapy for Substance Use Disorders and Potential Mechanisms of Action.","authors":"Rieser NM, Herdener M, Preller KH","journal":"Current topics in behavioral neurosciences","publication_date":"2022-01-01","publication_year":2022,"doi":"10.1007/7854_2021_284","topic_tags":"Addiction,Neuroplasticity,Mechanism of Action,Emotional Processing,Mystical Experience","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1883,"title":"Psilocybin Induces Aberrant Prediction Error Processing of Tactile Mismatch Responses-A Simultaneous EEG-FMRI Study.","authors":"Duerler P, Brem S, Fraga-González G, Neef T, Allen M, Zeidman P, Stämpfli P, Vollenweider FX, Preller KH","journal":"Cerebral cortex (New York, N.Y.: 1991)","publication_date":"2021-11-23","publication_year":2021,"doi":"10.1093/cercor/bhab202","topic_tags":"Brain Imaging,Receptor Pharmacology,Consciousness,Aging","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2148,"title":"Classical Psychedelics as Therapeutics in Psychiatry - Current Clinical Evidence and Potential Therapeutic Mechanisms in Substance Use and Mood Disorders.","authors":"Mertens LJ, Preller KH","journal":"Pharmacopsychiatry","publication_date":"2021-07-01","publication_year":2021,"doi":"10.1055/a-1341-1907","topic_tags":"Depression,Addiction,Mechanism of Action,Clinical Trial,Randomized Controlled Trial,Review Article,Animal Study,Safety","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2199,"title":"Hallucinogens in Mental Health: Preclinical and Clinical Studies on LSD, Psilocybin, MDMA, and Ketamine.","authors":"De Gregorio D, Aguilar-Valles A, Preller KH, Heifets BD, Hibicke M, Mitchell J, Gobbi G","journal":"The Journal of neuroscience: the official journal of the Society for Neuroscience","publication_date":"2021-02-03","publication_year":2021,"doi":"10.1523/jneurosci.1659-20.2020","topic_tags":"Depression,PTSD,Pharmacology,Review Article,Animal Study","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2229,"title":"P300-mediated modulations in self-other processing under psychedelic psilocybin are related to connectedness and changed meaning: A window into the self-other overlap.","authors":"Smigielski L, Kometer M, Scheidegger M, Stress C, Preller KH, Koenig T, Vollenweider FX","journal":"Human brain mapping","publication_date":"2020-12-01","publication_year":2020,"doi":"10.1002/hbm.25174","topic_tags":"Mechanism of Action,Receptor Pharmacology","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2263,"title":"Psilocybin Induces Time-Dependent Changes in Global Functional Connectivity.","authors":"Preller KH, Duerler P, Burt JB, Ji JL, Adkinson B, Stämpfli P, Seifritz E, Repovš G, Krystal JH, Murray JD, Anticevic A, Vollenweider FX","journal":"Biological psychiatry","publication_date":"2020-07-15","publication_year":2020,"doi":"10.1016/j.biopsych.2019.12.027","topic_tags":"Brain Imaging,Mechanism of Action,Receptor Pharmacology,Biomarkers,Aging","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2296,"title":"Rostral Anterior Cingulate Thickness Predicts the Emotional Psilocybin Experience.","authors":"Lewis CR, Preller KH, Braden BB, Riecken C, Vollenweider FX","journal":"Biomedicines","publication_date":"2020-02-18","publication_year":2020,"doi":"10.3390/biomedicines8020034","topic_tags":"Brain Imaging,Receptor Pharmacology,Consciousness,Aging,Emotional Processing,Healthy Volunteers","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2312,"title":"Neuropharmacological modulation of the aberrant bodily self through psychedelics.","authors":"Ho JT, Preller KH, Lenggenhager B","journal":"Neuroscience and biobehavioral reviews","publication_date":"2020-01-01","publication_year":2020,"doi":"10.1016/j.neubiorev.2019.12.006","topic_tags":"Mechanism of Action,Receptor Pharmacology","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2406,"title":"Psilocybin modulates functional connectivity of the amygdala during emotional face discrimination.","authors":"Grimm O, Kraehenmann R, Preller KH, Seifritz E, Vollenweider FX","journal":"European neuropsychopharmacology: the journal of the European College of Neuropsychopharmacology","publication_date":"2018-06-01","publication_year":2018,"doi":"10.1016/j.euroneuro.2018.03.016","topic_tags":"Receptor Pharmacology,Emotional Processing,Healthy Volunteers","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2444,"title":"Phenomenology, Structure, and Dynamic of Psychedelic States.","authors":"Preller KH, Vollenweider FX","journal":"Current topics in behavioral neurosciences","publication_date":"2018-01-01","publication_year":2018,"doi":"10.1007/7854_2016_459","topic_tags":"Anxiety,Mechanism of Action,Receptor Pharmacology,Consciousness,Personality Change,Emotional Processing,Creativity,Review Article","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2448,"title":"LSD Increases Primary Process Thinking via Serotonin 2A Receptor Activation.","authors":"Kraehenmann R, Pokorny D, Aicher H, Preller KH, Pokorny T, Bosch OG, Seifritz E, Vollenweider FX","journal":"Frontiers in pharmacology","publication_date":"2017-01-01","publication_year":2017,"doi":"10.3389/fphar.2017.00814","topic_tags":"Receptor Pharmacology,Consciousness,Emotional Processing","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2453,"title":"Two dose investigation of the 5-HT-agonist psilocybin on relative and global cerebral blood flow.","authors":"Lewis CR, Preller KH, Kraehenmann R, Michels L, Staempfli P, Vollenweider FX","journal":"NeuroImage","publication_date":"2017-10-01","publication_year":2017,"doi":"10.1016/j.neuroimage.2017.07.020","topic_tags":"Brain Imaging,Pharmacology,Receptor Pharmacology,Consciousness,Aging","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2460,"title":"Effect of Psilocybin on Empathy and Moral Decision-Making.","authors":"Pokorny T, Preller KH, Kometer M, Dziobek I, Vollenweider FX","journal":"The international journal of neuropsychopharmacology","publication_date":"2017-09-01","publication_year":2017,"doi":"10.1093/ijnp/pyx047","topic_tags":"Receptor Pharmacology,Emotional Processing","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2516,"title":"Effects of serotonin 2A/1A receptor stimulation on social exclusion processing.","authors":"Preller KH, Pokorny T, Hock A, Kraehenmann R, Stämpfli P, Seifritz E, Scheidegger M, Vollenweider FX","journal":"Proceedings of the National Academy of Sciences of the United States of America","publication_date":"2016-05-03","publication_year":2016,"doi":"10.1073/pnas.1524187113","topic_tags":"Chronic Pain,Brain Imaging,Receptor Pharmacology,Aging,Healthy Volunteers,Drug Interactions","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2518,"title":"Modulatory effect of the 5-HT1A agonist buspirone and the mixed non-hallucinogenic 5-HT1A/2A agonist ergotamine on psilocybin-induced psychedelic experience.","authors":"Pokorny T, Preller KH, Kraehenmann R, Vollenweider FX","journal":"European neuropsychopharmacology: the journal of the European College of Neuropsychopharmacology","publication_date":"2016-04-01","publication_year":2016,"doi":"10.1016/j.euroneuro.2016.01.005","topic_tags":"Receptor Pharmacology,Consciousness,Drug Interactions","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2525,"title":"The mixed serotonin receptor agonist psilocybin reduces threat-induced modulation of amygdala connectivity.","authors":"Kraehenmann R, Schmidt A, Friston K, Preller KH, Seifritz E, Vollenweider FX","journal":"NeuroImage. Clinical","publication_date":"2016-01-01","publication_year":2016,"doi":"10.1016/j.nicl.2015.08.009","topic_tags":"Depression,Anxiety,Brain Imaging,Receptor Pharmacology,Emotional Processing","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2530,"title":"Psilocybin-Induced Decrease in Amygdala Reactivity Correlates with Enhanced Positive Mood in Healthy Volunteers.","authors":"Kraehenmann R, Preller KH, Scheidegger M, Pokorny T, Bosch OG, Seifritz E, Vollenweider FX","journal":"Biological psychiatry","publication_date":"2015-10-15","publication_year":2015,"doi":"10.1016/j.biopsych.2014.04.010","topic_tags":"Depression,Anxiety,Brain Imaging,Receptor Pharmacology,Aging,Emotional Processing,Healthy Volunteers","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":3071,"title":"Epigenome-wide Association Study of Psilocybin-Induced Methylome Changes in Alcohol Use Disorder","authors":"Urban MM, Zillich L, Rieser NM, Herdener M, Vollenweider FX, Spanagel R, Preller KH, Meinhardt MW.","journal":"bioRxiv","publication_date":"2025-07-18","publication_year":2025,"doi":"10.1101/2025.07.18.664368","topic_tags":"Depression,Addiction,Neuroplasticity,Mechanism of Action,Epigenetics,Observational Study,Genomics,Immune Function","source_name":"bioRxiv","publication_status":"preprint","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":3178,"title":"Effective connectivity of emotion and cognition under psilocybin","authors":"Stoliker D, Novelli L, Vollenweider FX, Egan GF, Preller KH, Razi A.","journal":"medRxiv","publication_date":"2022-09-09","publication_year":2022,"doi":"10.1101/2022.09.06.22279626","topic_tags":"Depression,Addiction,Default Mode Network,Biomarkers,Emotional Processing,Clinical Trial","source_name":"medRxiv","publication_status":"preprint","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":3258,"title":"Neurocomputational evidence of sustained Self-Other mergence after psychedelics","authors":"Mallaroni P, Mason NL, Preller KH, Razi A, Ereira S, Ramaekers JG.","journal":"medRxiv","publication_date":"2025-10-08","publication_year":2025,"doi":"10.1101/2025.10.07.25337510","topic_tags":"Brain Imaging,Wellbeing","source_name":"medRxiv","publication_status":"preprint","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":3327,"title":"Neural mechanisms of psychedelic visual imagery","authors":"Stoliker D, Preller KH, Novelli L, Anticevic A, Egan GF, Vollenweider FX, Razi A.","journal":"medRxiv","publication_date":"2022-09-09","publication_year":2022,"doi":"10.1101/2022.09.07.22279700","topic_tags":"Neuroplasticity,Mechanism of Action,Receptor Pharmacology,Animal Study","source_name":"medRxiv","publication_status":"preprint","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":9,"title":"Psychedelics as a potential treatment for borderline personality disorder: A narrative review.","authors":"Artna E, Sandhu G, Chisamore N, Lipsitz O, Kaczmarek ES, Johnson DE, Rosenblat JD, Sediqzadah S","journal":"Psychiatry research","publication_date":"2026-07-01","publication_year":2026,"doi":"10.1016/j.psychres.2026.117152","topic_tags":"Anxiety,Personality Change,Review Article,Safety","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":326,"title":"Temporal dynamics in neuroimaging as correlates of therapeutic response to psilocybin in major depressive disorder: A systematic review and critical appraisal.","authors":"Sabbah SG, Li S, Wong S, Le GH, Badulescu S, Hawco C, Rosenblat JD, McIntyre RS","journal":"Journal of affective disorders","publication_date":"2026-01-15","publication_year":2026,"doi":"10.1016/j.jad.2025.120335","topic_tags":"Depression,Brain Imaging,Mechanism of Action,Default Mode Network,Aging,Systematic Review,Review Article,Treatment-Resistant Depression,Safety","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":390,"title":"Cognitive outcomes following psilocybin-assisted therapy in treatment-resistant depression: A post-hoc analysis of a randomized, waitlist-controlled trial.","authors":"Johnson DE, Meshkat S, Kaczmarek ES, Rabin JS, Brudner RM, Chisamore N, Doyle Z, Bawks J, Riva-Cambrin J, Mansur RB, Lipsitz O, McIntyre RS, Lanctôt KL, Rosenblat JD","journal":"Progress in neuro-psychopharmacology & biological psychiatry","publication_date":"2025-12-20","publication_year":2025,"doi":"10.1016/j.pnpbp.2025.111565","topic_tags":"Depression,Treatment-Resistant Depression","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":502,"title":"Comparing Antidepressant Effects of Psilocybin-Assisted Psychotherapy in Individuals That Were Unmedicated at Initial Screening Versus Individuals Discontinuing Medications for Study Participation: Comparaison des effets antidépresseurs de la psychothérapie assistée par la psilocybine (PAP) chez les personnes non médicamentées à la sélection initiale et les personnes ayant arrêté les médicaments pour participer à l'étude.","authors":"Chisamore N, Kaczmarek ES, Doyle Z, Johnson DE, Weiglein G, Meshkat S, Brudner RM, Blainey MG, Riva-Cambrin J, McIntyre RS, Rosenblat JD","journal":"Canadian journal of psychiatry. Revue canadienne de psychiatrie","publication_date":"2025-10-01","publication_year":2025,"doi":"10.1177/07067437251328316","topic_tags":"Depression,Anxiety,Mystical Experience,Clinical Trial,Treatment-Resistant Depression,Healthcare Workers","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":540,"title":"Examining mystical experiences as a predictor of psilocybin-assisted psychotherapy for treatment-resistant depression.","authors":"Brudner RM, Kaczmarek E, Blainey MG, Schulz-Quach C, Meshkat S, Doyle Z, Lipsitz O, Offman H, Sethi R, Weiglein G, McIntyre RS, Rosenblat JD","journal":"Journal of psychopharmacology (Oxford, England)","publication_date":"2025-09-01","publication_year":2025,"doi":"10.1177/02698811251346697","topic_tags":"Depression,Mechanism of Action,Mystical Experience,Treatment-Resistant Depression","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":794,"title":"Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression in Bipolar II Disorder.","authors":"Meshkat S, Kaczmarek E, Doyle Z, Brudner RM, Gomes FA, Blainey MG, Weiglein G, McIntyre RS, Mansur RB, Rosenblat JD","journal":"Psychedelic medicine (New Rochelle, N.Y.)","publication_date":"2025-03-01","publication_year":2025,"doi":"10.1089/psymed.2024.0032","topic_tags":"Depression,Treatment-Resistant Depression,Safety","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1064,"title":"Protocols and practices in psilocybin assisted psychotherapy for depression: A systematic review.","authors":"Chisamore N, Johnson D, Chen MJQ, Offman H, Chen-Li D, Kaczmarek ES, Doyle Z, McIntyre RS, Rosenblat JD","journal":"Journal of psychiatric research","publication_date":"2024-08-01","publication_year":2024,"doi":"10.1016/j.jpsychires.2024.05.051","topic_tags":"Depression,End-of-Life Distress,Clinical Trial,Randomized Controlled Trial,Systematic Review,Review Article,Safety","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1108,"title":"Spectral signatures of psilocybin, lysergic acid diethylamide (LSD) and ketamine in healthy volunteers and persons with major depressive disorder and treatment-resistant depression: A systematic review.","authors":"Le GH, Wong S, Badulescu S, Au H, Di Vincenzo JD, Gill H, Phan L, Rhee TG, Ho R, Teopiz KM, Kwan ATH, Rosenblat JD, Mansur RB, McIntyre RS","journal":"Journal of affective disorders","publication_date":"2024-06-15","publication_year":2024,"doi":"10.1016/j.jad.2024.03.165","topic_tags":"Depression,Brain Imaging,Mechanism of Action,Biomarkers,Systematic Review,Review Article,Healthy Volunteers,Treatment-Resistant Depression","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1177,"title":"A comparison between psilocybin and esketamine in treatment-resistant depression using number needed to treat (NNT): A systematic review.","authors":"Wong S, Kwan ATH, Teopiz KM, Le GH, Meshkat S, Ho R, d'Andrea G, Cao B, Di Vincenzo JD, Rosenblat JD, McIntyre RS","journal":"Journal of affective disorders","publication_date":"2024-04-01","publication_year":2024,"doi":"10.1016/j.jad.2024.01.142","topic_tags":"Depression,Headache / Migraine,Randomized Controlled Trial,Systematic Review,Review Article,Treatment-Resistant Depression","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1204,"title":"Psilocybin-assisted psychotherapy for treatment resistant depression: A randomized clinical trial evaluating repeated doses of psilocybin.","authors":"Rosenblat JD, Meshkat S, Doyle Z, Kaczmarek E, Brudner RM, Kratiuk K, Mansur RB, Schulz-Quach C, Sethi R, Abate A, Ali S, Bawks J, Blainey MG, Brietzke E, Cronin V, Danilewitz J, Dhawan S, Di Fonzo A, Di Fonzo M, Drzadzewski P, Dunlop W, Fiszter H, Gomes FA, Grewal S, Leon-Carlyle M, McCallum M, Mofidi N, Offman H, Riva-Cambrin J, Schmidt J, Smolkin M, Quinn JM, Zumrova A, Marlborough M, McIntyre RS","journal":"Med (New York, N.Y.)","publication_date":"2024-03-08","publication_year":2024,"doi":"10.1016/j.medj.2024.01.005","topic_tags":"Depression,Addiction,Personality Change,Clinical Trial,Treatment-Resistant Depression,Safety,Adverse Events","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1675,"title":"A Research Domain Criteria (RDoC)-Guided Dashboard to Review Psilocybin Target Domains: A Systematic Review.","authors":"Pouyan N, Halvaei Khankahdani Z, Younesi Sisi F, Lee Y, Rosenblat JD, Teopiz KM, Lui LMW, Subramaniapillai M, Lin K, Nasri F, Rodrigues N, Gill H, Lipsitz O, Cao B, Ho R, Castle D, McIntyre RS","journal":"CNS drugs","publication_date":"2022-10-01","publication_year":2022,"doi":"10.1007/s40263-022-00944-y","topic_tags":"Randomized Controlled Trial,Systematic Review,Review Article","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1744,"title":"The Effects of Psilocybin in Adults with Major Depressive Disorder and the General Population: Findings from Neuroimaging Studies.","authors":"Gill H, Puramat P, Patel P, Gill B, Marks CA, Rodrigues NB, Castle D, Cha DS, Mansur RB, Rosenblat JD, McIntyre RS","journal":"Psychiatry research","publication_date":"2022-07-01","publication_year":2022,"doi":"10.1016/j.psychres.2022.114577","topic_tags":"Depression,Brain Imaging,Aging,Review Article,Safety","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1858,"title":"Molecular Mechanisms of Psilocybin and Implications for the Treatment of Depression.","authors":"Ling S, Ceban F, Lui LMW, Lee Y, Teopiz KM, Rodrigues NB, Lipsitz O, Gill H, Subramaniapillai M, Mansur RB, Lin K, Ho R, Rosenblat JD, Castle D, McIntyre RS","journal":"CNS drugs","publication_date":"2022-01-01","publication_year":2022,"doi":"10.1007/s40263-021-00877-y","topic_tags":"Depression,Pharmacology,Mechanism of Action,Receptor Pharmacology,Default Mode Network,Review Article,Treatment-Resistant Depression","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2145,"title":"Registered clinical studies investigating psychedelic drugs for psychiatric disorders.","authors":"Siegel AN, Meshkat S, Benitah K, Lipsitz O, Gill H, Lui LMW, Teopiz KM, McIntyre RS, Rosenblat JD","journal":"Journal of psychiatric research","publication_date":"2021-07-01","publication_year":2021,"doi":"10.1016/j.jpsychires.2021.05.019","topic_tags":"Depression,Anxiety,PTSD,Addiction,Consciousness","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2228,"title":"The emerging role of psilocybin and MDMA in the treatment of mental illness.","authors":"Gill H, Gill B, Chen-Li D, El-Halabi S, Rodrigues NB, Cha DS, Lipsitz O, Lee Y, Rosenblat JD, Majeed A, Mansur RB, Nasri F, Ho R, McIntyre RS","journal":"Expert review of neurotherapeutics","publication_date":"2020-12-01","publication_year":2020,"doi":"10.1080/14737175.2020.1826931","topic_tags":"Depression,Anxiety,PTSD,Emotional Processing,Clinical Trial,Review Article,Safety","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2343,"title":"Pharmacological interventions targeting anhedonia in patients with major depressive disorder: A systematic review.","authors":"Cao B, Zhu J, Zuckerman H, Rosenblat JD, Brietzke E, Pan Z, Subramanieapillai M, Park C, Lee Y, McIntyre RS","journal":"Progress in neuro-psychopharmacology & biological psychiatry","publication_date":"2019-06-08","publication_year":2019,"doi":"10.1016/j.pnpbp.2019.01.002","topic_tags":"Depression,Systematic Review,Review Article","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1163,"title":"Author Correction: Psilocybin enhances insightfulness in meditation: a perspective on the global topology of brain imaging during meditation.","authors":"Singer B, Meling D, Hirsch-Hoffmann M, Michels L, Kometer M, Smigielski L, Dornbierer D, Seifritz E, Vollenweider FX, Scheidegger M","journal":"Scientific reports","publication_date":"2024-04-23","publication_year":2024,"doi":"10.1038/s41598-024-59897-5","topic_tags":"Brain Imaging,Aging","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1192,"title":"Psilocybin enhances insightfulness in meditation: a perspective on the global topology of brain imaging during meditation.","authors":"Singer B, Meling D, Hirsch-Hoffmann M, Michels L, Kometer M, Smigielski L, Dornbierer D, Seifritz E, Vollenweider FX, Scheidegger M","journal":"Scientific reports","publication_date":"2024-03-26","publication_year":2024,"doi":"10.1038/s41598-024-55726-x","topic_tags":"Brain Imaging,Biomarkers,Aging","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2323,"title":"Characterization and prediction of acute and sustained response to psychedelic psilocybin in a mindfulness group retreat.","authors":"Smigielski L, Kometer M, Scheidegger M, Krähenmann R, Huber T, Vollenweider FX","journal":"Scientific reports","publication_date":"2019-10-24","publication_year":2019,"doi":"10.1038/s41598-019-50612-3","topic_tags":"Anxiety,Mechanism of Action,Emotional Processing,Drug Interactions","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2336,"title":"Psilocybin-assisted mindfulness training modulates self-consciousness and brain default mode network connectivity with lasting effects.","authors":"Smigielski L, Scheidegger M, Kometer M, Vollenweider FX","journal":"NeuroImage","publication_date":"2019-08-01","publication_year":2019,"doi":"10.1016/j.neuroimage.2019.04.009","topic_tags":"Brain Imaging,Default Mode Network,Consciousness,Aging","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2445,"title":"Serotonergic Hallucinogen-Induced Visual Perceptual Alterations.","authors":"Kometer M, Vollenweider FX","journal":"Current topics in behavioral neurosciences","publication_date":"2018-01-01","publication_year":2018,"doi":"10.1007/7854_2016_461","topic_tags":"Mechanism of Action,Receptor Pharmacology","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2553,"title":"Spatiotemporal brain dynamics of emotional face processing modulations induced by the serotonin 1A/2A receptor agonist psilocybin.","authors":"Bernasconi F, Schmidt A, Pokorny T, Kometer M, Seifritz E, Vollenweider FX","journal":"Cerebral cortex (New York, N.Y.: 1991)","publication_date":"2014-12-01","publication_year":2014,"doi":"10.1093/cercor/bht178","topic_tags":"Brain Imaging,Mechanism of Action,Receptor Pharmacology,Aging,Emotional Processing","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2583,"title":"Activation of serotonin 2A receptors underlies the psilocybin-induced effects on α oscillations, N170 visual-evoked potentials, and visual hallucinations.","authors":"Kometer M, Schmidt A, Jäncke L, Vollenweider FX","journal":"The Journal of neuroscience: the official journal of the Society for Neuroscience","publication_date":"2013-06-19","publication_year":2013,"doi":"10.1523/jneurosci.3007-12.2013","topic_tags":"Receptor Pharmacology,Consciousness","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2597,"title":"Psilocybin biases facial recognition, goal-directed behavior, and mood state toward positive relative to negative emotions through different serotonergic subreceptors.","authors":"Kometer M, Schmidt A, Bachmann R, Studerus E, Seifritz E, Vollenweider FX","journal":"Biological psychiatry","publication_date":"2012-12-01","publication_year":2012,"doi":"10.1016/j.biopsych.2012.04.005","topic_tags":"Depression,Mechanism of Action,Receptor Pharmacology,Emotional Processing","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2607,"title":"Mismatch negativity encoding of prediction errors predicts S-ketamine-induced cognitive impairments.","authors":"Schmidt A, Bachmann R, Kometer M, Csomor PA, Stephan KE, Seifritz E, Vollenweider FX","journal":"Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology","publication_date":"2012-03-01","publication_year":2012,"doi":"10.1038/npp.2011.261","topic_tags":"Mechanism of Action,Receptor Pharmacology,Consciousness,Healthy Volunteers","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2609,"title":"Psilocybin-induced deficits in automatic and controlled inhibition are attenuated by ketanserin in healthy human volunteers.","authors":"Quednow BB, Kometer M, Geyer MA, Vollenweider FX","journal":"Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology","publication_date":"2012-02-01","publication_year":2012,"doi":"10.1038/npp.2011.228","topic_tags":"Receptor Pharmacology,Consciousness,Healthy Volunteers","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2610,"title":"Prediction of psilocybin response in healthy volunteers.","authors":"Studerus E, Gamma A, Kometer M, Vollenweider FX","journal":"PloS one","publication_date":"2012-01-01","publication_year":2012,"doi":"10.1371/journal.pone.0030800","topic_tags":"Anxiety,Personality Change,Emotional Processing,Mystical Experience,Healthy Volunteers","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2615,"title":"Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies.","authors":"Studerus E, Kometer M, Hasler F, Vollenweider FX","journal":"Journal of psychopharmacology (Oxford, England)","publication_date":"2011-11-01","publication_year":2011,"doi":"10.1177/0269881110382466","topic_tags":"Anxiety,Safety,Adverse Events","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2624,"title":"The 5-HT2A/1A agonist psilocybin disrupts modal object completion associated with visual hallucinations.","authors":"Kometer M, Cahn BR, Andel D, Carter OL, Vollenweider FX","journal":"Biological psychiatry","publication_date":"2011-03-01","publication_year":2011,"doi":"10.1016/j.biopsych.2010.10.002","topic_tags":"Receptor Pharmacology","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2629,"title":"The neurobiology of psychedelic drugs: implications for the treatment of mood disorders.","authors":"Vollenweider FX, Kometer M","journal":"Nature reviews. Neuroscience","publication_date":"2010-09-01","publication_year":2010,"doi":"10.1038/nrn2884","topic_tags":"Neuroplasticity,Brain Imaging,Mechanism of Action,Aging","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2630,"title":"Psychometric evaluation of the altered states of consciousness rating scale (OAV).","authors":"Studerus E, Gamma A, Vollenweider FX","journal":"PloS one","publication_date":"2010-08-31","publication_year":2010,"doi":"10.1371/journal.pone.0012412","topic_tags":"Consciousness","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2647,"title":"GMP-compliant radiosynthesis of [18F]altanserin and human plasma metabolite studies.","authors":"Hasler F, Kuznetsova OF, Krasikova RN, Cservenyak T, Quednow BB, Vollenweider FX, Ametamey SM, Westera G","journal":"Applied radiation and isotopes: including data, instrumentation and methods for use in agriculture, industry and medicine","publication_date":"2009-04-01","publication_year":2009,"doi":"10.1016/j.apradiso.2008.12.007","topic_tags":"Pharmacology,Receptor Pharmacology","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2652,"title":"Serotonin research: contributions to understanding psychoses.","authors":"Geyer MA, Vollenweider FX","journal":"Trends in pharmacological sciences","publication_date":"2008-09-01","publication_year":2008,"doi":"10.1016/j.tips.2008.06.006","topic_tags":"Brain Imaging,Receptor Pharmacology,Consciousness,Aging,Review Article","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2657,"title":"Effects of varied doses of psilocybin on time interval reproduction in human subjects.","authors":"Wackermann J, Wittmann M, Hasler F, Vollenweider FX","journal":"Neuroscience letters","publication_date":"2008-04-11","publication_year":2008,"doi":"10.1016/j.neulet.2008.02.006","topic_tags":"Consciousness","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2664,"title":"Psilocybin links binocular rivalry switch rate to attention and subjective arousal levels in humans.","authors":"Carter OL, Hasler F, Pettigrew JD, Wallis GM, Liu GB, Vollenweider FX","journal":"Psychopharmacology","publication_date":"2007-12-01","publication_year":2007,"doi":"10.1007/s00213-007-0930-9","topic_tags":"Receptor Pharmacology","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2668,"title":"The effects of the preferential 5-HT2A agonist psilocybin on prepulse inhibition of startle in healthy human volunteers depend on interstimulus interval.","authors":"Vollenweider FX, Csomor PA, Knappe B, Geyer MA, Quednow BB","journal":"Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology","publication_date":"2007-09-01","publication_year":2007,"doi":"10.1038/sj.npp.1301324","topic_tags":"Receptor Pharmacology,Consciousness,Animal Study","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2689,"title":"Using psilocybin to investigate the relationship between attention, working memory, and the serotonin 1A and 2A receptors.","authors":"Carter OL, Burr DC, Pettigrew JD, Wallis GM, Hasler F, Vollenweider FX","journal":"Journal of cognitive neuroscience","publication_date":"2005-10-01","publication_year":2005,"doi":"10.1162/089892905774597191","topic_tags":"Receptor Pharmacology","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2692,"title":"Modulating the rate and rhythmicity of perceptual rivalry alternations with the mixed 5-HT2A and 5-HT1A agonist psilocybin.","authors":"Carter OL, Pettigrew JD, Hasler F, Wallis GM, Liu GB, Hell D, Vollenweider FX","journal":"Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology","publication_date":"2005-06-01","publication_year":2005,"doi":"10.1038/sj.npp.1300621","topic_tags":"Pharmacology,Mechanism of Action,Receptor Pharmacology,Consciousness","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2698,"title":"Psilocybin impairs high-level but not low-level motion perception.","authors":"Carter OL, Pettigrew JD, Burr DC, Alais D, Hasler F, Vollenweider FX","journal":"Neuroreport","publication_date":"2004-08-26","publication_year":2004,"doi":"10.1097/00001756-200408260-00023","topic_tags":"Receptor Pharmacology","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2703,"title":"Acute psychological and physiological effects of psilocybin in healthy humans: a double-blind, placebo-controlled dose-effect study.","authors":"Hasler F, Grimberg U, Benz MA, Huber T, Vollenweider FX","journal":"Psychopharmacology","publication_date":"2004-03-01","publication_year":2004,"doi":"10.1007/s00213-003-1640-6","topic_tags":"Anxiety,Receptor Pharmacology,Consciousness,Emotional Processing","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2709,"title":"[Hallucinogens, amphetamines and entactogens].","authors":"Vollenweider FX, Vollenweider-Scherpenhuyzen MF","journal":"Therapeutische Umschau. Revue therapeutique","publication_date":"2003-06-01","publication_year":2003,"doi":"10.1024/0040-5930.60.6.323","topic_tags":"Emotional Processing,Observational Study,Safety,Toxicity","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2713,"title":"Effects of the 5-HT2A agonist psilocybin on mismatch negativity generation and AX-continuous performance task: implications for the neuropharmacology of cognitive deficits in schizophrenia.","authors":"Umbricht D, Vollenweider FX, Schmid L, Grübel C, Skrabo A, Huber T, Koller R","journal":"Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology","publication_date":"2003-01-01","publication_year":2003,"doi":"10.1038/sj.npp.1300005","topic_tags":"Pharmacology,Receptor Pharmacology,Healthy Volunteers","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2722,"title":"Mismatch negativity predicts psychotic experiences induced by NMDA receptor antagonist in healthy volunteers.","authors":"Umbricht D, Koller R, Vollenweider FX, Schmid L","journal":"Biological psychiatry","publication_date":"2002-03-01","publication_year":2002,"doi":"10.1016/s0006-3223(01)01242-2","topic_tags":"Receptor Pharmacology,Consciousness,Healthy Volunteers","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2726,"title":"Brain mechanisms of hallucinogens and entactogens.","authors":"Vollenweider FX","journal":"Dialogues in clinical neuroscience","publication_date":"2001-12-01","publication_year":2001,"doi":"10.31887/dcns.2001.3.4/fxvollenweider","topic_tags":"Brain Imaging,Mechanism of Action,Receptor Pharmacology,Aging,Emotional Processing,Review Article","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2727,"title":"A systems model of altered consciousness: integrating natural and drug-induced psychoses.","authors":"Vollenweider FX, Geyer MA","journal":"Brain research bulletin","publication_date":"2001-11-15","publication_year":2001,"doi":"10.1016/s0361-9230(01)00646-3","topic_tags":"Brain Imaging,Mechanism of Action,Receptor Pharmacology,Consciousness,Aging","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2750,"title":"5-HT modulation of dopamine release in basal ganglia in psilocybin-induced psychosis in man--a PET study with [11C]raclopride.","authors":"Vollenweider FX, Vontobel P, Hell D, Leenders KL","journal":"Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology","publication_date":"1999-05-01","publication_year":1999,"doi":"10.1016/s0893-133x(98)00108-0","topic_tags":"Receptor Pharmacology,Healthy Volunteers,Drug Interactions","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2753,"title":"Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action.","authors":"Vollenweider FX, Vollenweider-Scherpenhuyzen MF, Bäbler A, Vogel H, Hell D","journal":"Neuroreport","publication_date":"1998-12-01","publication_year":1998,"doi":"10.1097/00001756-199812010-00024","topic_tags":"Receptor Pharmacology","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2759,"title":"Advances and pathophysiological models of hallucinogenic drug actions in humans: a preamble to schizophrenia research.","authors":"Vollenweider FX","journal":"Pharmacopsychiatry","publication_date":"1998-07-01","publication_year":1998,"doi":"10.1055/s-2007-979353","topic_tags":"Receptor Pharmacology,Animal Study,Drug Interactions","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2764,"title":"Positron emission tomography and fluorodeoxyglucose studies of metabolic hyperfrontality and psychopathology in the psilocybin model of psychosis.","authors":"Vollenweider FX, Leenders KL, Scharfetter C, Maguire P, Stadelmann O, Angst J","journal":"Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology","publication_date":"1997-05-01","publication_year":1997,"doi":"10.1016/s0893-133x(96)00246-1","topic_tags":"Pharmacology,Receptor Pharmacology,Healthy Volunteers","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":3033,"title":"Ketamine and Psilocybin Differentially Impact Sensory Learning During the Mismatch Negativity","authors":"Allohverdi SG, Soltanzadeh M, Schmidt A, Charlton CE, Hauke DJ, Karvelis P, Vollenweider FX, Diaconescu AO.","journal":"bioRxiv","publication_date":"2025-11-07","publication_year":2025,"doi":"10.1101/2025.11.06.687023","topic_tags":"Depression,Brain Imaging,Mechanism of Action","source_name":"bioRxiv","publication_status":"preprint","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":3287,"title":"Psilocybin exerts distinct effects on resting state networks associated with serotonin and dopamine in mice","authors":"Grandjean J, Buehlmann D, Buerge M, Sigrist H, Seifritz E, Vollenweider FX, Pryce CR, Rudin M.","journal":"bioRxiv","publication_date":"2019-09-01","publication_year":2019,"doi":"10.1101/751255","topic_tags":"Depression,Brain Imaging,Mechanism of Action,Receptor Pharmacology,Default Mode Network,Animal Study,Drug Interactions","source_name":"bioRxiv","publication_status":"preprint","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":93,"title":"A systematic review of the pharmacokinetics of classical serotonergic psychedelic compounds in healthy adult subjects.","authors":"Hampsey E, Martin K, Kalfas M, Benson L, Wihlborg S, Jelen L, Young AH, Rucker J","journal":"Journal of psychopharmacology (Oxford, England)","publication_date":"2026-08-01","publication_year":2026,"doi":"10.1177/02698811261453938","topic_tags":"Pharmacology,Systematic Review,Review Article","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":139,"title":"Effects of psilocybin on personality, psychiatric symptoms, and values: Exploring mediating effects of the acute psychedelic experience.","authors":"Kerr-Gaffney J, Myrtle S, Askari F, Bird C, Modlin NL, Young AH, Rucker J","journal":"Journal of psychopharmacology (Oxford, England)","publication_date":"2026-05-01","publication_year":2026,"doi":"10.1177/02698811251408769","topic_tags":"Consciousness,Wellbeing,Personality Change,Clinical Trial,Healthy Volunteers","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":401,"title":"Investigational psilocybin treatment for post-traumatic stress disorder: a qualitative study of participant experience, trauma engagement, and differences from standard treatment.","authors":"Modlin NL, Williamson V, Goodwin GM, Malievskaia E, Atli M, Elek Z, Gaillard A, Koelpin D, Cleare A, Agrawal M, Yehuda R, Kirlic N, Rucker J","journal":"EClinicalMedicine","publication_date":"2025-12-01","publication_year":2025,"doi":"10.1016/j.eclinm.2025.103692","topic_tags":"Depression,PTSD,Mechanism of Action,Clinical Trial,Safety","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":448,"title":"Psilocybin-assisted physiotherapy for refractory motor functional neurological disorder: protocol for a randomised dose-comparison pilot study.","authors":"Bhagavan C, Bryson A, Carter O, Nielsen G, Berlowitz D, Issak S, Braat S, Zaloumis S, Attard Z, Eleftheriadis D, Oliver G, Mayne D, Roebuck G, Rucker J, Butler M, Kanaan R","journal":"Acta neuropsychiatrica","publication_date":"2025-11-04","publication_year":2025,"doi":"10.1017/neu.2025.10042","topic_tags":"Brain Imaging,Aging,Personality Change,Randomized Controlled Trial,Observational Study,Safety","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":598,"title":"Perspectives on Trauma Treatment, Self-Management Strategies, and Attitudes Toward Psychedelic Therapies in Individuals with Psychological Trauma Symptoms.","authors":"Modlin NL, Jessica L MK, Sarang M, Siebenaler L, Maggio C, Pick S, Williamson V, Cleare A, Rucker J","journal":"Psychiatry and clinical psychopharmacology","publication_date":"2025-07-30","publication_year":2025,"doi":"10.5152/pcp.2025.24934","topic_tags":"PTSD,Clinical Trial,Observational Study,Safety","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":663,"title":"Clinical conceptualisation of PTSD in psilocybin treatment: disrupting a pre-determined and over-determined maladaptive interpretive framework.","authors":"Modlin NL, Williamson V, Maggio C, Stubley J, Kirlic N, Cleare A, Rucker J","journal":"Therapeutic advances in psychopharmacology","publication_date":"2025-01-01","publication_year":2025,"doi":"10.1177/20451253251342319","topic_tags":"Depression,Anxiety,PTSD,Eating Disorders,End-of-Life Distress,Mechanism of Action,Review Article,Treatment-Resistant Depression,Safety","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":735,"title":"Probing the functional magnetic resonance imaging response to psilocybin in functional neurological disorder (PsiFUND): study protocol.","authors":"Butler M, Bird C, Maggio C, Durden A, Modlin N, Campbell-Coker K, Edwards M, Pick S, Millman LSM, Lowery E, Bhagavan C, Kanaan R, Golder D, Mildon B, Mehta M, Rucker J, Nicholson TR","journal":"Wellcome open research","publication_date":"2024-01-01","publication_year":2024,"doi":"10.12688/wellcomeopenres.22543.2","topic_tags":"Brain Imaging,Mechanism of Action,Aging","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":795,"title":"Participants' Experience of Psychedelic Integration Groups and Processes: A Qualitative Thematic Analysis.","authors":"Modlin NL, McPhee T, Zazon N, Sarang M, Hignett R, Pick S, Cleare A, Williamson V, Rucker J","journal":"Psychedelic medicine (New Rochelle, N.Y.)","publication_date":"2025-03-01","publication_year":2025,"doi":"10.1089/psymed.2024.0027","topic_tags":"Aging,Clinical Trial,Observational Study,Safety","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":846,"title":"Psychedelic-assisted treatment for substance use disorder: A narrative systematic review.","authors":"Piper T, Small F, Brown S, Kelleher M, Mitcheson L, Rucker J, Young AH, Marsden J","journal":"Addiction (Abingdon, England)","publication_date":"2025-01-30","publication_year":2025,"doi":"10.1111/add.16762","topic_tags":"Addiction,Clinical Trial,Randomized Controlled Trial,Systematic Review,Review Article,Observational Study,Safety,Adverse Events","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":974,"title":"Low-dose psilocybin in short-lasting unilateral neuralgiform headache attacks: results from an open-label phase Ib ascending dose study.","authors":"Rucker J, Butler M, Hambleton S, Bird C, Seynaeve M, Cheema S, Campbell-Coker K, Maggio C, Dunbar F, Lambru G, Matharu M","journal":"Headache","publication_date":"2024-01-01","publication_year":2024,"doi":"10.1111/head.14837","topic_tags":"Chronic Pain,Headache / Migraine,Receptor Pharmacology,Consciousness,Clinical Trial,Healthcare Workers,Safety,Adverse Events","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1072,"title":"Psilocybin and Motor Function: A Triple-Blind, Dose-Finding Study in Healthy Participants.","authors":"Bhagavan C, Kanaan R, Carter O, Nielsen G, Berlowitz D, Issak S, Braat S, Zaloumis S, Attard Z, Oliver G, Mayne D, McKernon D, Roebuck G, Rucker J, Butler M, Bryson A","journal":"Psychiatric research and clinical practice","publication_date":"2024-01-01","publication_year":2024,"doi":"10.1176/appi.prcp.20240047","topic_tags":"Brain Imaging,Aging,Healthy Volunteers,Safety","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1121,"title":"Psilocybin for dementia prevention? The potential role of psilocybin to alter mechanisms associated with major depression and neurodegenerative diseases","authors":"Haniff Z, Bocharova M, Mantingh T, Rucker J, Velayudhan L, Taylor D, Young A, Aarsland D, Vernon A, Thuret S.","journal":"Pharmacology & therapeutics","publication_date":"2024-06-01","publication_year":2024,"doi":null,"topic_tags":"Depression,Mechanism of Action","source_name":"Europe PMC","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1198,"title":"UK medical students' self-reported knowledge and harm assessment of psychedelics and their application in clinical research: a cross-sectional study.","authors":"Song-Smith C, Jacobs E, Rucker J, Saint M, Cooke J, Schlosser M","journal":"BMJ open","publication_date":"2024-03-14","publication_year":2024,"doi":"10.1136/bmjopen-2023-083595","topic_tags":"Observational Study","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1677,"title":"Expectancy in placebo-controlled trials of psychedelics: if so, so what?","authors":"Butler M, Jelen L, Rucker J","journal":"Psychopharmacology","publication_date":"2022-10-01","publication_year":2022,"doi":"10.1007/s00213-022-06221-6","topic_tags":"Clinical Trial,Randomized Controlled Trial","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1875,"title":"Psilocybin-assisted therapy for the treatment of resistant major depressive disorder (PsiDeR): protocol for a randomised, placebo-controlled feasibility trial.","authors":"Rucker J, Jafari H, Mantingh T, Bird C, Modlin NL, Knight G, Reinholdt F, Day C, Carter B, Young A","journal":"BMJ open","publication_date":"2021-12-01","publication_year":2021,"doi":"10.1136/bmjopen-2021-056091","topic_tags":"Depression,Brain Imaging,Biomarkers,Aging,Clinical Trial,Review Article","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2276,"title":"Psychedelic treatment of functional neurological disorder: a systematic review.","authors":"Butler M, Seynaeve M, Nicholson TR, Pick S, Kanaan RA, Lees A, Young AH, Rucker J","journal":"Therapeutic advances in psychopharmacology","publication_date":"2020-01-01","publication_year":2020,"doi":"10.1177/2045125320912125","topic_tags":"Systematic Review,Review Article,Healthcare Workers,Adverse Events","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":3055,"title":"A Randomised, Triple-Blind, Dose-Finding Study of the Impact of Psilocybin on Motor Function in Healthy Participants","authors":"Bhagavan C, Carter O, Nielsen G, Berlowitz D, Issak S, Braat S, Zaloumis S, Attard Z, Oliver G, Mayne D, Rucker J, Butler M, Dandash O, Bryson A, Kanaan RA.","journal":"medRxiv","publication_date":"2025-12-23","publication_year":2025,"doi":"10.64898/2025.12.22.25342874","topic_tags":"Headache / Migraine,Consciousness,Clinical Trial,Review Article,Healthy Volunteers,Safety,Adverse Events","source_name":"medRxiv","publication_status":"preprint","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":3165,"title":"Probing the functional magnetic resonance imaging response to psilocybin in functional neurological disorder (PsiFUND): study protocol","authors":"Butler M, Bird C, Maggio C, Durden A, Modlin N, Campbell-Coker K, Edwards M, Pick S, Millman LM, Lowery E, Bhagavan C, Kanaan R, Golder D, Mildon B, Mehta M, Rucker J, Nicholson TR.","journal":"Wellcome Open Res","publication_date":"2024-07-24","publication_year":2024,"doi":"10.12688/wellcomeopenres.22543.1","topic_tags":"Brain Imaging,Mechanism of Action,Default Mode Network,Aging","source_name":"Europe PMC","publication_status":"preprint","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":5781,"title":"Impact of Psilocybin on Motor Function in Healthy Participants: A Phase 1, Randomised, Triple-Blind, Dose-Finding Study.","authors":"Bhagavan C, Carter O, Nielsen G, Berlowitz D, Issak S, Braat S, Zaloumis S, Attard Z, Oliver G, Mayne D, Rucker J, Butler M, Dandash O, Bryson A, Kanaan RA.","journal":"CNS drugs","publication_date":"2026-08-07","publication_year":2026,"doi":"10.1007/s40263-026-01326-4","topic_tags":"Headache / Migraine,Consciousness,Clinical Trial,Healthy Volunteers,Safety,Adverse Events","source_name":"Europe PMC","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1066,"title":"Is it now time to prepare psychiatry for a psychedelic future?","authors":"Nutt D, Crome I, Young AH","journal":"The British journal of psychiatry: the journal of mental science","publication_date":"2024-08-01","publication_year":2024,"doi":"10.1192/bjp.2024.76","topic_tags":"Depression,PTSD,Treatment-Resistant Depression","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1257,"title":"Knowledge gaps in psychedelic medicalisation: Clinical studies and regulatory aspects.","authors":"E-Wen McCulloch D, Liechti ME, Kuypers KP, Nutt D, Lundberg J, Stenbæk DS, Goodwin GM, Gründer G, Butlen-Ducuing F, Haberkamp M, Thirstrup S, Knudsen GM","journal":"Neuroscience applied","publication_date":"2024-01-01","publication_year":2024,"doi":"10.1016/j.nsa.2024.103938","topic_tags":"Depression,Pharmacology,Clinical Trial","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1289,"title":"When the Trial Ends: The Case for Post-Trial Provisions in Clinical Psychedelic Research.","authors":"Jacobs E, Murphy-Beiner A, Rouiller I, Nutt D, Spriggs MJ","journal":"Neuroethics","publication_date":"2024-01-01","publication_year":2024,"doi":"10.1007/s12152-023-09536-z","topic_tags":"Clinical Trial","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1392,"title":"Bayesian analysis of real-world data as evidence for drug approval: Remembering Sir Michael Rawlins.","authors":"Szigeti B, Phillips LD, Nutt D","journal":"British journal of clinical pharmacology","publication_date":"2023-09-01","publication_year":2023,"doi":"10.1111/bcp.15841","topic_tags":"Depression,Randomized Controlled Trial","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1527,"title":"Default Mode Network Modulation by Psychedelics: A Systematic Review.","authors":"Gattuso JJ, Perkins D, Ruffell S, Lawrence AJ, Hoyer D, Jacobson LH, Timmermann C, Castle D, Rossell SL, Downey LA, Pagni BA, Galvão-Coelho NL, Nutt D, Sarris J","journal":"The international journal of neuropsychopharmacology","publication_date":"2023-03-22","publication_year":2023,"doi":"10.1093/ijnp/pyac074","topic_tags":"Depression,Anxiety,PTSD,OCD,Mechanism of Action,Default Mode Network,Mystical Experience,Systematic Review,Review Article","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2363,"title":"Psychedelic drugs-a new era in psychiatry?.","authors":"Nutt D","journal":"Dialogues in clinical neuroscience","publication_date":"2019-01-01","publication_year":2019,"doi":"10.31887/dcns.2019.21.2/dnutt","topic_tags":"Depression,Anxiety,PTSD,Addiction,OCD,Clinical Trial,Treatment-Resistant Depression","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2496,"title":"Psilocybin for anxiety and depression in cancer care? Lessons from the past and prospects for the future.","authors":"Nutt D","journal":"Journal of psychopharmacology (Oxford, England)","publication_date":"2016-12-01","publication_year":2016,"doi":"10.1177/0269881116675754","topic_tags":"Depression,Anxiety","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":3381,"title":"Neuroimaging in psychedelic drug development: Past, present, and future","authors":"Wall M, Harding R, Zafar R, Rabiner EA, Nutt D, Erritzoe D.","journal":"PsyArXiv","publication_date":"2022-06-30","publication_year":2022,"doi":"10.31234/osf.io/xwu4j","topic_tags":"Depression,PTSD,Addiction,Eating Disorders,Brain Imaging,Pharmacology,Aging","source_name":"PsyArXiv","publication_status":"preprint","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":76,"title":"Reorganization of Human Brain Waves Across Diverse States of Consciousness.","authors":"Fotiadis P, Jang H, Dai R, Li D, Cofré R, Timmermann C, Mashour GA, Hudetz AG, Huang Z","journal":"bioRxiv: the preprint server for biology","publication_date":"2026-06-01","publication_year":2026,"doi":"10.64898/2026.05.27.728182","topic_tags":"Mechanism of Action,Consciousness","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":232,"title":"Digital Intervention for Psychedelic Preparation (DIPP): protocol for a randomised controlled feasibility trial comparing meditation- and music-based programmes in healthy volunteers.","authors":"McAlpine R, Jaglinska M, Jedlovszky K, Kuc J, Castro A, Piot A, Timmermann C, Skipper JI, Sacchet MD, Kamboj SK","journal":"BMJ open","publication_date":"2026-03-12","publication_year":2026,"doi":"10.1136/bmjopen-2025-107512","topic_tags":"Brain Imaging,Aging,Wellbeing,Emotional Processing,Randomized Controlled Trial,Review Article,Healthy Volunteers","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":645,"title":"A Scoping Review of Research in Naturalistic Studies with Psychedelics.","authors":"Carvalho LC, Encantado J, Kettner H, Timmermann C, Veiga D, Teixeira PJ","journal":"Journal of psychoactive drugs","publication_date":"2025-06-28","publication_year":2025,"doi":"10.1080/02791072.2025.2520221","topic_tags":"Clinical Trial,Review Article,Observational Study","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":888,"title":"Effects of psychedelics on human oscillatory brain activity.","authors":"Godfrey K, Luan LX, Timmermann C","journal":"International review of neurobiology","publication_date":"2025-01-01","publication_year":2025,"doi":"10.1016/bs.irn.2025.04.012","topic_tags":"Brain Imaging,Mechanism of Action,Biomarkers,Aging,Review Article","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1045,"title":"Translation and Initial Psychometric Evaluation of Spanish Versions of Three Psychedelic Acute Effects Measures: Mystical, Challenging, and Insight Experiences.","authors":"Davis AK, Timmermann C, Ortiz Bernal AM, Lancelotta R, Nayak S, Sepeda ND, Nikolaidis A, Griffiths RR","journal":"Journal of psychoactive drugs","publication_date":"2024-01-01","publication_year":2024,"doi":"10.1080/02791072.2023.2232379","topic_tags":"Mystical Experience,Observational Study","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1690,"title":"Towards psychedelic apprenticeship: Developing a gentle touch for the mediation and validation of psychedelic-induced insights and revelations.","authors":"Timmermann C, Watts R, Dupuis D","journal":"Transcultural psychiatry","publication_date":"2022-10-01","publication_year":2022,"doi":"10.1177/13634615221082796","topic_tags":"Safety","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":3351,"title":"The entropic heart: Tracking the psychedelic state via heart rate dynamics","authors":"Rosas FE, Mediano PA, Timmermann C, Luppi AI, Candia-Rivera D, Abbasi-Asl R, Gazzaley A, Kringelbach ML, Muthukumaraswamy S, Bor D, Garfinkel S, Carhart-Harris RL.","journal":"bioRxiv","publication_date":"2023-11-09","publication_year":2023,"doi":"10.1101/2023.11.07.566008","topic_tags":"Biomarkers","source_name":"bioRxiv","publication_status":"preprint","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":383,"title":"Effects of Psilocybin on Religious and Spiritual Attitudes and Behaviors in Clergy from Various Major World Religions.","authors":"Griffiths RR, Jesse R, Richards WA, Johnson MW, Sepeda ND, Bossis AP, Ross S","journal":"Psychedelic medicine (New Rochelle, N.Y.)","publication_date":"2025-12-01","publication_year":2025,"doi":"10.1089/psymed.2023.0044","topic_tags":"Wellbeing,Spirituality,Mystical Experience,Clinical Trial,Safety,Adverse Events","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":641,"title":"Psychedelic Experiences Increase Mind Perception but do not Change Atheist-Believer Status: A Prospective Longitudinal Study.","authors":"Nayak SM, White SH, Hilbert SN, Lowe MX, Jackson H, Griffiths RR, Garcia-Romeu A, Yaden DB","journal":"Journal of psychoactive drugs","publication_date":"2025-01-01","publication_year":2025,"doi":"10.1080/02791072.2024.2346130","topic_tags":"General","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":968,"title":"Psilocybin-assisted psychotherapy improves psychiatric symptoms across multiple dimensions in patients with cancer.","authors":"Petridis PD, Grinband J, Agin-Liebes G, Kinslow CJ, Zeifman RJ, Bogenschutz MP, Griffiths RR, Ross S","journal":"Nature. Mental health","publication_date":"2024-11-01","publication_year":2024,"doi":"10.1038/s44220-024-00331-0","topic_tags":"Depression,Anxiety,Clinical Trial,Cancer Patients","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1315,"title":"Double-Blind Comparison of the Two Hallucinogens Dextromethorphan and Psilocybin: Experience-Dependent and Enduring Psychological Effects in Healthy Volunteers.","authors":"Mathai DS, Hilbert S, Sepeda ND, Strickland JC, Griffiths RR, Garcia-Romeu A","journal":"Psychedelic medicine (New Rochelle, N.Y.)","publication_date":"2023-12-01","publication_year":2023,"doi":"10.1089/psymed.2023.0035","topic_tags":"Receptor Pharmacology,Consciousness,Wellbeing,Spirituality,Healthy Volunteers,Safety","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1379,"title":"Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial.","authors":"Raison CL, Sanacora G, Woolley J, Heinzerling K, Dunlop BW, Brown RT, Kakar R, Hassman M, Trivedi RP, Robison R, Gukasyan N, Nayak SM, Hu X, O'Donnell KC, Kelmendi B, Sloshower J, Penn AD, Bradley E, Kelly DF, Mletzko T, Nicholas CR, Hutson PR, Tarpley G, Utzinger M, Lenoch K, Warchol K, Gapasin T, Davis MC, Nelson-Douthit C, Wilson S, Brown C, Linton W, Ross S, Griffiths RR","journal":"JAMA","publication_date":"2023-09-05","publication_year":2023,"doi":"10.1001/jama.2023.14530","topic_tags":"Depression,Addiction,Clinical Trial,Safety,Adverse Events","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1443,"title":"Attenuation of psilocybin mushroom effects during and after SSRI/SNRI antidepressant use.","authors":"Gukasyan N, Griffiths RR, Yaden DB, Antoine DG, Nayak SM","journal":"Journal of psychopharmacology (Oxford, England)","publication_date":"2023-07-01","publication_year":2023,"doi":"10.1177/02698811231179910","topic_tags":"Depression,Receptor Pharmacology,Observational Study,Drug Interactions","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1627,"title":"Psychedelic-Assisted Therapy for People with Eating Disorders.","authors":"Gukasyan N, Schreyer CC, Griffiths RR, Guarda AS","journal":"Current psychiatry reports","publication_date":"2022-12-01","publication_year":2022,"doi":"10.1007/s11920-022-01394-5","topic_tags":"Eating Disorders,Mechanism of Action,Receptor Pharmacology,Clinical Trial,Review Article,Safety","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1650,"title":"Psychedelic drug abuse potential assessment research for new drug applications and Controlled Substances Act scheduling.","authors":"Henningfield JE, Coe MA, Griffiths RR, Belouin SJ, Berger A, Coker AR, Comer SD, Heal DJ, Hendricks PS, Nichols CD, Sapienza F, Vocci FJ, Zia FZ","journal":"Neuropharmacology","publication_date":"2022-11-01","publication_year":2022,"doi":"10.1016/j.neuropharm.2022.109220","topic_tags":"Mechanism of Action,Consciousness,Spirituality,Safety,Abuse Liability","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1710,"title":"Comparison of psychedelic and near-death or other non-ordinary experiences in changing attitudes about death and dying.","authors":"Sweeney MM, Nayak S, Hurwitz ES, Mitchell LN, Swift TC, Griffiths RR","journal":"PloS one","publication_date":"2022-01-01","publication_year":2022,"doi":"10.1371/journal.pone.0271926","topic_tags":"Spirituality,Mystical Experience,Observational Study","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1851,"title":"The Potential of Psychedelics for End of Life and Palliative Care.","authors":"Yaden DB, Nayak SM, Gukasyan N, Anderson BT, Griffiths RR","journal":"Current topics in behavioral neurosciences","publication_date":"2022-01-01","publication_year":2022,"doi":"10.1007/7854_2021_278","topic_tags":"Depression,End-of-Life Distress,Wellbeing,Review Article,Healthcare Workers","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2158,"title":"Errors in a Response Rate and in Effect Sizes in Study of Psilocybin-Assisted Therapy for Major Depressive Disorder.","authors":"Davis AK, Griffiths RR","journal":"JAMA psychiatry","publication_date":"2021-05-01","publication_year":2021,"doi":"10.1001/jamapsychiatry.2020.4638","topic_tags":"Depression","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2261,"title":"Subjective features of the psilocybin experience that may account for its self-administration by humans: a double-blind comparison of psilocybin and dextromethorphan.","authors":"Carbonaro TM, Johnson MW, Griffiths RR","journal":"Psychopharmacology","publication_date":"2020-08-01","publication_year":2020,"doi":"10.1007/s00213-020-05533-9","topic_tags":"Mystical Experience,Healthy Volunteers,Abuse Liability","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2303,"title":"Persisting Reductions in Cannabis, Opioid, and Stimulant Misuse After Naturalistic Psychedelic Use: An Online Survey.","authors":"Garcia-Romeu A, Davis AK, Erowid E, Erowid F, Griffiths RR, Johnson MW","journal":"Frontiers in psychiatry","publication_date":"2019-01-01","publication_year":2019,"doi":"10.3389/fpsyt.2019.00955","topic_tags":"Addiction,Receptor Pharmacology,Mystical Experience,Observational Study","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2332,"title":"Cessation and reduction in alcohol consumption and misuse after psychedelic use.","authors":"Garcia-Romeu A, Davis AK, Erowid F, Erowid E, Griffiths RR, Johnson MW","journal":"Journal of psychopharmacology (Oxford, England)","publication_date":"2019-09-01","publication_year":2019,"doi":"10.1177/0269881119845793","topic_tags":"Addiction,Mystical Experience,Meta-Analysis,Observational Study","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2349,"title":"Survey of subjective \"God encounter experiences\": Comparisons among naturally occurring experiences and those occasioned by the classic psychedelics psilocybin, LSD, ayahuasca, or DMT.","authors":"Griffiths RR, Hurwitz ES, Davis AK, Johnson MW, Jesse R","journal":"PloS one","publication_date":"2019-01-01","publication_year":2019,"doi":"10.1371/journal.pone.0214377","topic_tags":"Spirituality,Mystical Experience,Observational Study","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2369,"title":"Intensity of Mystical Experiences Occasioned by 5-MeO-DMT and Comparison With a Prior Psilocybin Study.","authors":"Barsuglia J, Davis AK, Palmer R, Lancelotta R, Windham-Herman AM, Peterson K, Polanco M, Grant R, Griffiths RR","journal":"Frontiers in psychology","publication_date":"2018-01-01","publication_year":2018,"doi":"10.3389/fpsyg.2018.02459","topic_tags":"Spirituality,Mystical Experience","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2375,"title":"The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act.","authors":"Johnson MW, Griffiths RR, Hendricks PS, Henningfield JE","journal":"Neuropharmacology","publication_date":"2018-11-01","publication_year":2018,"doi":"10.1016/j.neuropharm.2018.05.012","topic_tags":"Depression,Anxiety,Addiction,Receptor Pharmacology,Review Article,Cancer Patients,Safety","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2402,"title":"Psychedelic therapy for smoking cessation: Qualitative analysis of participant accounts.","authors":"Noorani T, Garcia-Romeu A, Swift TC, Griffiths RR, Johnson MW","journal":"Journal of psychopharmacology (Oxford, England)","publication_date":"2018-07-01","publication_year":2018,"doi":"10.1177/0269881118780612","topic_tags":"Addiction,Mechanism of Action","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2428,"title":"Double-blind comparison of the two hallucinogens psilocybin and dextromethorphan: similarities and differences in subjective experiences.","authors":"Carbonaro TM, Johnson MW, Hurwitz E, Griffiths RR","journal":"Psychopharmacology","publication_date":"2018-02-01","publication_year":2018,"doi":"10.1007/s00213-017-4769-4","topic_tags":"Mechanism of Action,Receptor Pharmacology,Mystical Experience,Healthy Volunteers","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2467,"title":"Potential Therapeutic Effects of Psilocybin.","authors":"Johnson MW, Griffiths RR","journal":"Neurotherapeutics: the journal of the American Society for Experimental NeuroTherapeutics","publication_date":"2017-07-01","publication_year":2017,"doi":"10.1007/s13311-017-0542-y","topic_tags":"Depression,Anxiety,Addiction,Mechanism of Action,Review Article,Cancer Patients,Treatment-Resistant Depression,Safety","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2468,"title":"An online survey of tobacco smoking cessation associated with naturalistic psychedelic use.","authors":"Johnson MW, Garcia-Romeu A, Johnson PS, Griffiths RR","journal":"Journal of psychopharmacology (Oxford, England)","publication_date":"2017-07-01","publication_year":2017,"doi":"10.1177/0269881116684335","topic_tags":"Depression,Addiction,Mechanism of Action,Emotional Processing,Spirituality,Mystical Experience,Observational Study","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2485,"title":"Long-term follow-up of psilocybin-facilitated smoking cessation.","authors":"Johnson MW, Garcia-Romeu A, Griffiths RR","journal":"The American journal of drug and alcohol abuse","publication_date":"2017-01-01","publication_year":2017,"doi":"10.3109/00952990.2016.1170135","topic_tags":"Addiction,Receptor Pharmacology,Spirituality,Mystical Experience","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2494,"title":"Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial.","authors":"Griffiths RR, Johnson MW, Carducci MA, Umbricht A, Richards WA, Richards BD, Cosimano MP, Klinedinst MA","journal":"Journal of psychopharmacology (Oxford, England)","publication_date":"2016-12-01","publication_year":2016,"doi":"10.1177/0269881116675513","topic_tags":"Depression,Anxiety,End-of-Life Distress,Wellbeing,Spirituality,Mystical Experience,Cancer Patients,Healthcare Workers","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2507,"title":"Naltrexone but Not Ketanserin Antagonizes the Subjective, Cardiovascular, and Neuroendocrine Effects of Salvinorin-A in Humans.","authors":"Maqueda AE, Valle M, Addy PH, Antonijoan RM, Puntes M, Coimbra J, Ballester MR, Garrido M, González M, Claramunt J, Barker S, Lomnicka I, Waguespack M, Johnson MW, Griffiths RR, Riba J","journal":"The international journal of neuropsychopharmacology","publication_date":"2016-07-01","publication_year":2016,"doi":"10.1093/ijnp/pyw016","topic_tags":"Addiction,Pharmacology,Mechanism of Action,Receptor Pharmacology,Healthy Volunteers","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2534,"title":"Psilocybin, psychological distress, and suicidality.","authors":"Hendricks PS, Johnson MW, Griffiths RR","journal":"Journal of psychopharmacology (Oxford, England)","publication_date":"2015-09-01","publication_year":2015,"doi":"10.1177/0269881115598338","topic_tags":"General","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2555,"title":"Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction.","authors":"Johnson MW, Garcia-Romeu A, Cosimano MP, Griffiths RR","journal":"Journal of psychopharmacology (Oxford, England)","publication_date":"2014-11-01","publication_year":2014,"doi":"10.1177/0269881114548296","topic_tags":"Addiction,Receptor Pharmacology,Biomarkers,Safety","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2566,"title":"Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction.","authors":"Garcia-Romeu A, Griffiths RR, Johnson MW","journal":"Current drug abuse reviews","publication_date":"2014-01-01","publication_year":2014,"doi":"10.2174/1874473708666150107121331","topic_tags":"Addiction,Personality Change,Spirituality,Mystical Experience,Healthy Volunteers","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2596,"title":"Factor Analysis of the Mystical Experience Questionnaire: A Study of Experiences Occasioned by the Hallucinogen Psilocybin.","authors":"Maclean KA, Leoutsakos JM, Johnson MW, Griffiths RR","journal":"Journal for the scientific study of religion","publication_date":"2012-12-01","publication_year":2012,"doi":"10.1111/j.1468-5906.2012.01685.x","topic_tags":"Spirituality,Mystical Experience","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2601,"title":"High doses of dextromethorphan, an NMDA antagonist, produce effects similar to classic hallucinogens.","authors":"Reissig CJ, Carter LP, Johnson MW, Mintzer MZ, Klinedinst MA, Griffiths RR","journal":"Psychopharmacology","publication_date":"2012-09-01","publication_year":2012,"doi":"10.1007/s00213-012-2680-6","topic_tags":"Anxiety,Headache / Migraine,Spirituality,Mystical Experience,Healthy Volunteers","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2604,"title":"Psilocybin dose-dependently causes delayed, transient headaches in healthy volunteers.","authors":"Johnson MW, Sewell RA, Griffiths RR","journal":"Drug and alcohol dependence","publication_date":"2012-06-01","publication_year":2012,"doi":"10.1016/j.drugalcdep.2011.10.029","topic_tags":"Headache / Migraine,Mechanism of Action,Healthy Volunteers,Adverse Events","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2611,"title":"Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects.","authors":"Griffiths RR, Johnson MW, Richards WA, Richards BD, McCann U, Jesse R","journal":"Psychopharmacology","publication_date":"2011-12-01","publication_year":2011,"doi":"10.1007/s00213-011-2358-5","topic_tags":"Anxiety,Spirituality,Mystical Experience","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2612,"title":"Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness.","authors":"MacLean KA, Johnson MW, Griffiths RR","journal":"Journal of psychopharmacology (Oxford, England)","publication_date":"2011-11-01","publication_year":2011,"doi":"10.1177/0269881111420188","topic_tags":"Personality Change,Creativity,Spirituality,Mystical Experience","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2680,"title":"Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance.","authors":"Griffiths RR, Richards WA, McCann U, Jesse R","journal":"Psychopharmacology","publication_date":"2006-08-01","publication_year":2006,"doi":"10.1007/s00213-006-0457-5","topic_tags":"Anxiety,Spirituality,Mystical Experience","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":3359,"title":"Naturalistic Psilocybin Use Increases Mind Perception but not Atheist-Believer status: A Prospective Longitudinal Study","authors":"Nayak SM, White SH, Hilbert S, Lowe MX, Jackson H, Griffiths RR, Garcia-Romeu A, Yaden DB.","journal":"PsyArXiv","publication_date":"2023-06-09","publication_year":2023,"doi":"10.31234/osf.io/auycp_v1","topic_tags":"General","source_name":"PsyArXiv","publication_status":"preprint","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":3756,"title":"Serotonergic antidepressant use is associated with weaker psilocybin effects","authors":"Gukasyan N, Griffiths RR, Yaden DB, Antoine D, Nayak SM.","journal":"PsyArXiv","publication_date":"2022-10-28","publication_year":2022,"doi":"10.31234/osf.io/2zys9","topic_tags":"Depression,Observational Study","source_name":"PsyArXiv","publication_status":"preprint","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":3793,"title":"Naturalistic Psilocybin Use Increases Mind Perception but not Atheist-Believer status: A Prospective Longitudinal Study","authors":"Nayak SM, White S, Hilbert S, Lowe MX, Jackson H, Griffiths RR, Garcia-Romeu A, Yaden DB.","journal":"PsyArXiv","publication_date":"2023-06-09","publication_year":2023,"doi":"10.31234/osf.io/auycp","topic_tags":"General","source_name":"PsyArXiv","publication_status":"preprint","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":143,"title":"The effects of psilocybin on time perception in humans: A comparative analysis of subjective and objective measures.","authors":"Scholle P, Wenke Š, Nekovářová T, Zaytseva Y, Tylš F, Brunovský M, Horáček J, Andrashko V, Koudelka V, Viktorinová M, Viktorin V, Hájková K, Kuchař M, Páleníček T","journal":"Journal of psychopharmacology (Oxford, England)","publication_date":"2026-05-01","publication_year":2026,"doi":"10.1177/02698811251389552","topic_tags":"Consciousness,Clinical Trial,Healthy Volunteers","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":489,"title":"Concomitant use of antidepressants and classic psychedelics: A scoping review.","authors":"Tap SC, Thomas K, Páleníček T, Stenbæk DS, Oliveira-Maia AJ, van Dalfsen JH, Schoevers RA","journal":"Journal of psychopharmacology (Oxford, England)","publication_date":"2025-10-01","publication_year":2025,"doi":"10.1177/02698811251368360","topic_tags":"Depression,Receptor Pharmacology,Review Article,Safety","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":544,"title":"Effects of serotonergic psychedelics on synaptogenesis and immediate early genes expression - comparison with ketamine, fluoxetine and lithium.","authors":"Vella Y, Syrová K, Petrušková A, Koutrouli I, Kútna V, Pala J, Šíchová K, Nikolič M, Mazoch V, Jurok R, Kuchař M, Bendová Z, Páleníček T","journal":"Journal of psychopharmacology (Oxford, England)","publication_date":"2025-09-01","publication_year":2025,"doi":"10.1177/02698811251338232","topic_tags":"Neuroplasticity,Mechanism of Action,Biomarkers,Animal Study,In Vitro Study","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":607,"title":"Behavioural and pharmacological evaluation of the psilocybin analogue baeocystin in Wistar rats.","authors":"Danda H, Mazochová K, Šíchová K, Mazoch V, Olejníková-Ladislavová L, Syrová K, Jurásek B, Cihlářová P, Jurok R, Páleníček T, Kuchař M","journal":"Progress in neuro-psychopharmacology & biological psychiatry","publication_date":"2025-07-13","publication_year":2025,"doi":"10.1016/j.pnpbp.2025.111439","topic_tags":"Anxiety,Pharmacology","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":622,"title":"What fMRI studies say about the nature of the psychedelic effect: a scoping review.","authors":"Beneš M, Páleníček T, Horáček J","journal":"Frontiers in neuroscience","publication_date":"2025-01-01","publication_year":2025,"doi":"10.3389/fnins.2025.1606798","topic_tags":"Brain Imaging,Mechanism of Action,Default Mode Network,Biomarkers,Aging,Review Article","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":800,"title":"Serotonergic Psychedelics Rapidly Modulate Evoked Glutamate Release in Cultured Cortical Neurons.","authors":"Petrušková A, Guhathakurta D, Akdaş EY, Perelló-Amorós B, Frischknecht R, Weiss EM, Páleníček T, Fejtová A","journal":"Journal of neurochemistry","publication_date":"2025-03-01","publication_year":2025,"doi":"10.1111/jnc.70020","topic_tags":"Depression,Anxiety,Addiction,End-of-Life Distress,Neuroplasticity,Brain Imaging,Mechanism of Action,Aging,Animal Study","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":852,"title":"Exploring Strains: Cultivation Techniques, Psychoactive Compounds, Genetics and Research Gaps.","authors":"Kurzbaum E, Páleníček T, Shrchaton A, Azerrad S, Dekel Y","journal":"Journal of fungi (Basel, Switzerland)","publication_date":"2025-01-28","publication_year":2025,"doi":"10.3390/jof11020099","topic_tags":"Review Article","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1396,"title":"Psilocybin intoxication did not affect daytime or sleep-related declarative memory consolidation in a small sample exploratory analysis.","authors":"Nikolič M, Viktorin V, Zach P, Tylš F, Dudysová D, Janků K, Kopřivová J, Kuchař M, Brunovský M, Horáček J, Páleníček T","journal":"European neuropsychopharmacology: the journal of the European College of Neuropsychopharmacology","publication_date":"2023-09-01","publication_year":2023,"doi":"10.1016/j.euroneuro.2023.04.019","topic_tags":"Healthy Volunteers,Safety","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1757,"title":"Psilocybin-Mediated Attenuation of Gamma Band Auditory Steady-State Responses (ASSR) Is Driven by the Intensity of Cognitive and Emotional Domains of Psychedelic Experience.","authors":"Viktorin V, Griškova-Bulanova I, Voicikas A, Dojčánová D, Zach P, Bravermanová A, Andrashko V, Tylš F, Korčák J, Viktorinová M, Koudelka V, Hájková K, Kuchař M, Horáček J, Brunovský M, Páleníček T","journal":"Journal of personalized medicine","publication_date":"2022-06-19","publication_year":2022,"doi":"10.3390/jpm12061004","topic_tags":"Brain Imaging,Receptor Pharmacology,Emotional Processing,Healthy Volunteers","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2285,"title":"A single psilocybin dose is associated with long-term increased mindfulness, preceded by a proportional change in neocortical 5-HT2A receptor binding.","authors":"Madsen MK, Fisher PM, Stenbæk DS, Kristiansen S, Burmester D, Lehel S, Páleníček T, Kuchař M, Svarer C, Ozenne B, Knudsen GM","journal":"European neuropsychopharmacology: the journal of the European College of Neuropsychopharmacology","publication_date":"2020-04-01","publication_year":2020,"doi":"10.1016/j.euroneuro.2020.02.001","topic_tags":"Brain Imaging,Mechanism of Action,Receptor Pharmacology,Aging,Personality Change","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2426,"title":"Psilocybin disrupts sensory and higher order cognitive processing but not pre-attentive cognitive processing-study on P300 and mismatch negativity in healthy volunteers.","authors":"Bravermanová A, Viktorinová M, Tylš F, Novák T, Androvičová R, Korčák J, Horáček J, Balíková M, Griškova-Bulanova I, Danielová D, Vlček P, Mohr P, Brunovský M, Koudelka V, Páleníček T","journal":"Psychopharmacology","publication_date":"2018-02-01","publication_year":2018,"doi":"10.1007/s00213-017-4807-2","topic_tags":"Receptor Pharmacology,Biomarkers,Healthy Volunteers","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2562,"title":"Psilocybin--summary of knowledge and new perspectives.","authors":"Tylš F, Páleníček T, Horáček J","journal":"European neuropsychopharmacology: the journal of the European College of Neuropsychopharmacology","publication_date":"2014-03-01","publication_year":2014,"doi":"10.1016/j.euroneuro.2013.12.006","topic_tags":"Brain Imaging,Pharmacology,Receptor Pharmacology,Aging,Review Article","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":3064,"title":"Regional Specificity of the Cingulate Cortex Thickness Association with the Intensity of Psilocybin Experience: A Replication Study","authors":"Greguš D, Hlinka J, Tylš F, Viktorin V, Viktorinová M, Bravermanová A, Androvičová R, Andrashko V, Korčák J, Nikolič M, Adámek P, Beneš M, Páleníček T, Horáček J.","journal":"Research Square","publication_date":"2025-09-25","publication_year":2025,"doi":"10.21203/rs.3.rs-7544401/v1","topic_tags":"Anxiety,Brain Imaging,Consciousness,Biomarkers,Aging,Emotional Processing,Healthy Volunteers","source_name":"Europe PMC","publication_status":"preprint","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":3983,"title":"Surprising Variability in Tryptamine Profiles of Fruiting Bodies: Inter- and Intra-Strain Differences Across 14 Strains Cultivated Under Controlled Conditions.","authors":"Sharchaton A, Parsha S, Azerrad SP, Dekel Y, Rabah N, Páleníček T, Kurzbaum E","journal":"Journal of fungi (Basel, Switzerland)","publication_date":"2026-07-02","publication_year":2026,"doi":"10.3390/jof12070486","topic_tags":"General","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":5151,"title":"The Effects of Daytime Psilocybin Administration on Sleep: Implications for Antidepressant Action.","authors":"Dudysová D, Janků K, Šmotek M, Saifutdinova E, Kopřivová J, Bušková J, Mander BA, Brunovský M, Zach P, Korčák J, Andrashko V, Viktorinová M, Tylš F, Bravermanová A, Froese T, Páleníček T, Horáček J","journal":"Frontiers in pharmacology","publication_date":"2020-01-01","publication_year":2020,"doi":"10.3389/fphar.2020.602590","topic_tags":"Neuroplasticity,Brain Imaging,Mechanism of Action,Biomarkers,Healthy Volunteers","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":30,"title":"The intersection between psychedelics and schizophrenia spectrum disorders: Reevaluating risk and therapeutic potential.","authors":"Brar PS, Price RB, Ross S, Tofighi B, Sarpal DK","journal":"Journal of psychopharmacology (Oxford, England)","publication_date":"2026-07-01","publication_year":2026,"doi":"10.1177/02698811261456191","topic_tags":"Depression,Mechanism of Action,Review Article,Safety","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":900,"title":"Multidimensional Personality Changes Following Psilocybin-Assisted Therapy in Patients With Alcohol Use Disorder: Results From a Double-Blind, Placebo-Controlled Clinical Trial.","authors":"Pagni BA, Zeifman RJ, Mennenga SE, Carrithers BM, Goldway N, Bhatt S, O'Donnell KC, Ross S, Bogenschutz MP","journal":"The American journal of psychiatry","publication_date":"2025-01-01","publication_year":2025,"doi":"10.1176/appi.ajp.20230887","topic_tags":"Depression,Addiction,Personality Change,Clinical Trial,Randomized Controlled Trial,Safety","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":980,"title":"Psilocybin-assisted psychotherapy for existential distress: practical considerations for therapeutic application-a review.","authors":"Kim A, Halton B, Shah A, Seecof OM, Ross S","journal":"Annals of palliative medicine","publication_date":"2024-11-01","publication_year":2024,"doi":"10.21037/apm-24-35","topic_tags":"Depression,Anxiety,End-of-Life Distress,Pharmacology,Clinical Trial,Review Article","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1272,"title":"Older adults in psychedelic-assisted therapy trials: A systematic review.","authors":"Bouchet L, Sager Z, Yrondi A, Nigam KB, Anderson BT, Ross S, Petridis PD, Beaussant Y","journal":"Journal of psychopharmacology (Oxford, England)","publication_date":"2024-01-01","publication_year":2024,"doi":"10.1177/02698811231215420","topic_tags":"Depression,Anxiety,PTSD,Addiction,Aging,Clinical Trial,Systematic Review,Review Article,Older Adults,Safety,Adverse Events","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1368,"title":"Exploring the Potential Utility of Psychedelic Therapy for Patients With Amyotrophic Lateral Sclerosis.","authors":"Gold ND, Mallard AJ, Hermann JC, Zeifman RJ, Pagni BA, Bogenschutz MP, Ross S","journal":"Journal of palliative medicine","publication_date":"2023-10-01","publication_year":2023,"doi":"10.1089/jpm.2022.0604","topic_tags":"End-of-Life Distress,Mechanism of Action,Spirituality,Clinical Trial,Review Article,Animal Study,Safety","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1424,"title":"Are psychedelic medicines the reset for chronic pain? Preliminary findings and research needs.","authors":"Zia FZ, Baumann MH, Belouin SJ, Dworkin RH, Ghauri MH, Hendricks PS, Henningfield JE, Lanier RK, Ross S, Berger A","journal":"Neuropharmacology","publication_date":"2023-08-01","publication_year":2023,"doi":"10.1016/j.neuropharm.2023.109528","topic_tags":"Depression,Addiction,Chronic Pain,Pharmacology,Mechanism of Action,Spirituality,Clinical Trial,Safety,Adverse Events,Inflammation","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1466,"title":"Examining the Rationale for Studying Psychedelic-Assisted Psychotherapy for the Treatment of Caregiver Distress.","authors":"Gold ND, Podrebarac SK, White LA, Marini C, Simon NM, Mittelman MS, Ross S, Bogenschutz MP, Petridis PD","journal":"Psychedelic medicine (New Rochelle, N.Y.)","publication_date":"2023-06-01","publication_year":2023,"doi":"10.1089/psymed.2022.0011","topic_tags":"Depression,Anxiety,Spirituality,Clinical Trial,Review Article,Cancer Patients,Safety,Inflammation","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1630,"title":"Psilocybin for alcohol use disorder: Rationale and design considerations for a randomized controlled trial.","authors":"O'Donnell KC, Mennenga SE, Owens LT, Podrebarac SK, Baron T, Rotrosen J, Ross S, Forcehimes AA, Bogenschutz MP","journal":"Contemporary clinical trials","publication_date":"2022-12-01","publication_year":2022,"doi":"10.1016/j.cct.2022.106976","topic_tags":"Addiction,Receptor Pharmacology,Clinical Trial,Randomized Controlled Trial,Safety","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1681,"title":"Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder: A Randomized Clinical Trial.","authors":"Bogenschutz MP, Ross S, Bhatt S, Baron T, Forcehimes AA, Laska E, Mennenga SE, O'Donnell K, Owens LT, Podrebarac S, Rotrosen J, Tonigan JS, Worth L","journal":"JAMA psychiatry","publication_date":"2022-10-01","publication_year":2022,"doi":"10.1001/jamapsychiatry.2022.2096","topic_tags":"Addiction,Clinical Trial,Adverse Events","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1689,"title":"If the Doors of Perception Were Cleansed, Would Chronic Pain be Relieved? Evaluating the Benefits and Risks of Psychedelics.","authors":"Dworkin RH, Anderson BT, Andrews N, Edwards RR, Grob CS, Ross S, Satterthwaite TD, Strain EC","journal":"The journal of pain","publication_date":"2022-10-01","publication_year":2022,"doi":"10.1016/j.jpain.2022.05.003","topic_tags":"Chronic Pain,Headache / Migraine,Mechanism of Action,Consciousness,Spirituality,Mystical Experience,Clinical Trial,Safety","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2168,"title":"Acute and Sustained Reductions in Loss of Meaning and Suicidal Ideation Following Psilocybin-Assisted Psychotherapy for Psychiatric and Existential Distress in Life-Threatening Cancer.","authors":"Ross S, Agin-Liebes G, Lo S, Zeifman RJ, Ghazal L, Benville J, Franco Corso S, Bjerre Real C, Guss J, Bossis A, Mennenga SE","journal":"ACS pharmacology & translational science","publication_date":"2021-04-09","publication_year":2021,"doi":"10.1021/acsptsci.1c00020","topic_tags":"Depression,End-of-Life Distress,Clinical Trial,Randomized Controlled Trial,Safety","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2302,"title":"Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer.","authors":"Agin-Liebes GI, Malone T, Yalch MM, Mennenga SE, Ponté KL, Guss J, Bossis AP, Grigsby J, Fischer S, Ross S","journal":"Journal of psychopharmacology (Oxford, England)","publication_date":"2020-02-01","publication_year":2020,"doi":"10.1177/0269881119897615","topic_tags":"Depression,Anxiety,End-of-Life Distress,Wellbeing,Emotional Processing,Spirituality,Randomized Controlled Trial,Cancer Patients","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2394,"title":"Therapeutic use of classic psychedelics to treat cancer-related psychiatric distress.","authors":"Ross S","journal":"International review of psychiatry (Abingdon, England)","publication_date":"2018-08-01","publication_year":2018,"doi":"10.1080/09540261.2018.1482261","topic_tags":"Depression,Anxiety,End-of-Life Distress,Receptor Pharmacology,Clinical Trial,Randomized Controlled Trial,Review Article,Cancer Patients","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2413,"title":"Individual Experiences in Four Cancer Patients Following Psilocybin-Assisted Psychotherapy.","authors":"Malone TC, Mennenga SE, Guss J, Podrebarac SK, Owens LT, Bossis AP, Belser AB, Agin-Liebes G, Bogenschutz MP, Ross S","journal":"Frontiers in pharmacology","publication_date":"2018-01-01","publication_year":2018,"doi":"10.3389/fphar.2018.00256","topic_tags":"Depression,Anxiety,End-of-Life Distress,Wellbeing,Spirituality,Cancer Patients,Healthcare Workers","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2423,"title":"Clinical Interpretations of Patient Experience in a Trial of Psilocybin-Assisted Psychotherapy for Alcohol Use Disorder.","authors":"Bogenschutz MP, Podrebarac SK, Duane JH, Amegadzie SS, Malone TC, Owens LT, Ross S, Mennenga SE","journal":"Frontiers in pharmacology","publication_date":"2018-01-01","publication_year":2018,"doi":"10.3389/fphar.2018.00100","topic_tags":"Addiction,Consciousness,Mystical Experience,Clinical Trial","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2441,"title":"Therapeutic Applications of Classic Hallucinogens.","authors":"Bogenschutz MP, Ross S","journal":"Current topics in behavioral neurosciences","publication_date":"2018-01-01","publication_year":2018,"doi":"10.1007/7854_2016_464","topic_tags":"Depression,Anxiety,Addiction,End-of-Life Distress,Pharmacology,Mechanism of Action,Receptor Pharmacology,Aging,Clinical Trial,Review Article,Observational Study,In Vitro Study,Safety","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2495,"title":"Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial.","authors":"Ross S, Bossis A, Guss J, Agin-Liebes G, Malone T, Cohen B, Mennenga SE, Belser A, Kalliontzi K, Babb J, Su Z, Corby P, Schmidt BL","journal":"Journal of psychopharmacology (Oxford, England)","publication_date":"2016-12-01","publication_year":2016,"doi":"10.1177/0269881116675512","topic_tags":"Depression,Anxiety,End-of-Life Distress,Wellbeing,Spirituality,Mystical Experience,Randomized Controlled Trial,Cancer Patients","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":902,"title":"Single-Dose Psilocybin for Depression With Severe Treatment Resistance: An Open-Label Trial.","authors":"Aaronson ST, van der Vaart A, Miller T, LaPratt J, Swartz K, Shoultz A, Lauterbach M, Suppes T, Sackeim HA","journal":"The American journal of psychiatry","publication_date":"2025-01-01","publication_year":2025,"doi":"10.1176/appi.ajp.20231063","topic_tags":"Depression,PTSD,Pharmacology,Treatment-Resistant Depression,Safety,Drug Interactions","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1119,"title":"Treating Bipolar Depression Using Psilocybin-Validity Threats Regarding Efficacy and Safety-Reply.","authors":"Aaronson ST, van der Vaart A, Sackeim HA","journal":"JAMA psychiatry","publication_date":"2024-06-01","publication_year":2024,"doi":"10.1001/jamapsychiatry.2024.0423","topic_tags":"Depression,Safety","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1123,"title":"Single-Dose Synthetic Psilocybin With Psychotherapy for Treatment-Resistant Bipolar Type II Major Depressive Episodes: A Nonrandomized Open-Label Trial.","authors":"Aaronson ST, van der Vaart A, Miller T, LaPratt J, Swartz K, Shoultz A, Lauterbach M, Sackeim HA, Suppes T","journal":"JAMA psychiatry","publication_date":"2024-06-01","publication_year":2024,"doi":"10.1001/jamapsychiatry.2023.4685","topic_tags":"Depression,Safety","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1205,"title":"New evidence for flexible psilocybin dosing in patients with treatment-resistant depression.","authors":"Aaronson ST, Kozak Z","journal":"Med (New York, N.Y.)","publication_date":"2024-03-08","publication_year":2024,"doi":"10.1016/j.medj.2024.01.014","topic_tags":"Depression,Clinical Trial,Treatment-Resistant Depression","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1386,"title":"Psychedelics, With a Focus on Psilocybin: Issues for the Clinician.","authors":"Garakani A, Alexander JL, Sumner CR, Pine JH, Gross LS, Raison CL, Aaronson ST, Baron DA","journal":"Journal of psychiatric practice","publication_date":"2023-09-01","publication_year":2023,"doi":"10.1097/pra.0000000000000729","topic_tags":"Depression,Anxiety,PTSD,Addiction,Review Article,Cancer Patients,Treatment-Resistant Depression,Healthcare Workers","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1434,"title":"Assessing potential of psilocybin for depressive disorders.","authors":"Kozak Z, Johnson MW, Aaronson ST","journal":"Expert opinion on investigational drugs","publication_date":"2023-01-01","publication_year":2023,"doi":"10.1080/13543784.2023.2273493","topic_tags":"Depression,Mechanism of Action,Clinical Trial,Review Article,Treatment-Resistant Depression,Safety","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1513,"title":"Optimizing outcomes in psilocybin therapy: Considerations in participant evaluation and preparation.","authors":"Modlin NL, Miller TM, Rucker JJ, Kirlic N, Lennard-Jones M, Schlosser D, Aaronson ST","journal":"Journal of affective disorders","publication_date":"2023-04-01","publication_year":2023,"doi":"10.1016/j.jad.2023.01.077","topic_tags":"Depression,Anxiety,OCD,End-of-Life Distress,Safety","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1674,"title":"The Emerging Field of Psychedelic Psychotherapy.","authors":"Barber GS, Aaronson ST","journal":"Current psychiatry reports","publication_date":"2022-10-01","publication_year":2022,"doi":"10.1007/s11920-022-01363-y","topic_tags":"Depression,PTSD","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":550,"title":"A critical evaluation of psilocybin-assisted therapy protocol components from clinical trial patients, facilitators, and caregivers.","authors":"Palitsky R, Maples-Keller JL, Peacock C, Dunlop BW, Mletzko T, Grant GH, Raison CL, Chao S, Shub I, Mendelbaum-Kweller M, Smolyar L, Kaplan DM, Rothbaum BO, Zarrabi AJ","journal":"Psychotherapy (Chicago, Ill.)","publication_date":"2025-09-01","publication_year":2025,"doi":"10.1037/pst0000551","topic_tags":"Chronic Pain,Spirituality,Clinical Trial,Cancer Patients,Healthcare Workers","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":790,"title":"Results From a Long-Term Observational Follow-Up Study of a Single Dose of Psilocybin for a Treatment-Resistant Episode of Major Depressive Disorder.","authors":"Goodwin GM, Nowakowska A, Atli M, Dunlop BW, Feifel D, Hellerstein DJ, Marwood L, Shabir Z, Mistry S, Stansfield SC, Teoh E, Tsai J, Young MB, Malievskaia E","journal":"The Journal of clinical psychiatry","publication_date":"2025-03-03","publication_year":2025,"doi":"10.4088/jcp.24m15449","topic_tags":"Depression,Mechanism of Action,Observational Study,Treatment-Resistant Depression,Adverse Events","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":814,"title":"Prolonged adverse effects from repeated psilocybin use in an underground psychedelic therapy training program: a case report.","authors":"Perna J, Trop J, Palitsky R, Bosshardt Z, Vantine H, Dunlop BW, Zarrabi AJ","journal":"BMC psychiatry","publication_date":"2025-02-28","publication_year":2025,"doi":"10.1186/s12888-024-06303-z","topic_tags":"Emotional Processing,Case Report,Healthcare Workers","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":826,"title":"Emerging Medications for Treatment-Resistant Depression: A Review with Perspective on Mechanisms and Challenges.","authors":"Lucido MJ, Dunlop BW","journal":"Brain sciences","publication_date":"2025-02-06","publication_year":2025,"doi":"10.3390/brainsci15020161","topic_tags":"Depression,Mechanism of Action,Receptor Pharmacology,Clinical Trial,Review Article,Treatment-Resistant Depression,Inflammation,Immune Function","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":5721,"title":"Psilocybin-Assisted Early Palliative Care for Demoralization and Chronic Pain: An Open-Label Pilot Study.","authors":"Zarrabi AJ, Mletzko T, Grant G, Peacock C, Palitsky R, McPherson T, Shub I, Eisenacher S, Maples-Keller JL, Kaplan D, Rothbaum BO, Rab F, Dalal N, Curseen KA, Raison C, Dunlop BW","journal":"medRxiv: the preprint server for health sciences","publication_date":"2026-07-14","publication_year":2026,"doi":"10.64898/2026.07.11.26357570","topic_tags":"End-of-Life Distress,Chronic Pain,Spirituality,Cancer Patients,Healthcare Workers,Safety,Adverse Events","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":70,"title":"Trials, trips, and tribulations: pathways for implementing psychedelic therapy in Ireland.","authors":"Kelly JR, Sheridan C, Iusan P, Coakley L, Burke L, Brennan C, MacDonald A, Ivers JH, Trepel D, Tormey G, Finnegan M, Young GW, Harkin A","journal":"The international journal of neuropsychopharmacology","publication_date":"2026-06-02","publication_year":2026,"doi":"10.1093/ijnp/pyag028","topic_tags":"Depression,Anxiety,Addiction,Mechanism of Action,Aging,Clinical Trial,Treatment-Resistant Depression","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":235,"title":"Psychedelic therapy and postpartum depression: priorities and prospects.","authors":"Thuery G, Crossen F, Mc Loone D, Hinds C, Duffy R, Jairaj C, Harkin A, Kelly JR","journal":"Therapeutic advances in psychopharmacology","publication_date":"2026-01-01","publication_year":2026,"doi":"10.1177/20451253251408280","topic_tags":"Depression,Mechanism of Action,Aging,Review Article,Safety,Immune Function","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":392,"title":"Psilocybin reporting in media (PRiMe) for the treatment of depression.","authors":"Brar G, Burke T, Gribben AD, Harrington C, Thuery G, Kelly JR","journal":"Irish journal of psychological medicine","publication_date":"2025-12-18","publication_year":2025,"doi":"10.1017/ipm.2025.10142","topic_tags":"Depression,Clinical Trial,Safety","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":962,"title":"Amid magic and menace: psychiatrists' attitudes to psilocybin therapy.","authors":"Gribben A, Burke T, Harrington C, Husein A, Murnane KS, Hendricks PS, Tobin K, Ivers JH, Thuery G, Harkin A, Kelly JR","journal":"Irish journal of psychological medicine","publication_date":"2024-11-07","publication_year":2024,"doi":"10.1017/ipm.2024.49","topic_tags":"Depression,Personality Change,Emotional Processing","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1393,"title":"Psilocybin for treatment resistant depression in patients taking a concomitant SSRI medication.","authors":"Goodwin GM, Croal M, Feifel D, Kelly JR, Marwood L, Mistry S, O'Keane V, Peck SK, Simmons H, Sisa C, Stansfield SC, Tsai J, Williams S, Malievskaia E","journal":"Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology","publication_date":"2023-09-01","publication_year":2023,"doi":"10.1038/s41386-023-01648-7","topic_tags":"Depression,Receptor Pharmacology,Clinical Trial,Treatment-Resistant Depression,Safety,Adverse Events","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1515,"title":"Seeking the Psilocybiome: Psychedelics meet the microbiota-gut-brain axis.","authors":"Kelly JR, Clarke G, Harkin A, Corr SC, Galvin S, Pradeep V, Cryan JF, O'Keane V, Dinan TG","journal":"International journal of clinical and health psychology: IJCHP","publication_date":"2023-01-01","publication_year":2023,"doi":"10.1016/j.ijchp.2022.100349","topic_tags":"Mechanism of Action,Receptor Pharmacology,Review Article,Drug Interactions,Microbiome","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1633,"title":"The psychedelic renaissance: the next trip for psychiatry?","authors":"Kelly JR, Baker A, Babiker M, Burke L, Brennan C, O'Keane V","journal":"Irish journal of psychological medicine","publication_date":"2022-12-01","publication_year":2022,"doi":"10.1017/ipm.2019.39","topic_tags":"Depression,Anxiety,Neuroplasticity,Default Mode Network,Treatment-Resistant Depression","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1777,"title":"Psychedelic perceptions: mental health service user attitudes to psilocybin therapy.","authors":"Corrigan K, Haran M, McCandliss C, McManus R, Cleary S, Trant R, Kelly Y, Ledden K, Rush G, O'Keane V, Kelly JR","journal":"Irish journal of medical science","publication_date":"2022-06-01","publication_year":2022,"doi":"10.1007/s11845-021-02668-2","topic_tags":"Depression,Anxiety,Observational Study","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1872,"title":"Psychedelic Therapy's Transdiagnostic Effects: A Research Domain Criteria (RDoC) Perspective.","authors":"Kelly JR, Gillan CM, Prenderville J, Kelly C, Harkin A, Clarke G, O'Keane V","journal":"Frontiers in psychiatry","publication_date":"2021-01-01","publication_year":2021,"doi":"10.3389/fpsyt.2021.800072","topic_tags":"Depression,Anxiety,PTSD,Addiction,OCD,Eating Disorders,Pharmacology,Mechanism of Action,Emotional Processing,Review Article,Treatment-Resistant Depression","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2151,"title":"Psychedelic science in post-COVID-19 psychiatry.","authors":"Kelly JR, Crockett MT, Alexander L, Haran M, Baker A, Burke L, Brennan C, O'Keane V","journal":"Irish journal of psychological medicine","publication_date":"2021-06-01","publication_year":2021,"doi":"10.1017/ipm.2020.94","topic_tags":"Depression,Addiction,Mechanism of Action,Receptor Pharmacology,Clinical Trial,Randomized Controlled Trial,Treatment-Resistant Depression,Safety","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":4197,"title":"Assessing The Readiness of Psychiatrists in Louisiana to Incorporate Psilocybin into Clinical Practice-Lessons Learned from a State Underrepresented in Clinical Psychedelic Research.","authors":"Husein A, Traylor M, Vest MF, Wood BJ, Brogan M, Thomas A, McNeil S, Bhuiyan MAN, Hendricks P, Kelly JR, Gribben A, Al-Qahtani MM, Keys K, Edinoff AN, Patterson JC, Murnane KS","journal":"Psychedelic medicine (New Rochelle, N.Y.)","publication_date":"2026-09-01","publication_year":2026,"doi":"10.1177/28314425251381806","topic_tags":"Addiction,Observational Study,Safety","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1380,"title":"Psychedelics for treatment resistant depression: are they game changers?","authors":"Kalfas M, Taylor RH, Tsapekos D, Young AH","journal":"Expert opinion on pharmacotherapy","publication_date":"2023-01-01","publication_year":2023,"doi":"10.1080/14656566.2023.2281582","topic_tags":"Depression,PTSD,Mechanism of Action,Receptor Pharmacology,Systematic Review,Review Article,Treatment-Resistant Depression,Safety","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1453,"title":"Investigation of self-treatment with lysergic acid diethylamide and psilocybin mushrooms: Findings from the Global Drug Survey 2020.","authors":"Kopra EI, Ferris JA, Winstock AR, Kuypers KP, Young AH, Rucker JJ","journal":"Journal of psychopharmacology (Oxford, England)","publication_date":"2023-07-01","publication_year":2023,"doi":"10.1177/02698811231158245","topic_tags":"PTSD,Aging,Wellbeing,Emotional Processing,Observational Study","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1728,"title":"Adverse experiences resulting in emergency medical treatment seeking following the use of magic mushrooms.","authors":"Kopra EI, Ferris JA, Winstock AR, Young AH, Rucker JJ","journal":"Journal of psychopharmacology (Oxford, England)","publication_date":"2022-08-01","publication_year":2022,"doi":"10.1177/02698811221084063","topic_tags":"Anxiety,Spirituality,Observational Study,Safety","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1847,"title":"The effects of psilocybin on cognitive and emotional functions in healthy participants: Results from a phase 1, randomised, placebo-controlled trial involving simultaneous psilocybin administration and preparation.","authors":"Rucker JJ, Marwood L, Ajantaival RJ, Bird C, Eriksson H, Harrison J, Lennard-Jones M, Mistry S, Saldarini F, Stansfield S, Tai SJ, Williams S, Weston N, Malievskaia E, Young AH","journal":"Journal of psychopharmacology (Oxford, England)","publication_date":"2022-01-01","publication_year":2022,"doi":"10.1177/02698811211064720","topic_tags":"Depression,Receptor Pharmacology,Emotional Processing,Clinical Trial,Randomized Controlled Trial,Healthy Volunteers,Safety,Adverse Events","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2164,"title":"Psilocybin: From Serendipity to Credibility?","authors":"Rucker JJ, Young AH","journal":"Frontiers in psychiatry","publication_date":"2021-01-01","publication_year":2021,"doi":"10.3389/fpsyt.2021.659044","topic_tags":"Depression,Aging,Clinical Trial,Safety","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2230,"title":"Historic psychedelic drug trials and the treatment of anxiety disorders.","authors":"Weston NM, Gibbs D, Bird CIV, Daniel A, Jelen LA, Knight G, Goldsmith D, Young AH, Rucker JJ","journal":"Depression and anxiety","publication_date":"2020-12-01","publication_year":2020,"doi":"10.1002/da.23065","topic_tags":"Anxiety,Review Article,Case Report","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2497,"title":"Psychedelics in the treatment of unipolar mood disorders: a systematic review.","authors":"Rucker JJ, Jelen LA, Flynn S, Frowde KD, Young AH","journal":"Journal of psychopharmacology (Oxford, England)","publication_date":"2016-12-01","publication_year":2016,"doi":"10.1177/0269881116679368","topic_tags":"Depression,Clinical Trial,Systematic Review,Review Article,Healthcare Workers,Safety","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":3724,"title":"Psilocybin for dementia prevention? The potential role of psilocybin to alter mechanisms associated with major depression and neurodegenerative diseases.","authors":"Haniff ZR, Bocharova M, Mantingh T, Rucker JJ, Velayudhan L, Taylor DM, Young AH, Aarsland D, Vernon AC, Thuret S","journal":"Pharmacology & therapeutics","publication_date":"2024-06-01","publication_year":2024,"doi":"10.1016/j.pharmthera.2024.108641","topic_tags":"Depression,Neuroplasticity,Neurogenesis,Mechanism of Action,Biomarkers,Review Article,Animal Study,Safety,Immune Function","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":33,"title":"Cardiovascular effects associated with acute recreational drug toxicity presentations to the emergency department: a European drug emergencies network (Euro-DEN plus) study.","authors":"van den Busken WJ, Dines AM, Eyer F, Heyerdahl F, Hovda KE, Liechti ME, Miró Ò, Vallersnes OM, Wood DM, Yates C, Dargan PI, (on behalf of the Euro-DEN Plus Research Group), Gresnigt FMJ, Euro-DEN Plus Research Group","journal":"Clinical toxicology (Philadelphia, Pa.)","publication_date":"2026-09-01","publication_year":2026,"doi":"10.1080/15563650.2026.2669671","topic_tags":"Addiction,Chronic Pain,Mechanism of Action,Safety,Toxicity","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":145,"title":"The 3D-ASCr scale: A revalidation of the core dimensions of the Altered States of Consciousness Rating Scale 5D(11)-ASC for psychedelic research.","authors":"Stocker K, Hartmann M, Schmid Y, Vogt SB, Becker AM, Ley L, Straumann I, Arikci D, Klaiber A, Erne L, Vizeli P, Holze F, Liechti ME","journal":"Journal of psychopharmacology (Oxford, England)","publication_date":"2026-05-01","publication_year":2026,"doi":"10.1177/02698811251397328","topic_tags":"Anxiety,Consciousness,Healthy Volunteers","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":374,"title":"Pharmacological Properties of Psychedelics with a Special Focus on Potential Harms.","authors":"Holze F, Liechti ME, Müller F","journal":"Current topics in behavioral neurosciences","publication_date":"2026-01-01","publication_year":2026,"doi":"10.1007/7854_2024_510","topic_tags":"Anxiety,Pharmacology,Receptor Pharmacology,Emotional Processing,Safety,Adverse Events,Drug Interactions","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":592,"title":"Motivation and retrospective appraisal of psychedelic study participation: a qualitative study in healthy volunteers.","authors":"Ley L, Liechti ME, Becker AM, Straumann I, Klaiber A, Holze F, Vogt SB, Arikci D, Schmid Y","journal":"Psychopharmacology","publication_date":"2025-08-01","publication_year":2025,"doi":"10.1007/s00213-025-06772-4","topic_tags":"Healthy Volunteers","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":596,"title":"Implementing psychedelic-assisted therapy: History and characteristics of the Swiss limited medical use program.","authors":"Liechti ME, Gasser P, Aicher HD, Mueller F, Hawrot T, Schmid Y","journal":"Neuroscience applied","publication_date":"2025-01-01","publication_year":2025,"doi":"10.1016/j.nsa.2025.105525","topic_tags":"General","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":681,"title":"Acute Effects and Pharmacokinetics of LSD after Paroxetine or Placebo Pre-Administration in a Randomized, Double-Blind, Cross-Over Phase I Trial.","authors":"Becker AM, Humbert-Droz M, Mueller L, Jelušić A, Tolev A, Straumann I, Avedisian I, Erne L, Thomann J, Luethi D, Grünblatt E, Meyer Zu Schwabedissen H, Liechti ME","journal":"Clinical pharmacology and therapeutics","publication_date":"2025-06-01","publication_year":2025,"doi":"10.1002/cpt.3618","topic_tags":"Depression,Anxiety,Pharmacology,Receptor Pharmacology,Clinical Trial,Randomized Controlled Trial,Healthy Volunteers,Drug Interactions","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":881,"title":"Clinical pharmacology.","authors":"Vogt SB, Liechti ME","journal":"International review of neurobiology","publication_date":"2025-01-01","publication_year":2025,"doi":"10.1016/bs.irn.2025.02.003","topic_tags":"Pharmacology,Mechanism of Action,Receptor Pharmacology,Clinical Trial,Safety,Drug Interactions","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1001,"title":"Naturalistic psychedelic therapy: The role of relaxation and subjective drug effects in antidepressant response.","authors":"Calder AE, Rausch B, Liechti ME, Holze F, Hasler G","journal":"Journal of psychopharmacology (Oxford, England)","publication_date":"2024-10-01","publication_year":2024,"doi":"10.1177/02698811241278873","topic_tags":"Depression,Mystical Experience,Healthy Volunteers","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1154,"title":"Serotonergic Psychedelics: A Comparative Review of Efficacy, Safety, Pharmacokinetics, and Binding Profile.","authors":"Holze F, Singh N, Liechti ME, D'Souza DC","journal":"Biological psychiatry. Cognitive neuroscience and neuroimaging","publication_date":"2024-05-01","publication_year":2024,"doi":"10.1016/j.bpsc.2024.01.007","topic_tags":"Depression,Pharmacology,Mechanism of Action,Receptor Pharmacology,Review Article,Safety","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1196,"title":"Safety pharmacology of acute psilocybin administration in healthy participants.","authors":"Straumann I, Holze F, Becker AM, Ley L, Halter N, Liechti ME","journal":"Neuroscience applied","publication_date":"2024-01-01","publication_year":2024,"doi":"10.1016/j.nsa.2024.104060","topic_tags":"Depression,Anxiety,Addiction,Pharmacology,Healthy Volunteers,Safety","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1290,"title":"The revival of the psychedelic experience scale: Revealing its extended-mystical, visual, and distressing experiential spectrum with LSD and psilocybin studies.","authors":"Stocker K, Hartmann M, Ley L, Becker AM, Holze F, Liechti ME","journal":"Journal of psychopharmacology (Oxford, England)","publication_date":"2024-01-01","publication_year":2024,"doi":"10.1177/02698811231199112","topic_tags":"Consciousness,Mystical Experience,Healthy Volunteers","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1367,"title":"Comparative acute effects of mescaline, lysergic acid diethylamide, and psilocybin in a randomized, double-blind, placebo-controlled cross-over study in healthy participants.","authors":"Ley L, Holze F, Arikci D, Becker AM, Straumann I, Klaiber A, Coviello F, Dierbach S, Thomann J, Duthaler U, Luethi D, Varghese N, Eckert A, Liechti ME","journal":"Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology","publication_date":"2023-10-01","publication_year":2023,"doi":"10.1038/s41386-023-01607-2","topic_tags":"Pharmacology,Consciousness,Healthy Volunteers,Safety","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1518,"title":"Pharmacokinetics and Pharmacodynamics of Oral Psilocybin Administration in Healthy Participants.","authors":"Holze F, Becker AM, Kolaczynska KE, Duthaler U, Liechti ME","journal":"Clinical pharmacology and therapeutics","publication_date":"2023-04-01","publication_year":2023,"doi":"10.1002/cpt.2821","topic_tags":"Pharmacology,Clinical Trial,Healthy Volunteers","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1574,"title":"Classic psychedelics do not affect T cell and monocyte immune responses.","authors":"Rudin D, Areesanan A, Liechti ME, Gründemann C","journal":"Frontiers in psychiatry","publication_date":"2023-01-01","publication_year":2023,"doi":"10.3389/fpsyt.2023.1042440","topic_tags":"End-of-Life Distress,Safety,Immune Function","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1771,"title":"Flashback phenomena after administration of LSD and psilocybin in controlled studies with healthy participants.","authors":"Müller F, Kraus E, Holze F, Becker A, Ley L, Schmid Y, Vizeli P, Liechti ME, Borgwardt S","journal":"Psychopharmacology","publication_date":"2022-06-01","publication_year":2022,"doi":"10.1007/s00213-022-06066-z","topic_tags":"Clinical Trial,Healthy Volunteers","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1791,"title":"Direct comparison of the acute effects of lysergic acid diethylamide and psilocybin in a double-blind placebo-controlled study in healthy subjects.","authors":"Holze F, Ley L, Müller F, Becker AM, Straumann I, Vizeli P, Kuehne SS, Roder MA, Duthaler U, Kolaczynska KE, Varghese N, Eckert A, Liechti ME","journal":"Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology","publication_date":"2022-05-01","publication_year":2022,"doi":"10.1038/s41386-022-01297-2","topic_tags":"Anxiety,Pharmacology","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1800,"title":"Acute Effects of Psilocybin After Escitalopram or Placebo Pretreatment in a Randomized, Double-Blind, Placebo-Controlled, Crossover Study in Healthy Subjects.","authors":"Becker AM, Holze F, Grandinetti T, Klaiber A, Toedtli VE, Kolaczynska KE, Duthaler U, Varghese N, Eckert A, Grünblatt E, Liechti ME","journal":"Clinical pharmacology and therapeutics","publication_date":"2022-04-01","publication_year":2022,"doi":"10.1002/cpt.2487","topic_tags":"Depression,Anxiety,Pharmacology,Drug Interactions","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1860,"title":"Dosing Psychedelics and MDMA.","authors":"Liechti ME, Holze F","journal":"Current topics in behavioral neurosciences","publication_date":"2022-01-01","publication_year":2022,"doi":"10.1007/7854_2021_270","topic_tags":"Depression,Anxiety,PTSD,Headache / Migraine,Microdosing","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2434,"title":"Advances and challenges in neuroimaging studies on the effects of serotonergic hallucinogens: Contributions of the resting brain.","authors":"Müller F, Liechti ME, Lang UE, Borgwardt S","journal":"Progress in brain research","publication_date":"2018-01-01","publication_year":2018,"doi":"10.1016/bs.pbr.2018.08.004","topic_tags":"Brain Imaging,Aging","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2457,"title":"Pharmacokinetics and Pharmacodynamics of Lysergic Acid Diethylamide in Healthy Subjects.","authors":"Dolder PC, Schmid Y, Steuer AE, Kraemer T, Rentsch KM, Hammann F, Liechti ME","journal":"Clinical pharmacokinetics","publication_date":"2017-10-01","publication_year":2017,"doi":"10.1007/s40262-017-0513-9","topic_tags":"Brain Imaging,Pharmacology,Aging","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2471,"title":"Alterations of consciousness and mystical-type experiences after acute LSD in humans.","authors":"Liechti ME, Dolder PC, Schmid Y","journal":"Psychopharmacology","publication_date":"2017-05-01","publication_year":2017,"doi":"10.1007/s00213-016-4453-0","topic_tags":"Brain Imaging,Consciousness,Aging,Mystical Experience","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2506,"title":"Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens.","authors":"Rickli A, Moning OD, Hoener MC, Liechti ME","journal":"European neuropsychopharmacology: the journal of the European College of Neuropsychopharmacology","publication_date":"2016-08-01","publication_year":2016,"doi":"10.1016/j.euroneuro.2016.05.001","topic_tags":"Receptor Pharmacology,Drug Interactions","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":5873,"title":"Low-dose lysergic acid diethylamide alters subjective visual perception but not visual contrast surround suppression.","authors":"Jaeckel LF, Logvinski D, Kanana M, Müller F, Rohner N, Becker AM, Liechti ME, Sterzer P.","journal":"Neuroscience of consciousness","publication_date":"2026-08-20","publication_year":2026,"doi":"10.1093/nc/niag050","topic_tags":"Mechanism of Action,Healthy Volunteers","source_name":"Europe PMC","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":399,"title":"Acute and post-dosing effects of single-dose psilocybin for obsessive-compulsive disorder in a randomized, double-blind, placebo-controlled trial: an interpretative phenomenological analysis.","authors":"Ching THW, Stahnke B, Shnayder S, Agin-Liebes G, Adams TG, Amoroso L, Baiz O, Belser A, Bohner C, Burke M, D'Amico E, DePalmer G, Eilbott J, Fram G, Grazioplene R, Hokanson J, Jankovsky A, Kichuk SA, Martins B, Purohit P, Schaer H, Sierra YP, Witherow C, Pittenger C, Kelmendi B","journal":"Frontiers in psychiatry","publication_date":"2025-01-01","publication_year":2025,"doi":"10.3389/fpsyt.2025.1726818","topic_tags":"OCD,Mechanism of Action,Emotional Processing","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":441,"title":"Psychedelic Augmentation of 12-Step Engagement: A Novel, Accessible Approach to Enhance Community-Based Recovery from Substance Use Disorders.","authors":"Mehtani NJ, Mian MN, Agin-Liebes G, Coker AR, Huebner C, Anderson BT, Mitchell JM","journal":"Journal of psychoactive drugs","publication_date":"2025-11-10","publication_year":2025,"doi":"10.1080/02791072.2025.2583960","topic_tags":"Addiction,Mechanism of Action,Wellbeing,Spirituality,Safety","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1067,"title":"Content analysis of Reddit posts about coadministration of selective serotonin reuptake inhibitors and psilocybin mushrooms.","authors":"Sakai K, Bradley ER, Zamaria JA, Agin-Liebes G, Kelley DP, Fish A, Martini V, Ferris MC, Morton E, Michalak EE, O'Donovan A, Woolley JD","journal":"Psychopharmacology","publication_date":"2024-08-01","publication_year":2024,"doi":"10.1007/s00213-024-06585-x","topic_tags":"Receptor Pharmacology,Safety,Toxicity,Drug Interactions","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1248,"title":"Reports of self-compassion and affect regulation in psilocybin-assisted therapy for alcohol use disorder: An interpretive phenomenological analysis.","authors":"Agin-Liebes G, Nielson EM, Zingman M, Kim K, Haas A, Owens LT, Rogers U, Bogenschutz M","journal":"Psychology of addictive behaviors: journal of the Society of Psychologists in Addictive Behaviors","publication_date":"2024-02-01","publication_year":2024,"doi":"10.1037/adb0000935","topic_tags":"Addiction,Chronic Pain,Mechanism of Action,Emotional Processing,Randomized Controlled Trial","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1451,"title":"The need for establishing best practices and gold standards in psychedelic medicine.","authors":"Feduccia A, Agin-Liebes G, Price CM, Grinsell N, Paradise S, Rabin DM","journal":"Journal of affective disorders","publication_date":"2023-07-01","publication_year":2023,"doi":"10.1016/j.jad.2023.03.083","topic_tags":"Depression,PTSD,Clinical Trial,Review Article,Safety","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1706,"title":"Comment and Response: (Lugo-Radillo & Cortez-Lopez, 2020) Long-Term Amelioration of OCD Symptoms in a Patient with Chronic Consumption of Psilocybin-Containing Mushrooms.","authors":"Fitzpatrick CM, Anderson BT, Agin-Liebes G, Guydish J","journal":"Journal of psychoactive drugs","publication_date":"2022-01-01","publication_year":2022,"doi":"10.1080/02791072.2021.1983673","topic_tags":"OCD","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1708,"title":"Attitudes and Beliefs about the Therapeutic Use of Psychedelic Drugs among Psychologists in the United States.","authors":"Davis AK, Agin-Liebes G, España M, Pilecki B, Luoma J","journal":"Journal of psychoactive drugs","publication_date":"2022-01-01","publication_year":2022,"doi":"10.1080/02791072.2021.1971343","topic_tags":"Observational Study,Safety","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1804,"title":"Race, Ethnic, and Sex Differences in Prevalence of and Trends in Hallucinogen Consumption Among Lifetime Users in the United States Between 2015 and 2019.","authors":"Davis AK, Arterberry BJ, Xin Y, Agin-Liebes G, Schwarting C, Williams MT","journal":"Frontiers in epidemiology","publication_date":"2022-01-01","publication_year":2022,"doi":"10.3389/fepid.2022.876706","topic_tags":"Observational Study,Safety","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1857,"title":"Psilocybin for the Treatment of Depression: A Promising New Pharmacotherapy Approach.","authors":"Agin-Liebes G, Davis AK","journal":"Current topics in behavioral neurosciences","publication_date":"2022-01-01","publication_year":2022,"doi":"10.1007/7854_2021_282","topic_tags":"Depression,Brain Imaging,Aging,Clinical Trial,Review Article,Treatment-Resistant Depression","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2238,"title":"Psilocybin-assisted group therapy for demoralized older long-term AIDS survivor men: An open-label safety and feasibility pilot study.","authors":"Anderson BT, Danforth A, Daroff PR, Stauffer C, Ekman E, Agin-Liebes G, Trope A, Boden MT, Dilley PJ, Mitchell J, Woolley J","journal":"EClinicalMedicine","publication_date":"2020-10-01","publication_year":2020,"doi":"10.1016/j.eclinm.2020.100538","topic_tags":"Depression,Anxiety,Veterans,Safety,Adverse Events","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":3746,"title":"Psilocybin-Assisted Therapy Increases Self-Compassion in Patients with Alcohol Use Disorder","authors":"Agin-Liebes G, Petridis P, Zeifman R, Link M, Cordova MJ, Bogenschutz M.","journal":"PsyArXiv","publication_date":"2025-06-10","publication_year":2025,"doi":"10.31234/osf.io/f27jm_v1","topic_tags":"Addiction,Safety","source_name":"PsyArXiv","publication_status":"preprint","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":5903,"title":"Surrender, disidentification, and reappraisal: a qualitative comparison of psilocybin responders and non-responders in treatment-resistant OCD","authors":"Agin-Liebes G, Shnayder S, Fram G, Swift T, Ching T, Jankovsky A, Hokanson J, Pittenger C, Kelmendi B.","journal":"Frontiers in psychiatry","publication_date":"2026-09-16","publication_year":2026,"doi":"10.3389/fpsyt.2026.1791689","topic_tags":"OCD","source_name":"Europe PMC","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":534,"title":"Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous RE104: A Double-Blind, Randomized, Single Ascending Dose Placebo-Controlled Study.","authors":"Ludbrook G, Bryson N, Taylor B, Hocevar-Trnka J, Johnson MW, Hirman J, Morrish G, Alexander R, Pollack M","journal":"Journal of clinical psychopharmacology","publication_date":"2025-01-01","publication_year":2025,"doi":"10.1097/jcp.0000000000002047","topic_tags":"Chronic Pain,Pharmacology,Mystical Experience,Clinical Trial,Observational Study,Safety,Adverse Events,Toxicity","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":543,"title":"Adverse reactions among psychedelic users: Norwegian validation of the Challenging Experience Questionnaire.","authors":"Andersen KAA, Holmøy B, Kvam TM, Johnson MW","journal":"Journal of psychiatric research","publication_date":"2025-09-01","publication_year":2025,"doi":"10.1016/j.jpsychires.2025.05.062","topic_tags":"Observational Study","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":884,"title":"Psychedelics and substance use disorder treatment.","authors":"DuPont CM, Johnson MW","journal":"International review of neurobiology","publication_date":"2025-01-01","publication_year":2025,"doi":"10.1016/bs.irn.2025.03.005","topic_tags":"Addiction,Emotional Processing,Clinical Trial,Observational Study,Safety","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1202,"title":"The Mystical Experience Questionnaire 4-Item and Challenging Experience Questionnaire 7-Item.","authors":"Strickland JC, Garcia-Romeu A, Johnson MW","journal":"Psychedelic medicine (New Rochelle, N.Y.)","publication_date":"2024-03-01","publication_year":2024,"doi":"10.1089/psymed.2023.0046","topic_tags":"Depression,Anxiety,Mystical Experience,Toxicity","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1282,"title":"IUPHAR-review: The integration of classic psychedelics into current substance use disorder treatment models.","authors":"Yaden DB, Berghella AP, Hendricks PS, Yaden ME, Levine M, Rohde JS, Nayak S, Johnson MW, Garcia-Romeu A","journal":"Pharmacological research","publication_date":"2024-01-01","publication_year":2024,"doi":"10.1016/j.phrs.2023.106998","topic_tags":"Addiction,Review Article","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1338,"title":"Beliefs and Perceived Barriers Regarding Psychedelic-assisted Therapy in a Pilot Study of Service Members and Veterans With a History of Traumatic Brain Injury.","authors":"Gray JC, Murphy M, Carter SE, Johnson MW, Wolfgang AS, Roy MJ, Maples-Keller JL","journal":"Military medicine","publication_date":"2023-11-03","publication_year":2023,"doi":"10.1093/milmed/usac400","topic_tags":"Depression,PTSD,Aging,Personality Change,Veterans","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1783,"title":"Psychedelics and Psychotherapy: Cognitive-Behavioral Approaches as Default.","authors":"Yaden DB, Earp D, Graziosi M, Friedman-Wheeler D, Luoma JB, Johnson MW","journal":"Frontiers in psychology","publication_date":"2022-01-01","publication_year":2022,"doi":"10.3389/fpsyg.2022.873279","topic_tags":"Spirituality,Safety","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1801,"title":"Verbal behavior related to drug reinforcement in polysubstance cannabis users: Comparison across drugs.","authors":"Cox DJ, Johnson MW","journal":"Experimental and clinical psychopharmacology","publication_date":"2022-04-01","publication_year":2022,"doi":"10.1037/pha0000404","topic_tags":"Addiction,Pharmacology,Healthcare Workers","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1837,"title":"Psychedelic Identity Shift: A Critical Approach to Set And Setting.","authors":"Devenot N, Seale-Feldman A, Smith E, Noorani T, Garcia-Romeu A, Johnson MW","journal":"Kennedy Institute of Ethics journal","publication_date":"2022-01-01","publication_year":2022,"doi":"10.1353/ken.2022.0022","topic_tags":"Addiction,Mechanism of Action","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1841,"title":"Classic Psychedelics in Addiction Treatment: The Case for Psilocybin in Tobacco Smoking Cessation.","authors":"Johnson MW","journal":"Current topics in behavioral neurosciences","publication_date":"2022-01-01","publication_year":2022,"doi":"10.1007/7854_2022_327","topic_tags":"Addiction,Receptor Pharmacology,Review Article,Safety","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1845,"title":"Human behavioral pharmacology of psychedelics.","authors":"Strickland JC, Johnson MW","journal":"Advances in pharmacology (San Diego, Calif.)","publication_date":"2022-01-01","publication_year":2022,"doi":"10.1016/bs.apha.2021.10.003","topic_tags":"Depression,Addiction,Pharmacology,Mechanism of Action,Mystical Experience,Clinical Trial,Treatment-Resistant Depression,Abuse Liability","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1878,"title":"Classic psychedelics in the treatment of substance use disorder: Potential synergies with twelve-step programs.","authors":"Yaden DB, Berghella AP, Regier PS, Garcia-Romeu A, Johnson MW, Hendricks PS","journal":"The International journal on drug policy","publication_date":"2021-12-01","publication_year":2021,"doi":"10.1016/j.drugpo.2021.103380","topic_tags":"Addiction,Aging,Clinical Trial,Review Article","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2143,"title":"Predicting changes in substance use following psychedelic experiences: natural language processing of psychedelic session narratives.","authors":"Cox DJ, Garcia-Romeu A, Johnson MW","journal":"The American journal of drug and alcohol abuse","publication_date":"2021-07-04","publication_year":2021,"doi":"10.1080/00952990.2021.1910830","topic_tags":"Addiction","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2273,"title":"Editorial: Hallucinogens and Entactogens: Establishing a New Class of Drugs?","authors":"Müller F, Johnson MW, Borgwardt S","journal":"Frontiers in psychiatry","publication_date":"2020-01-01","publication_year":2020,"doi":"10.3389/fpsyt.2020.00497","topic_tags":"General","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2477,"title":"Psychedelics as Medicines: An Emerging New Paradigm.","authors":"Nichols DE, Johnson MW, Nichols CD","journal":"Clinical pharmacology and therapeutics","publication_date":"2017-02-01","publication_year":2017,"doi":"10.1002/cpt.557","topic_tags":"Depression,Anxiety,Addiction,Mechanism of Action,Receptor Pharmacology,Inflammation","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2523,"title":"Classic hallucinogens in the treatment of addictions.","authors":"Bogenschutz MP, Johnson MW","journal":"Progress in neuro-psychopharmacology & biological psychiatry","publication_date":"2016-01-04","publication_year":2016,"doi":"10.1016/j.pnpbp.2015.03.002","topic_tags":"Addiction,Mechanism of Action,Mystical Experience,Clinical Trial,Meta-Analysis,Review Article,Safety","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2544,"title":"Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population.","authors":"Hendricks PS, Thorne CB, Clark CB, Coombs DW, Johnson MW","journal":"Journal of psychopharmacology (Oxford, England)","publication_date":"2015-03-01","publication_year":2015,"doi":"10.1177/0269881114565653","topic_tags":"Observational Study","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2550,"title":"Can psychedelic compounds play a part in drug dependence therapy?","authors":"Sessa B, Johnson MW","journal":"The British journal of psychiatry: the journal of mental science","publication_date":"2015-01-01","publication_year":2015,"doi":"10.1192/bjp.bp.114.148031","topic_tags":"General","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2568,"title":"Hallucinogen use predicts reduced recidivism among substance-involved offenders under community corrections supervision.","authors":"Hendricks PS, Clark CB, Johnson MW, Fontaine KR, Cropsey KL","journal":"Journal of psychopharmacology (Oxford, England)","publication_date":"2014-01-01","publication_year":2014,"doi":"10.1177/0269881113513851","topic_tags":"Addiction","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":705,"title":"From molecules to meaning: unpacking the antidepressant mechanisms of psychedelic drugs.","authors":"Acero VP, Flatt TA, Gooch PM, Gaughan SJ, Levin AW, Davis AK","journal":"Expert review of clinical pharmacology","publication_date":"2025-05-01","publication_year":2025,"doi":"10.1080/17512433.2025.2515866","topic_tags":"Depression,Pharmacology,Mechanism of Action,Spirituality,Review Article","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1018,"title":"Psychedelic research at a crossroads.","authors":"Armstrong SB, Davis AK","journal":"Science (New York, N.Y.)","publication_date":"2024-09-20","publication_year":2024,"doi":"10.1126/science.adt1024","topic_tags":"Depression,PTSD,Consciousness,Clinical Trial,Safety","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1491,"title":"Study protocol of an open-label proof-of-concept trial examining the safety and clinical efficacy of psilocybin-assisted therapy for veterans with PTSD.","authors":"Davis AK, Levin AW, Nagib PB, Armstrong SB, Lancelotta RL","journal":"BMJ open","publication_date":"2023-05-04","publication_year":2023,"doi":"10.1136/bmjopen-2022-068884","topic_tags":"Anxiety,PTSD,Pharmacology,Clinical Trial,Review Article,Veterans,Healthcare Workers,Safety,Adverse Events","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1612,"title":"Knowledge, Perceptions, and Use of Psychedelics among Individuals with Fibromyalgia.","authors":"Glynos NG, Pierce J, Davis AK, McAfee J, Boehnke KF","journal":"Journal of psychoactive drugs","publication_date":"2023-01-01","publication_year":2023,"doi":"10.1080/02791072.2021.2022817","topic_tags":"Chronic Pain,Observational Study","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1685,"title":"Inconsistencies between national drug policy and professional beliefs about psychoactive drugs among psychiatrists in the United States.","authors":"Levin A, Nagib PB, Deiparine S, Gao T, Mitchell J, Davis AK","journal":"The International journal on drug policy","publication_date":"2022-10-01","publication_year":2022,"doi":"10.1016/j.drugpo.2022.103816","topic_tags":"Aging,Observational Study,Safety","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1700,"title":"Psilocybin use patterns and perception of risk among a cohort of Black individuals with Opioid Use Disorder.","authors":"Clifton JM, Belcher AM, Greenblatt AD, Welsh CM, Cole TO, Davis AK","journal":"Journal of psychedelic studies","publication_date":"2022-09-01","publication_year":2022,"doi":"10.1556/2054.2022.00214","topic_tags":"Addiction,Observational Study,Safety","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2210,"title":"People of color in North America report improvements in racial trauma and mental health symptoms following psychedelic experiences.","authors":"Williams MT, Davis AK, Xin Y, Sepeda ND, Grigas PC, Sinnott S, Haeny AM","journal":"Drugs (Abingdon, England)","publication_date":"2021-01-01","publication_year":2021,"doi":"10.1080/09687637.2020.1854688","topic_tags":"Depression,Anxiety,Addiction,Mystical Experience,Observational Study","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":2271,"title":"Long-term effects of psychedelic drugs: A systematic review.","authors":"Aday JS, Mitzkovitz CM, Bloesch EK, Davoli CC, Davis AK","journal":"Neuroscience and biobehavioral reviews","publication_date":"2020-06-01","publication_year":2020,"doi":"10.1016/j.neubiorev.2020.03.017","topic_tags":"Depression,Anxiety,Wellbeing,Personality Change,Emotional Processing,Spirituality,Mystical Experience,Systematic Review,Review Article,Adverse Events","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":3134,"title":"Preliminary safety and effectiveness of psilocybin-assisted therapy in adults with fibromyalgia: An open-label, pilot clinical trial","authors":"Aday JS, McAfee J, Conroy DA, Hosanagar A, Tarnal V, Weston C, Scott K, Horowitz D, Harte SE, Pouyan N, Glynos NG, Baker AK, Guss J, Davis AK, Burgess HJ, Mashour GA, Clauw DJ, Boehnke KF.","journal":"PsyArXiv","publication_date":"2024-11-04","publication_year":2024,"doi":"10.31234/osf.io/j8zb5","topic_tags":"Anxiety,Chronic Pain,Headache / Migraine,Clinical Trial,Randomized Controlled Trial,Safety,Adverse Events","source_name":"PsyArXiv","publication_status":"preprint","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":3402,"title":"A Meta-Analysis of Placebo-Controlled Trials of Psychedelic-Assisted Therapy","authors":"Luoma JB, Chwyl C, Bathje G, Davis AK, Lancelotta RL.","journal":"PsyArXiv","publication_date":"2020-10-28","publication_year":2020,"doi":"10.31234/osf.io/nhbjk","topic_tags":"Depression,Anxiety,PTSD,End-of-Life Distress,Clinical Trial,Meta-Analysis","source_name":"PsyArXiv","publication_status":"preprint","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":396,"title":"The Role of Touch in Psychedelic Therapy: Perspectives From a Survey of Practitioners in Research Settings.","authors":"Bender DA, Nayak SM, Siegel JS, Hellerstein DJ, Ercal BC, Lenze EJ","journal":"American journal of psychotherapy","publication_date":"2025-12-15","publication_year":2025,"doi":"10.1176/appi.psychotherapy.20240025","topic_tags":"Observational Study","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":468,"title":"Provider perspectives on challenges in treatment during psychedelic therapy.","authors":"Bender DA, Nayak SM, Siegel JS, Hellerstein DJ, Ercal BC, Lenze EJ","journal":"Psychopharmacology","publication_date":"2026-07-01","publication_year":2026,"doi":"10.1007/s00213-025-06907-7","topic_tags":"PTSD,Aging,Clinical Trial,Review Article,Observational Study,Adverse Events","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":828,"title":"Psychological Support Approaches in Psychedelic Therapy: Results From a Survey of Psychedelic Practitioners.","authors":"Bender DA, Nayak SM, Siegel JS, Hellerstein DJ, Ercal BC, Lenze EJ","journal":"The Journal of clinical psychiatry","publication_date":"2025-02-05","publication_year":2025,"doi":"10.4088/jcp.24m15521","topic_tags":"Emotional Processing,Spirituality,Clinical Trial,Observational Study","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":909,"title":"Practical considerations in the establishment of psychedelic research programs.","authors":"Barnett BS, Vest MF, Delatte MS, King Iv F, Mauney EE, Coulson AJ, Nayak SM, Hendricks PS, Greer GR, Murnane KS","journal":"Psychopharmacology","publication_date":"2025-01-01","publication_year":2025,"doi":"10.1007/s00213-024-06722-6","topic_tags":"Aging,Clinical Trial,Review Article","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":951,"title":"Adverse Events in Studies of Classic Psychedelics: A Systematic Review and Meta-Analysis.","authors":"Hinkle JT, Graziosi M, Nayak SM, Yaden DB","journal":"JAMA psychiatry","publication_date":"2024-12-01","publication_year":2024,"doi":"10.1001/jamapsychiatry.2024.2546","topic_tags":"Depression,Anxiety,Headache / Migraine,Meta-Analysis,Systematic Review,Review Article,Healthy Volunteers,Safety,Adverse Events","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":1124,"title":"Psilocybin in Bipolar II Study Provides Preliminary Data on Safety.","authors":"Yaden DB, Gukasyan N, Nayak SM","journal":"JAMA psychiatry","publication_date":"2024-06-01","publication_year":2024,"doi":"10.1001/jamapsychiatry.2023.4680","topic_tags":"Safety","source_name":"PubMed","publication_status":"published","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":3070,"title":"Psilocybin treatment for symptoms of depression: a living systematic review, meta-analysis, and data resource","authors":"Singleton SP, Sevchik BL, Lahey A, Cuijpers P, Harrer M, Jones MT, Nayak SM, Strain EC, Vandekar SN, Dworkin RH, Scott JC, Satterthwaite TD.","journal":"medRxiv","publication_date":"2025-08-16","publication_year":2025,"doi":"10.1101/2025.08.13.25333530","topic_tags":"Depression,Clinical Trial,Randomized Controlled Trial,Meta-Analysis,Systematic Review,Review Article,Safety","source_name":"medRxiv","publication_status":"preprint","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":3158,"title":"Shame, guilt and psychedelic experience: Results from a prospective, longitudinal survey of real-world psilocybin use","authors":"Mathai DS, Roberts DE, Nayak SM, Sepeda ND, Lehrner A, Johnson M, Lowe MX, Jackson H, Garcia-Romeu A.","journal":"PsyArXiv","publication_date":"2023-10-14","publication_year":2023,"doi":"10.31234/osf.io/hm6jn_v1","topic_tags":"Chronic Pain,Wellbeing,Emotional Processing,Observational Study","source_name":"PsyArXiv","publication_status":"preprint","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":3159,"title":"Shame, guilt and psychedelic experience: Results from a prospective, longitudinal survey of real-world psilocybin use","authors":"Mathai DS, Roberts DE, Nayak SM, Sepeda ND, Lehrner A, Johnson M, Lowe MX, Jackson H, Garcia-Romeu A.","journal":"PsyArXiv","publication_date":"2023-10-14","publication_year":2023,"doi":"10.31234/osf.io/hm6jn","topic_tags":"Chronic Pain,Wellbeing,Emotional Processing,Observational Study","source_name":"PsyArXiv","publication_status":"preprint","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"},{"id":5709,"title":"Acute Cardiovascular Effects of Psilocybin: A Pooled Analysis of 14 Studies with Safety Recommendations","authors":"Nayak SM, Sepeda ND, Dick MN, Tiwari P, Zahid Z, Sayalı C, Weiss BM, Yaden DB, Garcia-Romeu A, Barnett BS, Barrett FS.","journal":"medRxiv","publication_date":"2026-04-30","publication_year":2026,"doi":"10.64898/2026.04.28.26351625","topic_tags":"Clinical Trial,Safety","source_name":"medRxiv","publication_status":"preprint","abstract_redistributed":false,"text_rights_status":"not_applicable_no_text"}],"limitations":"Names are metadata labels, not disambiguated people. Co-authorship is not evidence of influence or research quality. Registry sponsors are excluded; lists above 100 authors are omitted. Visual views are bounded for readability; all matching names and connections are available through the free full JSON export."}